

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 April 2003 (10.04.2003)

PCT

(10) International Publication Number
WO 03/029245 A1

(51) International Patent Classification⁷: **C07D 401/04**,
401/14, 487/10, 487/20, A61K 31/4166

Malmaison (FR). **IWANOWICZ, Edwin J.** [US/US]; 30
Haverford Road, West Windsor, NJ 08550 (US).

(21) International Application Number: PCT/US02/31283

(74) Agents: **WINSLOW, Anastasia** et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).

(22) International Filing Date:
30 September 2002 (30.09.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/326,361 1 October 2001 (01.10.2001) US
60/354,113 4 February 2002 (04.02.2002) US
60/400,259 1 August 2002 (01.08.2002) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants (*for all designated States except US*): **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; P. O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000 (US). **CEREP SA** [FR/FR]; 128, rue Danton-BP50601, F-92506 Rueil-Malmaison Cede (FR).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **DHAR, T. G. Murali** [US/US]; 247 Crittenden Drive, Newtown, PA 18940 (US). **POTIN, Dominique** [FR/FR]; 14 Chemin Vert, F-78780 Epone (FR). **MAILLET, Magaili Jeannine Blandine** [FR/FR]; 80 avenue de Fouilleuse, F-92150 Suresnes (FR). **LAUNAY, Michele** [FR/FR]; 11 rue Diderot, F-92500 Ruel Malmaison (FR). **NICOLAI, Eric Antoine** [FR/FR]; 16 rue Alexis Bouvier, F-92500 Rueil

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SPIRO-HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS



(57) Abstract: Compounds having the formula (I), and pharmaceutically-acceptable salts, hydrates, enantiomers, and diastereomers, and prodrugs thereof, (I) are useful as inhibitors of LFA-1/ICAM and as anti-inflammatory agents, wherein L and K are O or S; Z is N or CR_{4b}; Ar is an optionally-substituted aryl or heteroaryl; G is a linker attached to T or M or is absent; J, M and T are selected to define a three to six membered saturated or partially unsaturated non-aromatic ring; and R₂, R_{4a}, R_{4b}, and R_{4c} are as defined in the specification.

SPIRO-HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS**Related Applications**

5

This application claims the benefit of U.S. Provisional Application No. 60/326,361, filed October 1, 2001, U.S. Provisional Application No. 60/354,113, filed February 4, 2002, and U.S. Provisional Application No. 60/400,259, filed August 1, 2002, each of which is incorporated herein by reference.

10

Field of the Invention

The present invention relates to spiro-hydantoin compounds, pharmaceutical compositions containing them, and methods of using such compounds in treating inflammatory or immune disease.

15

Background of the Invention

Cells adhere to other cells and to substrates through specific, regulated processes that are critical to various biological functions. The proper functioning of the immune system is dependent upon adhesive interactions and cell migration. A key event in an immune response involves the migration of leukocytes to a disease site.

20

During an inflammatory response, leukocytes are recruited to the site of injury and extravasated by a series of cellular interactions involving cell-cell and cell-substrate adhesion.

25

One family of molecules that serves an important adhesive function is integrins. Integrins are expressed on cell surfaces and function in cell-cell and cell-substrate adhesion. Integrins are alpha-beta heterodimers: each integrin has an alpha (α) subunit non-covalently bound to a beta (β) subunit. When activated, integrins bind to extracellular ligands and induce adhesion (the expression of integrins on a cell surface alone is inadequate for adhesion - they must be activated to become adhesive). The integrin activation state is transient, such that there is a rapid flux between adhesive and non-adhesive states which is important for cell movement, *e.g.*, a cell is endowed with the ability to rapidly adhere to various cell surfaces and matrices and to migrate among cells and tissue.

30

There are four known integrins having a β_2 or CD18 subunit which comprise the CD11/CD18 integrin sub-family, namely, Lymphocyte Function-associated Antigen 1 (LFA-1) (CD11a/CD18 or $\alpha_L\beta_2$); Macrophage Antigen 1 (Mac-1) (CD11b/CD18 or $\alpha_M\beta_2$); p150,95 (CD11c/CD18 or $\alpha_X\beta_2$); and $\alpha_D\beta_2$. The CD11/CD18 family of integrins is also referred to as Leukointegrins as they are expressed on the surface of various leukocyte cells, and they mediate a number of inflammation-related cellular interactions. *See Diamond et al., "The Dynamic Regulation of Integrin Adhesiveness," Current Biology, Vol. 4 (1994) at pp. 506-532.*

Ligands to LFA-1 and Mac-1 comprise the intercellular adhesion molecule (ICAM) ICAM-1. The primary CD11/CD18 integrin is LFA-1, which also binds with ICAM-2 and ICAM-3. ICAMs are found on endothelium cells, leukocytes, and other cell types, and their interaction with CD11/CD18 integrins is critical to immune system function. The interaction between the CD18 integrins, particularly LFA-1, and ICAMs mediates antigen presentation, T-cell proliferation, and adhesion between the endothelium and activated leukocytes which is necessary for leukocytes to migrate from the circulatory system into tissue. A condition termed "Leukocyte Adhesion Deficiency" has been identified in patients having a deficiency in CD18 integrins. These patients are unable to mount a normal inflammatory or immune response; they suffer from disorders such as recurrent infections, poor wound healing, granulocytosis, progressive periodontitis, and umbilical cord separation. *See Anderson et al., "Leukocyte LFA-1, OKMI, p150,95 Deficiency Syndrome: Functional and Biosynthesis Studies of Three Kindreds," Fed. Proc., Vol. 44 (1985), at pp. 2671-2677.*

While sufficient levels of CD18 integrins interacting with ICAMs are needed to mount a normal immune response, significant cellular and tissue injury can result in chronic inflammatory states where there is an inappropriate influx of leukocytes to the disease site. Continuous recruitment of leukocytes from blood vessels into inflamed tissue, as in chronic inflammatory states, can perpetuate tissue injury and lead to excessive fibrous repair and autoimmune disease. Thus, inhibition of the interaction between LFA-1 and/or Mac-1 and their ICAMs can be advantageous in treating inflammatory or immune disease. For example, monoclonal antibody blockade of either ICAM or LFA-1 has been shown to prevent the migration of leukocytes into

tissue and the subsequent development of inflammatory disease in animal models of rheumatoid arthritis, inflammatory bowel disease, and pulmonary inflammation (*e.g.*, asthma). Knockout mice deficient in ICAMs have reduced susceptibility to induced arthritis, ischemia injury, impaired lung inflammatory responses, and increased tolerance to transplantations (*e.g.* heart grafts). *See* Anderson, *supra*. Antibodies blocking the ICAM-LFA-1 interaction reportedly suppress cardiac allograft rejection and islet cell xenograft rejection in animal models. *See* Gorski, "The Role of Cell Adhesion Molecules in Immunopathology," Immunology Today, Vol. 15 (1994), at pp. 251-255.

Compounds inhibiting CD18 integrins, ICAMs, and/or the LFA-1:ICAM interaction could potentially demonstrate a wide range of utilities in treating inflammatory or immune diseases. Blocking LFA-1 reportedly inhibits the influx of leukocytes in almost every system, including the skin, peritoneum, synovium, lung, kidney, and heart, and blocking ICAM-1 would be expected to have similar effects. Also, present therapies for many inflammatory and immune diseases have drawbacks. For example, current treatments for asthma include β_2 -agonists, inhaled corticosteroids, and LTD₄ antagonists. However, β_2 -agonists have limited efficacy and inhaled corticosteroids raise safety concerns. To treat psoriasis, current therapies include PUVA, methotrexate, cyclosporin A, and topical treatments. The first three of these therapies raise toxicity issues over long-term (*e.g.*, 6-9 month) use, whereas topical treatments have limited efficacy. Additionally, these treatments typically are applied only in response to flares and not as a prophylaxis measure.

Compounds that reportedly inhibit LFA-1/ICAM for use as anti-inflammatory agents include thiadiazole-based compounds (*see* Intern. Pub. No. WO 99/20,618, "Thiadiazole Amides Useful as Anti-Inflammatory Agents" filed by Pharmacia & Upjohn Co.; and WO 99/20,617, also to Pharmacia and Upjohn); and thiazole compounds linked to phenyl and pyrazole rings (Sanfilippo *et al.*, "Novel Thiazole Based Heterocycles as Inhibitors of LFA-1/ICAM-1 Mediated Cell Adhesion," J. Med. Chem., Vol. 38 (1995) at pp.1057-1059). Small molecules that reportedly are antagonists to the binding of ICAMs with CD18 integrins include various benzylamines and 2-bromobenzoyltryptophan compounds (*see* Intern. Pub. No. WO99/49,856, "Antagonists for Treatment of CD11/CD18 Adhesion Receptor

Mediated Disorders,” filed by Genentech, Inc.), and 1-(3,5 dichlorophenyl) imidazolidines (*see* Intern. Pub. No. WO98/39303, “*Small Molecules Useful in the Treatment of Inflammatory Disease*,” filed by Boehringer Ingelheim Pharmaceuticals, Inc. *See also* Boehringer patent applications WO 01/07052, WO 01/07048, WO 01/07044, WO 01/06984, and WO 01/07440). Hydantoin compounds are disclosed in Intern. Pub. No's WO 00/59880, WO 00/39081, WO 02/02522, WO 02/02539 (all to Abbott Laboratories). LFA-1 antagonist compounds are also claimed in WO 02/059114 (to Genentech), WO 02/42294 (to Celltech), WO 01/51508 (to Science and Technology corporation), WO 00/21920 and WO 01/58853 (both to Hoffmann-LaRoche), WO 99/11258, WO 00/48989 and WO 02/28832 (all to Novartis). Hydantoin compounds are disclosed in Intern. Pub. No. WO 01/30781 A2 (published May 3, 2001) to Tanabe Seiyaku Co. Ltd, “*Inhibitors of $\alpha_L\beta_2$ Mediated Cell Adhesion*,” and in Intern. Pub. No. WO 02/44181 (published June 6, 2002), “*Hydantoin Compounds Useful as Anti-Inflammatory Agents*”, to the present assignee and having common inventors herewith.

As may be appreciated, those in the field of pharmaceutical research continue to develop new compounds and compositions for treating inflammatory and immune disease such as inhibitors of Leukointegrins and/or ICAMs. Particularly in the area of immune response, many individuals respond differently to different drugs. Thus, there is an interest in providing consumers not only with pharmaceutical compositions demonstrating increased effectiveness and reduced side-effects but also different structures or mechanisms of action to provide consumers with a choice of options. The instant invention is directed to aryl or heteroaryl substituted spiro-hydantoin compounds that are effective as antagonists of Leukointegrins and/or ICAMs. Diazaspiroheptane compounds are disclosed in Park *et al.*, “*Preparation of a 990 Member Chemical Compound Library of Hydantoin and Isoxazoline-Containing Heterocycles Using Multipin Technology*,” *J. Comb. Chem.*, Vol. 3(2) (2001), at pp. 171-76. Spiro heterocycles are also disclosed in Couture *et al.*, “*Chemistry of Cyclic Aminooxycarbenes*,” *Can. J. Chem.*, Vol. 75(9) (1997) at pp. 1281-1294; Brandstetter *et al.*, “*Glucofuranose Analogs of Hydantocidin*,” *Tetrahedron*, Vol. 52(32) (1996), at pp. 10721-10736; Brandstetter *et al.*, “*Spirohydantoins of Glucofuranose: Analogs of Hydantocidin*,” *Tetrahedron Lett.*, Vol. 36(12) (1995) at pp. 2149-52; in US Pats.


Nos. 6,022,875, 4,241,208, 4,066,615, and 3,941,744, and International patent application WO 01/45704. WO 01/94346 discloses 1,3,8-triaza-spiro[4,5]decan-4-one derivatives as neurokinin receptor antagonists.

Each of the patents, patent applications and publications referenced above and
5 hereinafter is incorporated herein by reference.

Summary of the Invention

The present invention provides compounds useful in treating inflammatory or immune disease having the formula (I):

10



their enantiomers, diastereomers, and pharmaceutically-acceptable salts, hydrates, solvates, and prodrugs thereof, in which:

L and K, taken independently, are O or S;

15 Z is N or CR_{4b};

Ar is aryl or heteroaryl;

G is attached to ring A at T or M; and (i) when attached to a carbon atom of ring A, G is selected from a bond, -O-, -N-, -S-, C₁₋₄alkylene, C₁₋₄substituted alkylene, or bivalent alkoxy, alkylthio, aminoalkyl, sulfonyl, sulfonamidyl, acyl, and alkoxycarbonyl; or (ii) when attached to a nitrogen atom of ring A, G is
20 selected from a bond, C₁₋₄alkylene, C₁₋₄substituted alkylene, and bivalent acyl or alkoxycarbonyl, or bivalent alkoxy, alkylthio, aminoalkyl, sulfonyl, or sulfonamidyl wherein in (ii), each of said G groups have at least one carbon atom directly attached to ring A;

25 J is -O-, -S-, -NR₃-, -N=, -S(=O)-, -SO₂-, -NHSO₂-, a substituted or unsubstituted C₁₋₃alkylene, a substituted or unsubstituted C₂₋₃alkenylene, an unsubstituted C₁₋

heteroalkylene, a substituted heteroalkylene having from one to two carbon atoms in the heteroalkylene straight chain, or J is absent so that ring A is a three-membered ring;

T is T₁ when G-Ar is attached to T, and T₂ when G-Ar is attached to M;

5 M is M₁ when G-Ar is attached to M, and M₂ when G-Ar is attached to T;

T₁ and M₁ are selected from -N- and -C(R₅)-;

10 T₂ and M₂ are selected from -O-, -S-, -N(R₆)-, -N=, -S(=O)-, -SO₂-, -NH-SO₂-, and -C(R₇R₈)-, provided that J, M, and T are selected so that ring A defines a three to six membered saturated or partially unsaturated cycloalkyl or heterocyclic ring having 1 to 4 heteroatoms, wherein no two adjacent heteroatoms of said heterocyclic ring A are simultaneously selected from -O- and -S-;

R₂ is selected from hydrogen, alkyl, substituted alkyl, OR₁₂, NR₁₂R₁₃, C(=O)R₁₂, CO₂R₁₂, C(=O)NR₁₂R₁₃, NR₁₂C(=O)R₁₃, NR₁₂C(=O)OR₁₃, S(O)_pR_{13a}, NR₁₂SO₂R_{13a}, SO₂NR₁₂R₁₃, cycloalkyl, heterocyclo, aryl, and heteroaryl;

15 R_{4a}, R_{4b} and R_{4c} are independently selected from hydrogen, halogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, nitro, cyano, SR₁₄, OR₁₄, NR₁₄R₁₅, NR₁₄C(=O)R₁₅, CO₂R₁₄, C(=O)R₁₄, -C(=O)NR₁₄R₁₅, aryl, heterocyclo, cycloalkyl, and heteroaryl;

20 R₃ and R₆ are independently selected from hydrogen, alkyl, substituted alkyl, hydroxy, alkoxy, alkenyl, substituted alkenyl, aminoalkyl, alkylthio, C(=O)H, acyl, amide, alkoxycarbonyl, sulfonyl, sulfonamidyl, cycloalkyl, heterocyclo, aryl, and heteroaryl;

25 R₅, R₇, and R₈ are (i) independently selected from hydrogen, alkyl, substituted alkyl, halogen, nitro, cyano, hydroxy, alkoxy, alkenyl, substituted alkenyl, aminoalkyl, alkylthio, C(=O)H, acyl, CO₂H, amide, alkoxycarbonyl, sulfonyl, sulfonamidyl, cycloalkyl, heterocyclo, aryl, and heteroaryl; or (ii) R₇ with R₈ may form a cycloalkyl or heterocyclic ring or a double bond to an oxygen atom to define a keto (=O) group; or (iii) one of R₅ or R₈ may be a bond so that there is a double bond between T and M, or between M and J,
30 respectively, so that ring A is partially unsaturated;

R₁₂, R₁₃, R₁₄ and R₁₅ (i) are selected independently of each other from hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclo; or (ii) R₁₂ is taken together with R₁₃, and/or R₁₄ is taken together with R₁₅, to form a heteroaryl or heterocyclo ring;

- 5 R_{13a} is selected from alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclo; and

p is 1 or 2.

The present invention is also directed to pharmaceutical compositions useful in treating immune or inflammatory diseases comprising compounds of formula (I), or
10 pharmaceutically-acceptable salts thereof, and pharmaceutically-acceptable carriers or diluents. The invention further relates to methods of treating immune or inflammatory diseases comprising administering to a patient in need of such treatment a therapeutically-effective amount of a compound according to formula (I).

Detailed Description of the Invention

15 The following are definitions of terms used in this specification and appended claims. The initial definition provided for a group or term herein applies to that group or term throughout the specification and claims, individually or as part of another group, unless otherwise indicated.

The term "alkyl" refers to straight or branched chain hydrocarbon groups
20 having 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms. Lower alkyl groups, that is, alkyl groups of 1 to 4 carbon atoms, are most preferred. When numbers appear in a subscript after the symbol "C", the subscript defines with more specificity the number of carbon atoms that a particular group may contain. For example, "C₁₋₆alkyl" refers to straight and branched chain alkyl groups with one to six carbon atoms, such as
25 methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, and so forth. The subscript "0" refers to a bond. Thus, the term hydroxy(C₀₋₂)alkyl or (C₀₋₂)hydroxyalkyl includes hydroxy, hydroxymethyl and hydroxyethyl.

The term "substituted alkyl" refers to an alkyl group as defined above having one, two, or three substituents selected from the group consisting of halo (*e.g.*,
30 trifluoromethyl), alkenyl, substituted alkenyl, alkynyl, nitro, cyano, oxo (=O), OR_a,

SR_a , ($=S$), $-NR_aR_b$, $-N(alkyl)_3^+$, $-NR_aSO_2$, $-NR_aSO_2R_c$, $-SO_2R_c-SO_2NR_aR_b$, $-SO_2NR_aC(=O)R_b$, SO_3H , $-PO(OH)_2$, $-C(=O)R_a$, $-CO_2R_a$, $-C(=O)NR_aR_b$, $-C(=O)(C_{1-4}alkylene)NR_aR_b$, $-C(=O)NR_a(SO_2)R_b$, $-CO_2(C_{1-4}alkylene)NR_aR_b$, $-NR_aC(=O)R_b$, $-NR_aCO_2R_b$, $-NR_a(C_{1-4}alkylene)CO_2R_b$, $=N-OH$, $=N-O-alkyl$, aryl, cycloalkyl, heterocyclo, and/or heteroaryl, wherein R_a and R_b are selected from hydrogen, alkyl, alkenyl, CO_2H , $CO_2(alkyl)$, $C_{3-7}cycloalkyl$, phenyl, benzyl, phenylethyl, naphthyl, a four to seven membered heterocyclo, or a five to six membered heteroaryl, or when attached to the same nitrogen atom may join to form a heterocyclo or heteroaryl, and R_c is selected from same groups as R_a and R_b but is not hydrogen. Each group R_a and R_b when other than hydrogen, and each R_c group optionally has up to three further substituents attached at any available carbon or nitrogen atom of R_a , R_b , and/or R_c , said substituent(s) being selected from the group consisting of $(C_{1-6}alkyl)$, $(C_{2-6}alkenyl)$, hydroxy, halogen, cyano, nitro, CF_3 , $O(C_{1-6}alkyl)$, OCF_3 , $C(=O)H$, $C(=O)(C_{1-6}alkyl)$, CO_2H , $CO_2(C_{1-6}alkyl)$, $NHCO_2(C_{1-6}alkyl)$, $-S(C_{1-6}alkyl)$, $-NH_2$, $NH(C_{1-6}alkyl)$, $N(C_{1-6}alkyl)_2$, $N(CH_3)_3^+$, $SO_2(C_{1-6}alkyl)$, $C(=O)(C_{1-4}alkylene)NH_2$, $C(=O)(C_{1-4}alkylene)NH(alkyl)$, $C(=O)(C_{1-4}alkylene)N(C_{1-4}alkyl)_2$, $C_{3-7}cycloalkyl$, phenyl, benzyl, phenylethyl, phenyloxy, benzyloxy, naphthyl, a four to seven membered heterocyclo, or a five to six membered heteroaryl. When a substituted alkyl is substituted with an aryl, heterocyclo, cycloalkyl, or heteroaryl group, said ringed systems are as defined below and thus may have zero, one, two, or three substituents, also as defined below.

One skilled in the field will understand that, when the designation "CO₂" is used herein, this is intended to refer to the group $\begin{array}{c} O \\ || \\ -C-O- \end{array}$.

When the term "alkyl" is used together with another group, such as in "arylalkyl", this conjunction defines with more specificity at least one of the substituents that the substituted alkyl will contain. For example, "arylalkyl" refers to a substituted alkyl group as defined above where at least one of the substituents is an aryl, such as benzyl. Thus, the term aryl(C₀₋₄)alkyl includes a substituted lower alkyl having at least one aryl substituent and also includes an aryl directly bonded to another group, *i.e.*, aryl(C₀)alkyl.

The term “alkenyl” refers to straight or branched chain hydrocarbon groups having 2 to 12 carbon atoms and at least one double bond. Alkenyl groups of 2 to 6 carbon atoms and having one double bond are most preferred.

The term “alkynyl” refers to straight or branched chain hydrocarbon groups having 2 to 12 carbon atoms and at least one triple bond. Alkynyl groups of 2 to 6 carbon atoms and having one triple bond are most preferred.

The term “alkylene” refers to bivalent straight or branched chain hydrocarbon groups having 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms, *e.g.*, $\{-\text{CH}_2-\}_n$, wherein n is 1 to 12, preferably 1-8. Lower alkylene groups, that is, alkylene groups of 1 to 4 carbon atoms, are most preferred. The terms “alkenylene” and “alkynylene” refer to bivalent radicals of alkenyl and alkynyl groups, respectively, as defined above.

When reference is made to a substituted alkenyl, alkynyl, alkylene, alkenylene, or alkynylene group, these groups are substituted with one to three substituents as defined above for substituted alkyl groups.

The term “heteroalkylene” is used herein to refer to saturated and unsaturated bivalent straight or branched chain hydrocarbon groups having 2 to 12 carbon atoms, preferably 2 to 8 carbon atoms, wherein one or two carbon atoms in the straight chain are replaced by heteroatom(s) selected from $-\text{O}-$, $-\text{S}-$, $-\text{S}(=\text{O})-$, $-\text{SO}_2-$, $-\text{NH}-$, and $-\text{NHSO}_2-$. Thus, the term “heteroalkylene” includes bivalent alkoxy, thioalkyl, and aminoalkyl groups, as defined below, as well as alkylene and alkenylene groups having a combination of heteroatoms in the alkyl chain. As an illustration, a “heteroalkylene” herein may comprise groups such as $-\text{S}-(\text{CH}_2)_{1-5}\text{NH}-\text{CH}_2-$, $-\text{O}-(\text{CH}_2)_{1-5}\text{S}(=\text{O})-\text{CH}_2-$, $-\text{NHSO}_2-\text{CH}_2-$, $-\text{CH}_2-\text{NH}-$, and so forth. Preferably, a heteroalkylene does not have two adjacent atoms simultaneously selected from $-\text{O}-$ and $-\text{S}-$. When a subscript is used with the term heteroalkylene, *e.g.*, as in C_{2-3} heteroalkylene, the subscript refers to the number of carbon atoms in the group in addition to heteroatoms. Thus, for example, a C_{1-2} heteroalkylene may include groups such as $-\text{NH}-\text{CH}_2-$, $-\text{CH}_2-\text{NH}-\text{CH}_2-$, $-\text{CH}_2-\text{CH}_2-\text{NH}-$, $-\text{S}-\text{CH}_2-$, $-\text{CH}_2-\text{S}-\text{CH}_2-$, $-\text{O}-\text{CH}_2-$, $\text{NH}-\text{CH}_2-$, $\text{CH}_2-\text{O}-\text{CH}_2$ and so forth.

The term “substituted heteroalkylene” refers to a heteroalkylene group as defined above wherein at least one of the nitrogen or carbon atoms in the heteroalkylene chain is bonded to (or substituted with) a group other than hydrogen. Carbon atoms in the heteroalkylene chain may be substituted with a group selected from those recited above for substituted alkyl groups, or with a further alkyl or substituted alkyl group. Nitrogen atoms of the heteroalkylene chain may be substituted with a group selected from alkyl, alkenyl, alkynyl, cyano, or $A_1-Q-A_2-R_h$, wherein A_1 is a bond, C_{1-2} alkylene, or C_{2-3} alkenylene; Q is a bond, $-C(=O)-$, $-C(=O)NR_d-$, $-C(=S)NR_d-$, $-SO_2-$, $-SO_2NR_d-$, $-CO_2-$, or $-NR_dCO_2-$; A_2 is a bond, C_{1-3} alkylene, C_{2-3} alkenylene, $-C_{1-4}$ alkylene- NR_d- , $-C_{1-4}$ alkylene- $NR_dC(=O)-$, $-C_{1-4}$ alkylene- $S-$, $-C_{1-4}$ alkylene- SO_2- , or $-C_{1-4}$ alkylene- $O-$, wherein said A_2 alkylene groups are branched or straight chain and optionally substituted as defined herein for substituted alkylene; R_h is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, heteroaryl, heterocyclo, or cycloalkyl; and R_d is selected from hydrogen, alkyl, and substituted alkyl, as defined herein, provided, however, that for a substituted heteroalkylene R_h is not hydrogen when A_1 , Q and A_2 are each bonds. When R_h is aryl, heteroaryl, cycloalkyl, or heterocyclo, these rings are, in turn, optionally substituted with one to three groups as defined below in the definitions for these terms.

The term “alkoxy” refers to an alkyl or substituted alkyl group as defined above having one or two oxygen atoms ($-O-$) in the alkyl chain. For example, the term “alkoxy” includes the groups $-O-C_{1-12}$ alkyl, $-(C_{1-6}$ alkylene)- $O-C_{1-6}$ alkyl, $-(C_{1-4}$ alkylene- $O-C_{1-4}$ alkylene)- $O-C_{1-4}$ alkyl, and so forth.

The term “thioalkyl” or “alkylthio” refers to an alkyl or substituted alkyl group as defined having one or two sulfur atoms in the alkyl chain. For example, the term “thioalkyl” or “alkylthio” includes the groups $-S-C_{1-12}$ alkyl, $-(S-C_{1-6}$ alkylene)- $S-C_{1-6}$ alkyl, and so forth.

The terms “aminoalkyl” or “alkylamino” refer to an alkyl or substituted alkyl group as defined above having one or two nitrogen ($-NR-$) atoms in the alkyl chain. For example, the term “aminoalkyl” includes the groups $-NR-C_{1-12}$ alkyl, $-NR-C_{1-6}$ alkylene- $NR-C_{1-6}$ alkyl, etc. (where R is preferably hydrogen but may include alkyl or

substituted alkyl as defined above.) When a subscript is used with reference to an alkoxy, thioalkyl or aminoalkyl, the subscript refers to the number of carbon atoms that the group may contain in addition to heteroatoms. Thus, for example, monovalent C₁₋₂aminoalkyl includes the groups -CH₂-NH₂, -NH-CH₃, -(CH₂)₂-NH₂, -NH-CH₂-
 5 CH₃, -CH₂-NH₂-CH₃, and -N-(CH₃)₂. A lower aminoalkyl comprises an aminoalkyl having one to four carbon atoms. "Amino" refers to the group NH₂.

The alkoxy, thioalkyl, or aminoalkyl groups may be monovalent or bivalent. By "monovalent" it is meant that the group has a valency (*i.e.*, ability to combine with another group), of one, and by "bivalent" it is meant that the group has a valency of
 10 two. Thus, for example, a monovalent alkoxy includes groups such as -O-C₁₋₁₂alkyl, -C₁₋₆alkylene-O-C₁₋₆alkyl, -C₁₋₄alkylene-O-C₁₋₄alkylene-O-C₁₋₄alkyl, whereas a bivalent alkoxy includes groups such as -O-C₁₋₁₂alkylene-, -C₁₋₆alkylene-O-C₁₋₆alkylene-, -C₁₋₄alkylene-O-C₁₋₄alkylene-O-C₁₋₄alkylene-, and so forth.

It should be understood that the selections for alkoxy, thioalkyl, and
 15 aminoalkyl will be made by one skilled in the field to provide stable compounds. Thus, for example, in compounds of formula (I), when G is attached to a nitrogen atom (N*) of ring A and is selected from an alkoxy or alkylthio group, the alkoxy and alkylthio groups will have at least one carbon atom bonded directly to ring A (at N*), with the oxygen or sulfur atoms being at least one atom away from said nitrogen
 20 atom.

The term "acyl" refers to a carbonyl group linked to an organic radical, more particularly, the group C(=O)R_e, as well as the bivalent groups -C(=O)- or -C(=O)R_e-, which are linked to organic radicals or ring A in compounds of formula (I). The group R_e can be selected from alkyl, alkenyl, alkynyl, aminoalkyl, substituted
 25 alkyl, substituted alkenyl, or substituted alkynyl, as defined herein, or when appropriate, the corresponding bivalent group, *e.g.*, alkylene, alkenylene, etc. Accordingly, in compounds of formula (I), when it is recited that G can be "acyl," this is intended to encompass a selection for G of -C(=O)- and also the groups -C(=O)R_e- or -R_eC(=O)-, wherein in this instance, the group R_e will be selected
 30 from bivalent groups, *e.g.*, alkylene, alkenylene, alkynylene, bivalent aminoalkyl, substituted alkylene, substituted alkenylene, or substituted alkynylene.

The term "alkoxycarbonyl" refers to a carboxy group ($\text{—}\overset{\text{O}}{\underset{\text{||}}{\text{C}}}\text{—O—}$ or $\text{—O—}\overset{\text{O}}{\underset{\text{||}}{\text{C}}}\text{—}$) linked to an organic radical (CO_2R_e), as well as the bivalent groups $\text{—CO}_2\text{—}$, $\text{—CO}_2\text{R}_e\text{—}$ which are linked to organic radicals in compounds of formula (I), wherein R_e is as defined above for acyl. The organic radical to which the carboxy group is attached may be monovalent (*e.g.*, $\text{—CO}_2\text{—alkyl}$ or —OC(=O)alkyl), or bivalent (*e.g.*, $\text{—CO}_2\text{—alkylene}$, —OC(=O)alkylene , etc.) Accordingly, in compounds of formula (I), when it is recited that G can be "alkoxycarbonyl," this is intended to encompass a selection for G of $\text{—CO}_2\text{—}$ and also the groups $\text{—CO}_2\text{R}_e\text{—}$ or $\text{—R}_e\text{CO}_2\text{—}$, wherein in this instance, the group R_e will be selected from bivalent groups, *e.g.*, alkylene, alkenylene, alkynylene, bivalent aminoalkyl, substituted alkylene, substituted alkenylene, or substituted alkynylene.

The term "amide" or "amidyl" refers to the group $\text{C(=O)NR}_a\text{R}_b$, wherein the groups R_a and R_b are defined as recited above in the definition for substituted alkyl groups.


The term "sulfonyl" refers to a sulphoxide group linked to an organic radical in compounds of formula (I), more particularly, the monovalent group $\text{S(O)}_{1-2}\text{—R}_e$, or the bivalent group $\text{—S(O)}_{1-2}\text{—}$ linked to organic radicals in compounds of formula (I). Accordingly, in compounds of formula (I), when it is recited that G can be "sulfonyl," this is intended to encompass a selection for G of —S(=O)— or $\text{—SO}_2\text{—}$ as well as the groups $\text{—S(=O)R}_e\text{—}$, $\text{—R}_e\text{S(=O)—}$, $\text{—SO}_2\text{R}_e\text{—}$, or $\text{—R}_e\text{SO}_2\text{—}$, wherein in this instance, the group R_e will be selected from those recited above for acyl and alkoxycarbonyl groups.



The term "sulfonamidyl" refers to the group $\text{—S(O)}_2\text{NR}_a\text{R}_b$, wherein R_a and R_b are as defined above for substituted alkyl groups. Additionally, the sulfonamidyl group may be bivalent, in which case one of the groups R_a and R_b will be a bond. Thus, in compounds of formula (I), when it is stated that G may be sulfonamidyl, it is intended to mean that G is a group $\text{—S(O)}_2\text{NR}_a\text{—}$.

The term "cycloalkyl" refers to fully saturated and partially unsaturated hydrocarbon rings of 3 to 9, preferably 3 to 7 carbon atoms. The term "cycloalkyl" includes such rings having zero, one, two, or three substituents selected from the

group consisting of halogen, trifluoromethyl, trifluoromethoxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, nitro, cyano, oxo (=O), OR_a, SR_a, (=S), -NR_aR_b, -N(alkyl)₃⁺, -NR_aSO₂, -NR_aSO₂R_c, -SO₂R_c-SO₂NR_aR_b, -SO₂NR_aC(=O)R_b, SO₃H, -PO(OH)₂, -C(=O)R_a, -CO₂R_a, -C(=O)NR_aR_b, -C(=O)(C₁₋₄alkylene)NR_aR_b, -C(=O)NR_a(SO₂)R_b, -CO₂(C₁₋₄alkylene)NR_aR_b, -NR_aC(=O)R_b, -NR_aCO₂R_b, -NR_a(C₁₋₄alkylene)CO₂R_b, =N-OH, =N-O-alkyl, aryl, cycloalkyl, heterocyclo, and/or heteroaryl, wherein R_a, R_b and R_c are as defined above for substituted alkyl groups, and are also in turn optionally substituted as recited above in the definition for substituted alkyl groups. The term "cycloalkyl" also includes such rings having a second ring fused thereto (*e.g.*, including benzo, heterocyclo, or heteroaryl rings) or having a carbon-carbon bridge of 3 to 4 carbon atoms. When a cycloalkyl is substituted with a further ring (or has a second ring fused thereto), said ring in turn is optionally substituted with one to two of (C₁₋₄)alkyl, (C₂₋₄)alkenyl, halogen, hydroxy, cyano, nitro, CF₃, O(C₁₋₄alkyl), OCF₃, C(=O)H, C(=O)(C₁₋₄alkyl), CO₂H, CO₂(C₁₋₄alkyl), NHCO₂(C₁₋₄alkyl), -S(C₁₋₄alkyl), -NH₂, NH(C₁₋₄alkyl), N(C₁₋₄alkyl)₂, N(C₁₋₄alkyl)₃⁺, SO₂(C₁₋₄alkyl), C(=O)(C₁₋₄alkylene)NH₂, C(=O)(C₁₋₄alkylene)NH(alkyl), and/or C(=O)(C₁₋₄alkylene)N(C₁₋₄alkyl)₂.

Accordingly, in compounds of formula (I), the term "cycloalkyl" includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, etc., as well as the following ring systems,



cyclobutyl, cyclopentyl, cyclohexyl,  and .


The term “halo” or “halogen” refers to chloro, bromo, fluoro and iodo.


The term “haloalkyl” means a substituted alkyl having one or more halo substituents. For example, “haloalkyl” includes mono, bi, and trifluoromethyl.

The term “haloalkoxy” means an alkoxy group having one or more halo substituents. For example, “haloalkoxy” includes OCF₃.

The term “aryl” refers to phenyl, biphenyl, 1-naphthyl and 2-naphthyl. The term “aryl” includes such rings having zero, one, two or three substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, nitro, cyano, OR_a, SR_a, (=S), -NR_aR_b, -N(alkyl)₃⁺, -NR_aSO₂, -NR_aSO₂R_c, -SO₂R_c, -SO₂NR_aR_b, -SO₂NR_aC(=O)R_b, SO₃H, -PO(OH)₂, -C(=O)R_a, -CO₂R_a, -C(=O)NR_aR_b, -C(=O)(C₁₋₄alkylene)NR_aR_b, -C(=O)NR_a(SO₂)R_b, -CO₂(C₁₋₄alkylene)NR_aR_b, -NR_aC(=O)R_b, -NR_aCO₂R_b, -NR_a(C₁₋₄alkylene)CO₂R_b, aryl, cycloalkyl, heterocyclo, and/or heteroaryl, wherein R_a, R_b and R_c are as defined above for substituted alkyl groups, and are also in turn optionally substituted as recited above. Additionally, two substituents attached to an aryl, particularly a phenyl group, may join to form a further ring such as a fused or spiro-ring, *e.g.*, cyclopentyl or cyclohexyl, or fused heterocyclo or heteroaryl. When an aryl is substituted with a further ring (or has a second ring fused thereto), said ring in turn is optionally substituted with one to two of (C₁₋₄)alkyl, (C₂₋₄)alkenyl, halogen, hydroxy, cyano, nitro, CF₃, O(C₁₋₄alkyl), OCF₃, C(=O)H, C(=O)(C₁₋₄alkyl), CO₂H, CO₂(C₁₋₄alkyl), NHCO₂(C₁₋₄alkyl), -S(C₁₋₄alkyl), -NH₂, NH(C₁₋₄alkyl), N(C₁₋₄alkyl)₂, N(C₁₋₄alkyl)₃⁺, SO₂(C₁₋₄alkyl), C(=O)(C₁₋₄alkylene)NH₂, C(=O)(C₁₋₄alkylene)NH(alkyl), and/or C(=O)(C₁₋₄alkylene)N(C₁₋₄alkyl)₂.

Thus, examples of aryl groups include:





, and the like, which optionally may be substituted at any available carbon or nitrogen atom. A preferred aryl group is optionally-substituted phenyl.


The terms “heterocyclo” or “heterocyclic” refers to substituted and unsubstituted non-aromatic 3 to 7 membered monocyclic groups, 7 to 11 membered bicyclic groups, and 10 to 15 membered tricyclic groups, in which at least one of the rings has at least one heteroatom (O, S or N). Each ring of the heterocyclo group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less, and further provided that the ring contains at least one carbon atom.

The fused rings completing bicyclic and tricyclic groups may contain only carbon atoms and may be saturated, partially saturated, or unsaturated. The nitrogen and sulfur atoms may optionally be oxidized and the nitrogen atoms may optionally be quaternized. The heterocyclo group may be attached at any available nitrogen or carbon atom. The heterocyclo ring may contain zero, one, two or three substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, nitro, cyano, oxo (=O), OR_a, SR_a, (=S), -NR_aR_b, -N(alkyl)₃⁺, -NR_aSO₂, -NR_aSO₂R_c, -SO₂R_c -SO₂NR_aR_b, -SO₂NR_aC(=O)R_b, SO₃H, -PO(OH)₂, -C(=O)R_a, -CO₂R_a, -C(=O)NR_aR_b, -C(=O)(C₁₋₄alkylene)NR_aR_b, -C(=O)NR_a(SO₂)R_b, -CO₂(C₁₋₄alkylene)NR_aR_b, -NR_aC(=O)R_b, -NR_aCO₂R_b, -NR_a(C₁₋₄alkylene)CO₂R_b, =N-OH, =N-O-alkyl, aryl, cycloalkyl, heterocyclo, and/or heteroaryl, wherein R_a, R_b and R_c are as defined above for substituted alkyl groups, and are also in turn optionally substituted as recited above. When a heterocyclo is substituted with a further ring, said ring in turn is optionally substituted with one to two of (C₁₋₄)alkyl, (C₂₋₄)alkenyl, halogen, hydroxy, cyano, nitro, CF₃, O(C₁₋₄alkyl), OCF₃, C(=O)H, C(=O)(C₁₋₄alkyl), CO₂H, CO₂(C₁₋₄alkyl), NHCO₂(C₁₋₄alkyl), -S(C₁₋₄alkyl), -NH₂, NH(C₁₋₄alkyl), N(C₁₋₄alkyl)₂, N(C₁₋₄alkyl)₃⁺, SO₂(C₁₋₄alkyl), C(=O)(C₁₋₄alkylene)NH₂, C(=O)(C₁₋₄alkylene)NH(alkyl), and/or C(=O)(C₁₋₄alkylene)N(C₁₋₄alkyl)₂.

Exemplary monocyclic groups include azetidiny, pyrrolidiny, oxetany, imidazolinyl, oxazolidinyl, isoxazolinyl, thiazolidinyl, isothiazolidinyl,

tetrahydrofuranyl, piperidyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidyl, 2-oxopyrrolodiny, 2-oxoazepinyl, azepinyl, 4-piperidonyl, tetrahydropyranyl, morpholinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, 1,3-dioxolane and tetrahydro-1,1-dioxothienyl and the like. Exemplary bicyclic
 5 heterocyclo groups include quinuclidinyl.

Preferred heterocyclo groups in compounds of formula (I) include



10 The term “heteroaryl” refers to substituted and unsubstituted aromatic 5 or 6 membered monocyclic groups, 9 or 10 membered bicyclic groups, and 11 to 14 membered tricyclic groups which have at least one heteroatom (O, S or N) in at least one of the rings. Each ring of the heteroaryl group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms
 15 provided that the total number of heteroatoms in each ring is four or less and each ring has at least one carbon atom. The fused rings completing the bicyclic and tricyclic groups may contain only carbon atoms and may be saturated, partially saturated, or unsaturated. The nitrogen and sulfur atoms may optionally be oxidized and the nitrogen atoms may optionally be quaternized. Heteroaryl groups which are bicyclic
 20 or tricyclic must include at least one fully aromatic ring but the other fused ring or rings may be aromatic or non-aromatic. The heteroaryl group may be attached at any available nitrogen or carbon atom of any ring. The heteroaryl ring system may contain zero, one, two or three substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, alkyl, substituted alkyl, alkenyl, substituted
 25 alkenyl, alkynyl, nitro, cyano, OR_a , SR_a , $(=\text{S})$, $-\text{NR}_a\text{R}_b$, $-\text{N}(\text{alkyl})_3^+$, $-\text{NR}_a\text{SO}_2$, $-\text{NR}_a\text{SO}_2\text{R}_c$, $-\text{SO}_2\text{R}_c$, $-\text{SO}_2\text{NR}_a\text{R}_b$, $-\text{SO}_2\text{NR}_a\text{C}(=\text{O})\text{R}_b$, SO_3H , $-\text{PO}(\text{OH})_2$, $-\text{C}(=\text{O})\text{R}_a$, $-\text{CO}_2\text{R}_a$, $-\text{C}(=\text{O})\text{NR}_a\text{R}_b$, $-\text{C}(=\text{O})(\text{C}_{1-4}\text{alkylene})\text{NR}_a\text{R}_b$, $-\text{C}(=\text{O})\text{NR}_a(\text{SO}_2)\text{R}_b$, $-\text{CO}_2(\text{C}_{1-4}\text{alkylene})\text{NR}_a\text{R}_b$, $-\text{NR}_a\text{C}(=\text{O})\text{R}_b$, $-\text{NR}_a\text{CO}_2\text{R}_b$, $-\text{NR}_a(\text{C}_{1-4}\text{alkylene})\text{CO}_2\text{R}_b$, aryl,


cycloalkyl, heterocyclo, and/or heteroaryl, wherein R_a , R_b and R_c are as defined above for substituted alkyl groups, and are also in turn optionally substituted as recited above. When a heteroaryl is substituted with a further ring, said ring in turn is optionally substituted with one to two of (C₁₋₄)alkyl, (C₂₋₄)alkenyl, halogen, hydroxy, cyano, nitro, CF₃, O(C₁₋₄alkyl), OCF₃, C(=O)H, C(=O)(C₁₋₄alkyl), CO₂H, CO₂(C₁₋₄alkyl), NHCO₂(C₁₋₄alkyl), -S(C₁₋₄alkyl), -NH₂, NH(C₁₋₄alkyl), N(C₁₋₄alkyl)₂, N(C₁₋₄alkyl)₃⁺, SO₂(C₁₋₄alkyl), C(=O)(C₁₋₄alkylene)NH₂, C(=O)(C₁₋₄alkylene)NH(alkyl), and/or C(=O)(C₁₋₄alkylene)N(C₁₋₄alkyl)₂.

Exemplary monocyclic heteroaryl groups include pyrrolyl, pyrazolyl, pyrazolinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furanyl, thienyl, oxadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl and the like.

Exemplary bicyclic heteroaryl groups include indolyl, benzothiazolyl, benzodioxolyl, benzoxazolyl, benzothieryl, quinolyl, tetrahydroisoquinolyl, isoquinolyl, benzimidazolyl, benzopyranyl, indoliziny, benzofuranyl, chromonyl, coumarinyl, benzopyranyl, cinnolyl, quinoxalyl, indazolyl, pyrrolopyridyl, furopyridyl, dihydroisoindolyl, tetrahydroquinolyl and the like.

Exemplary tricyclic heteroaryl groups include carbazolyl, benzidolyl, phenanthrollinyl, acridinyl, phenanthridinyl, xanthenyl and the like.

In compounds of formula (I), preferred heteroaryl groups include



optionally may be substituted at any available carbon or nitrogen atom.

Unless otherwise indicated, when reference is made to a specifically-named aryl (*e.g.*, phenyl), cycloalkyl (*e.g.*, cyclohexyl), heterocyclo (*e.g.*, pyrrolidinyl) or heteroaryl (*e.g.*, imidazolyl), unless otherwise specifically indicated the reference is intended to include rings having 0 to 3, preferably 0-2, substituents selected from those recited above for the aryl, cycloalkyl, heterocyclo and/or heteroaryl groups, as appropriate.


The term "heteroatoms" shall include oxygen, sulfur and nitrogen.

The term "carbocyclic" means a saturated or unsaturated monocyclic or bicyclic ring in which all atoms of all rings are carbon. Thus, the term includes cycloalkyl and aryl rings. The carbocyclic ring may be substituted in which case the substituents are selected from those recited above for cycloalkyl and aryl groups.


When the term "unsaturated" is used herein to refer to a ring or group, the ring or group may be fully unsaturated or partially unsaturated.


Throughout the specification, groups and substituents thereof may be chosen by one skilled in the field to provide stable moieties and compounds and compounds useful as pharmaceutically-acceptable compounds and/or intermediate compounds useful in making pharmaceutically-acceptable compounds. For example, in compounds of formula (I), below, the groups J, M, and T are selected so that no two adjacent members of the ring A (defined by J, M and T) are simultaneously selected from S and O. As a further example, J is defined as being selected from groups including heteroalkylene optionally substituted by R₉. One skilled in the field may make the appropriate selections for R₉ as substituents for the heteroalkylene to provide stable compounds.


According to the foregoing definitions, the instant invention provides compounds having the formula (Ia) or (Ib):








wherein the groups Ar, G, L, K, Z, T₁, M₁, T₂, M₂, R₂, R_{4a}, and R_{4c}, are as defined herein, and the group J may be selected from alkylene or heteroalkylene groups, including, without limitation, the following specific examples:














5






5








5






5









5






10















5



10





The compounds of formula (I) can form salts which are also within the scope of this invention. Unless otherwise indicated, reference to an inventive compound is understood to include reference to salts thereof. The term "salt(s)" denotes acidic and/or basic salts formed with inorganic and/or organic acids and bases. In addition, the term "salt(s)" may include zwitterions (inner salts), *e.g.*, when a compound of formula (I) contains both a basic moiety, such as an amine or a pyridine or imidazole ring, and an acidic moiety, such as a carboxylic acid. Pharmaceutically acceptable (*i.e.*, non-toxic, physiologically acceptable) salts are preferred, such as, for example, acceptable metal and amine salts in which the cation does not contribute significantly to the toxicity or biological activity of the salt. However, other salts may be useful, *e.g.*, in isolation or purification steps which may be employed during preparation, and thus, are contemplated within the scope of the invention. Salts of the compounds of the formula (I) may be formed, for example, by reacting a compound of the formula (I) with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.

Exemplary acid addition salts include acetates (such as those formed with acetic acid or trihaloacetic acid, for example, trifluoroacetic acid), adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, digluconates, dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides (formed with hydrochloric acid), hydrobromides (formed with hydrogen bromide), hydroiodides, 2-hydroxyethanesulfonates, lactates, maleates (formed with maleic acid), methanesulfonates (formed with methanesulfonic acid), 2-naphthalenesulfonates, nicotines, nitrates, oxalates, pectinates, persulfates, 3-phenylpropionates, phosphates, picrates, pivalates, propionates, salicylates, succinates, sulfates (such as

those formed with sulfuric acid), sulfonates (such as those mentioned herein), tartrates, thiocyanates, toluenesulfonates such as tosylates, undecanoates, and the like.

Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts; alkaline earth metal salts such as calcium and magnesium salts; barium, zinc, and aluminum salts; salts with organic bases (for
5 example, organic amines) such as trialkylamines such as triethylamine, procaine, dibenzylamine, N-benzyl- β -phenethylamine, 1-phenamine, N,N'-dibenzylethylene-diamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, dicyclohexylamine or similar pharmaceutically acceptable amines and salts with amino acids such as
10 arginine, lysine and the like. Basic nitrogen-containing groups may be quaternized with agents such as lower alkyl halides (*e.g.*, methyl, ethyl, propyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (*e.g.*, dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (*e.g.*, decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides), aralkyl halides (*e.g.*, benzyl and phenethyl bromides), and
15 others. Preferred salts include monohydrochloride, hydrogensulfate, methanesulfonate, phosphate or nitrate salts.

Prodrugs and solvates of the inventive compounds are also contemplated. The term "prodrug" denotes a compound which, upon administration to a subject, undergoes chemical conversion by metabolic or chemical processes to yield a
20 compound of the formula (I), and/or a salt and/or solvate thereof. For example, compounds containing a carboxy group can form physiologically hydrolyzable esters which serve as prodrugs by being hydrolyzed in the body to yield formula (I) compounds *per se*. Such prodrugs are preferably administered orally since hydrolysis in many instances occurs principally under the influence of the digestive enzymes.
25 Parenteral administration may be used where the ester *per se* is active, or in those instances where hydrolysis occurs in the blood. Examples of physiologically hydrolyzable esters of compounds of formula (I) include C₁₋₆alkylbenzyl, 4-methoxybenzyl, indanyl, phthalyl, methoxymethyl, C₁₋₆alkanoyloxy-C₁₋₆alkyl, *e.g.* acetoxymethyl, pivaloyloxymethyl or propionyloxymethyl, C₁₋₆alkoxycarbonyloxy-
30 C₁₋₆alkyl, *e.g.* methoxycarbonyl-oxymethyl or ethoxycarbonyloxymethyl, glycyloxymethyl, phenylglycyloxymethyl, (5-methyl-2-oxo-1,3-dioxolen-4-yl)-

methyl and other well known physiologically hydrolyzable esters used, for example, in the penicillin and cephalosporin arts. Such esters may be prepared by conventional techniques known in the art.

Compounds of the formula (I) and salts thereof may exist in their tautomeric form, in which hydrogen atoms are transposed to other parts of the molecules and the chemical bonds between the atoms of the molecules are consequently rearranged. It should be understood that the all tautomeric forms, insofar as they may exist, are included within the invention. Additionally, inventive compounds may have *trans* and *cis* isomers and may contain one or more chiral centers, therefore existing in enantiomeric and diastereomeric forms. The invention includes all such isomers, as well as mixtures of *cis* and *trans* isomers, mixtures of diastereomers and racemic mixtures of enantiomers (optical isomers). When no specific mention is made of the configuration (*cis*, *trans* or R or S) of a compound (or of an asymmetric carbon), then any one of the isomers or a mixture of more than one isomer is intended. The processes for preparation can use racemates, enantiomers or diastereomers as starting materials. When enantiomeric or diastereomeric products are prepared, they can be separated by conventional methods for example, chromatographic or fractional crystallization. The inventive compounds may be in the free or hydrate form.

Compounds of the Formula (I) may also have prodrug forms. Any compound that will be converted in vivo to provide the bioactive agent (*i.e.*, the compound for formula I) is a prodrug within the scope and spirit of the invention.

Various forms of prodrugs are well known in the art. For examples of such prodrug derivatives, see:


- a) **Design of Prodrugs**, edited by H. Bundgaard, (Elsevier, 1985) and **Methods in Enzymology**, Vol. 42, pp. 309-396, edited by K. Widder, et al. (Academic Press, 1985);
- b) **A Textbook of Drug Design and Development**, edited by Krosgaard-Larsen and H. Bundgaard, Chapter 5, "Design and Application of Prodrugs," by H. Bundgaard, pp. 113-191 (1991); and
- c) H. Bundgaard, **Advanced Drug Delivery Reviews**, Vol. 8, pp. 1-38 (1992), each of which is incorporated herein by reference.

It should further be understood that solvates (*e.g.*, hydrates) of the compounds of Formula (I) are also with the scope of the present invention. Methods of solvation are generally known in the art.

5

Preferred Compounds

Preferred compounds are those having formula (I),



including enantiomers, diastereomers, and pharmaceutically-acceptable salts, hydrates, solvates, and prodrugs thereof, in which:

L and K, taken independently, are O or S;

Z is N or CR_{4b};

G is a bond;

Ar is directly attached to T or M and is ;

15

J is -O-, -S-, -NH-, -S(=O)-, -SO₂-, -NHSO₂-, a C₁₋₃ alkylene optionally substituted with one to two R₉, or a C₂₋₃ alkenylene or C₁₋₂ heteroalkylene optionally substituted with one to two R₉;

T is T₁ when Ar is attached to T and T₂ when Ar is attached to M;

M is M₁ when Ar is attached to M and M₂ when Ar is attached to T;

20

T₁ and M₁ are selected from -N- and -CH-, and T₂ and M₂ are selected from -O-, -S-, -NH-, -S(=O)-, -SO₂-, -NHSO₂-, -C(=O)- and -CH₂-;

provided that J, M, and T are selected to define a four to six membered saturated or partially unsaturated cycloalkyl or heterocyclo ring having from 1 to 2

heteroatoms wherein no two adjacent heteroatoms of said heterocyclo ring are simultaneously selected from -O- and -S-;

R_{1a} and R_{1b} are independently selected from halogen, C_{1-4} alkyl, hydroxy, alkoxy, haloalkyl, haloalkoxy, cyano, nitro, $-CO_2H$, $-C(=O)H$, $-CO_2$ alkyl, -
 5 $C(=O)$ alkyl, $-C(=O)NH(CH_2)_rCO_2H$, $-C(=O)NH(CH_2)_rCO_2$ (alkyl), and $S(O)_2$ alkyl; or from phenyl, benzyl, phenyloxy, benzyloxy, and heteroaryl; wherein each group R_{1a} and R_{1b} in turn is optionally substituted at any available carbon or nitrogen atom with one to two of C_{1-4} alkyl, halogen, hydroxy, alkoxy, haloalkyl, haloalkoxy, cyano, nitro, $-CO_2H$, $-C(=O)H$, -
 10 CO_2 alkyl, and/or $-C(=O)$ alkyl; or alternatively, two R_{1b} groups join together with each other or one R_{1b} joins together with R_{1a} to form a fused-benzo ring;

R_2 is selected from hydrogen, alkyl, substituted alkyl, OR_{12} , $NR_{12}R_{13}$, $C(=O)R_{12}$, CO_2R_{12} , $C(=O)NR_{12}R_{13}$, $NR_{12}C(=O)R_{13}$, $NR_{12}C(=O)OR_{13}$, SR_{12} , $S(O)_pR_{13a}$, $NR_{12}SO_2R_{13a}$, $SO_2NR_{12}R_{13}$, cycloalkyl, heterocycle, aryl, and heteroaryl;

15 R_{4a} and R_{4c} are halogen, alkyl, cyano, haloalkyl, haloalkoxy, or nitro;

R_{4b} is hydrogen, halogen, alkyl, substituted alkyl, nitro, cyano, hydroxy, alkoxy, haloalkoxy, phenyloxy, $-CO_2H$, $-C(=O)H$, NH (alkyl), N (alkyl) $_2$, CO_2 alkyl, $C(=O)$ alkyl, alkylthio, $-C(=O)NH(CH_2)_rCO_2H$, $-C(=O)NH(CH_2)_rCO_2$ (alkyl), aryl, heteroaryl, or heterocycle, wherein each of the aryl, heteroaryl, and
 20 heterocycle groups are optionally substituted with one to two of halogen, C_{1-4} alkyl, OMe, CF_3 , CN, OCF_3 , CO_2H , $-C(=O)H$, CO_2 alkyl, and/or $C(=O)$ alkyl;

R_9 is $-A_1-Q-A_2-R_{16}$;

A_1 is a bond, C_{1-2} alkylene, or C_{2-3} alkenylene;

Q is a bond, $-C(=O)-$, $-C(=O)NR_{17}-$, $-C(=S)NR_{17}-$, $-SO_2-$, $-SO_2NR_{17}-$, $-CO_2-$, or -
 25 $NR_{17}CO_2-$;

A_2 is a bond, C_{1-3} alkylene, C_{2-3} alkenylene, $-C_{1-4}$ alkylene- $NR_{17}-$, $-C_{1-4}$ alkylene- $NR_{17}C(=O)-$, $-C_{1-4}$ alkylene-S-, $-C_{1-4}$ alkylene- SO_2- , or $-C_{1-4}$ alkylene-O-, wherein said A_2 alkylene groups are branched or straight chain and optionally substituted with a group selected from $-CO_2H$, $-CO_2(C_{1-4}alkyl)$, $-S(C_{1-4}alkyl)$,
 30 NH_2 , $-NH(C_{1-4}alkyl)$, or $-N(C_{1-4}alkyl)_2$;

R_{12} and R_{13} (i) are selected independently of each other from hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclo; or (ii) taken together form a heteroaryl or heterocyclo;

R_{13a} is alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclo;

- 5 R_{16} is selected from (i) hydrogen or a C_{1-8} alkyl or C_{2-8} alkenyl optionally substituted with up to three of OR_{23} , SR_{23} , $-CO_2R_{23}$, $-SO_2(alkyl)$, and/or $NR_{23a}R_{23b}$, or from (ii) phenyl, naphthyl, five to ten membered monocyclic or bicyclic heteroaryl, four to eleven membered monocyclic or bicyclic heterocyclo, and three to nine membered monocyclic or bicyclic cycloalkyl, wherein each of
- 10 said R_{16} cyclic groups in turn is optionally substituted with up to three R_{18} ;

R_{17} is selected from hydrogen, lower alkyl, and substituted lower alkyl;

- R_{18} is selected from $-(CH_2)_q$ halogen, $-(CH_2)_q$ nitro, $-(CH_2)_q$ cyano, $-(CH_2)_q$ haloalkyl, $-(CH_2)_q$ haloalkoxy, $-(CH_2)_qSR_{24}$, C_{3-7} cycloalkyl, $-SO_2R_{24}$, $-OR_{24}$, $-(CH_2)_qCO_2R_{24}$, $-(CH_2)_qNR_{24}R_{25}$, $-(CH_2)_qNHCO_2R_{24}$, $-C(=O)NH-SO_2R_{24}$, $-C(=O)(CH_2)_qNR_{24}R_{25}$, $-O(CH_2)_rNR_{24}R_{25}$, $-C(=O)R_{24}$, $-(CH_2)_qR_{24}$ and $-C_{1-4}$ alkyl or $-C_{2-4}$ alkenyl optionally substituted with CO_2R_{24} ;
- 15

R_{23} , R_{23a} , and R_{23b} are independently selected from hydrogen and alkyl;

- R_{24} is selected from hydrogen, alkyl, phenyl, benzyl, C_{3-7} cycloalkyl, five or six membered heteroaryl, and four to seven membered heterocyclo, in turn optionally substituted with one to two C_{1-4} alkyl, halogen, hydroxy, trifluoromethyl, trifluoromethoxy, $-CO_2H$, CO_2C_{1-4} alkyl, C_{1-4} alkoxy, $-S(C_{1-4}alkyl)$, amino, and/or amino C_{1-4} alkyl, provided that when R_{24} is attached to a sulfonyl group as in $-SO_2R_{24}$, then R_{24} is not hydrogen;
- 20


R_{25} is selected from hydrogen and alkyl; and

- 25 n is 0, 1, or 2;

p is 1 or 2;

q is 0, 1, 2, 3, or 4; and

r is 1, 2, 3, or 4.



In compounds of formula (I), the group Ar is preferably wherein R_{1a} is preferably halogen, cyano, haloalkyl, haloalkoxy, or optionally substituted phenyl or heteroaryl, and R_{1b} is absent or selected from halogen, C₁₋₄alkyl, hydroxy, alkoxy, haloalkyl, haloalkoxy, cyano, nitro, -CO₂H, -C(=O)H, -CO₂alkyl, -
 5 C(=O)alkyl, -C(=O)NH(CH₂)₁₋₄CO₂H, and -C(=O)NH(CH₂)₁₋₄CO₂(alkyl). Alternatively, two R_{1b} groups may join together with each other or one R_{1b} may join together with R_{1a} to form a fused benzo ring.


In compounds of formula (I), the groups R_{4a} and R_{4c} are preferably selected
 10 from halogen, alkyl, cyano, nitro, haloalkyl, haloalkyl, aryloxy, and arylthio, and more preferably, R_{4a} and R_{4c} are both chlorine.

In compounds of formula (I), the group G is preferably a bond; the groups L and K are preferably oxygen; and Z is preferably CH.
 15

In compounds of formula (I), the group T is preferably T₁ and is CH, M is preferably M₂ and is CH₂, and J is preferably an optionally-substituted C₁heteroalkylene so that A is a five-membered ring, more preferably J is a group -CH₂-NR₉- .
 20

In compounds of formula (I), the group R₂ is preferably C(=O)lower alkyl or C₁₋₆alkyl optionally substituted with CO₂H or CO₂(alkyl), more preferably R₂ is methyl.

25 Also preferred are compounds according to formula (Ic),



and pharmaceutically-acceptable salts, hydrates, and prodrugs thereof, in which:

5 L and K, taken independently, are O or S;

J is -O-, -S-, -NH-, -S(=O)-, -SO₂-, -NHSO₂-, an optionally substituted C₁₋₃alkylene, an optionally substituted C₂₋₃ alkenylene, or an optionally-substituted C₁₋₂heteroalkylene;

T₁ is -N- or -CH-;

10 R_{1a} is halogen, cyano, or optionally-substituted phenyl or heteroaryl;

R_{1b} is selected from halogen, C₁₋₄alkyl, hydroxy, alkoxy, haloalkyl, haloalkoxy, cyano, nitro, -CO₂H, -C(=O)H, -CO₂alkyl, -C(=O)alkyl, -C(=O)NH(CH₂)₁₋₄CO₂H, and -C(=O)NH(CH₂)₁₋₄CO₂(alkyl); or from phenyl, benzyl, phenyloxy, benzyloxy, and heteroaryl in turn optionally substituted with one to two of C₁₋₄alkyl, halogen, hydroxy, alkoxy, haloalkyl, haloalkoxy, cyano, nitro, -CO₂H, -C(=O)H, -CO₂alkyl, and/or -C(=O)alkyl;

15

R₂ is selected from hydrogen, alkyl, substituted alkyl, O(C₁₋₄alkyl), amino, NH(C₁₋₄alkyl), N(alkyl)₂, C(=O)H, C(=O)alkyl, CO₂(alkyl), SO₂alkyl, C₃₋₆cycloalkyl, heterocycle, aryl, and heteroaryl;

20 R_{4a} and R_{4c} are halogen, alkyl, cyano, trifluoromethyl, or nitro; and

n is 0, 1, or 2.

In compounds of formula (Ic), as immediately defined above, more preferably J is -CH₂-, -CH₂-CH(R₉)-, or -CH₂-N(R₉)-, wherein:

25 R₉ is -A₁-Q-A₂-R₁₆;

A₁ is a bond, C₁₋₂alkylene, or C₂₋₃alkenylene;

Q is a bond, -C(=O)-, -C(=O)NR₁₇-, -SO₂-, -CO₂-, or -NR₁₇CO₂-;

A₂ is a bond, C₁₋₂alkylene, C₂₋₃alkenylene, -C₁₋₄alkylene-NR₁₇-, -C₁₋₄alkylene-NR₁₇C(=O)-, -C₁₋₄alkylene-S-, -C₁₋₄alkylene-SO₂-, or -C₁₋₄alkylene-O-,

5 wherein said A₂ alkylene groups are branched or straight chain and optionally substituted with a group selected from -CO₂H, -CO₂(C₁₋₄alkyl), -S(C₁₋₄alkyl), NH₂, -NH(C₁₋₄alkyl), or -N(C₁₋₄alkyl)₂;

R₁₆ is selected from (a) hydrogen and C₁₋₆alkyl or C₂₋₆alkenyl optionally substituted with one to two of OH, O(C₁₋₄alkyl), -CO₂H, -CO₂(C₁₋₄alkyl), NH₂, -NH(C₁₋₄alkyl), and/or N(C₁₋₄alkyl)₂, or from (b) furanyl, indolyl, carbazolyl, pyrazolyl, pyrrolyl, thienyl, pyridyl, pyrimidinyl, benzofuranyl, isoxazolyl, imidazolyl, triazolyl, tetrazolyl, phenyl, piperidyl, pyrrolidinyl, pyridazinyl, C₃₋₇cycloalkyl, piperazinyl, thiazolyl, morpholinyl, 1,2,5,6-tetrahydropyridyl, quinoxalinyl, benzothiazolyl, benzotriazolyl, benzodioxanyl, benzooxadiazolyl, thienopyrazolyl, tetrahydroquinolyl, and quinolyl, 15 wherein each of said cyclic R₁₆ groups in turn is optionally substituted with up to three R₁₈;

R₁₇ is selected from hydrogen, lower alkyl, and substituted lower alkyl;

R₁₈ is selected from -C₁₋₄alkyl, -S(C₁₋₄alkyl), C₃₋₇cycloalkyl, -SO₂(C₁₋₄alkyl), -O(C₁₋₄alkyl), -SO₂-phenyl, halogen, hydroxy, nitro, cyano, -(CH₂)_qCO₂H, - (CH₂)_qCO₂C₁₋₄alkyl, -(CH₂)_qNH₂, -O(CH₂)_qCO₂H, -CH=CH-CO₂H, -CH=CH-CO₂(alkyl), -(CH₂)_qNH(alkyl), -(CH₂)_qNHCO₂alkyl, -(C=O)NH-SO₂alkyl, - (CH₂)_qNH(benzyl), -(CH₂)_qN(alkyl)₂, -O(CH₂)_rN(alkyl)₂, -Obenzyl, - C(=O)(CH₂)_qNH₂, -C(=O)(CH₂)_qNH(alkyl), -C(=O)(CH₂)_qN(alkyl)₂, - O(CH₂)_rNH₂, -O(CH₂)_rNH(alkyl), -O(CH₂)_rN(alkyl)₂, -C(=O)pyridyl, -- (CH₂)_qphenyl, -(CH₂)_qpyridyl, -(CH₂)_qtriazolyl, -(CH₂)_qtetrazolyl, - (CH₂)_qimidazolyl, -(CH₂)_qpyrazolyl, -(CH₂)_qthiamorpholinyl, - (CH₂)_qmorpholinyl, -(CH₂)_qthienyl, -(CH₂)_qpyrazinyl, wherein each alkyl or cyclic group of each R₁₈ in turn is optionally substituted with one to two C₁₋₄alkyl, halogen, hydroxy, trifluoromethyl, trifluoromethoxy, -CO₂H, CO₂C₁₋₄alkyl, C₁₋₄alkoxy, -S(C₁₋₄alkyl), amino, and/or aminoC₁₋₄alkyl; 30


q is 0, 1, 2, 3, or 4; and

r is 1, 2, 3 or 4.

Further preferred are compounds as immediately defined above wherein R_9 is
 5 $-C_{1-4}$ alkylene- R_{16} , $-C(=O)R_{16}$, or $-C(=O)C_{1-4}$ alkylene- R_{16} , more preferably $-CH_2R_{16}$,
 and R_{16} is as immediately defined above, more preferably thienyl, phenyl, or pyridyl,
 optionally substituted with one to two R_{18} .

Also preferred are compounds according to formula (Id),

10



and pharmaceutically-acceptable salts, hydrates, and prodrugs thereof, in
 which

J is $-(CR_{9a}R_{9b})_x-$ or $-(CR_{9a}R_{9b})_y-NR_{9c}-(CR_{9a}R_{9b})_z-$, wherein x is 1, 2 or 3, y is 0, 1 or
 15 2, and z is 0, 1 or 2, provided that y and z together are not greater than 2;

T_1 is $-N-$ or $-CH-$;

R_{1a} is halogen, cyano, nitro, trifluoromethyl, OCF_3 , heterocyclo, or heteroaryl;

R_{1b} is hydrogen, halogen, C_{1-4} alkyl, cyano, nitro, $-CO_2H$, $-C(=O)H$, $-CO_2$ alkyl, or $-C(=O)$ alkyl;

20 R_2 is selected from hydrogen, C_{1-4} alkyl, amino, $NH(C_{1-4}$ alkyl), $N(alkyl)_2$, $C(=O)H$,
 $C(=O)C_{1-4}$ alkyl, $CO_2(C_{1-4}$ alkyl), SO_2C_{1-4} alkyl, C_{3-6} cycloalkyl, heterocycle,
 aryl, and heteroaryl, or C_{1-4} alkyl substituted with one to three of amino,
 $NH(C_{1-4}$ alkyl), $N(alkyl)_2$, $C(=O)H$, $C(=O)C_{1-4}$ alkyl, CO_2H , $CO_2(C_{1-4}$ alkyl),
 SO_2C_{1-4} alkyl, SO_3H , and/or $PO(OH)_2$;


- R_{9a} and R_{9b} at each occurrence are independently selected from hydrogen, halogen, C_{1-4} alkyl, substituted alkyl, hydroxy, alkoxy, haloalkyl, haloalkoxy, cyano, nitro, $-CO_2H$, $-C(=O)H$, $-CO_2$ alkyl, $-C(=O)$ alkyl, $-C(=O)NH(CH_2)_{1-4}CO_2H$, and/or $-C(=O)NH(CH_2)_{1-4}CO_2$ (alkyl); or R_{9a} and R_{9b} together form keto ($=O$);
- 5 R_{9c} is selected from hydrogen, C_{1-4} alkyl, substituted alkyl, hydroxy, alkoxy, haloalkyl, haloalkoxy, SO_2R_{16} , $C(=O)R_{16}$, $SO_2NR_{16}R_{17}$, CO_2R_{16} , $-C(=S)NR_{16}R_{17}$, $C(=O)C(=O)R_{16}$, $C(=O)NH(CH_2)_{1-4}CO_2H$, $-C(=O)NH(CH_2)_{1-4}CO_2$ (alkyl), phenyl, C_{3-7} cycloalkyl, and five to six membered heteroaryl or heterocyclo; and
- 10 R_{16} and R_{17} are selected from hydrogen, lower alkyl, substituted alkyl, phenyl, C_{3-7} cycloalkyl, five to six membered heteroaryl, five to six membered heterocyclo, or nine to ten membered aryl or heteroaryl, in turn optionally substituted with one to two of C_{1-4} alkyl, halogen, nitro, cyano, amino, C_{1-4} aminoalkyl, C_{1-4} thioalkyl, hydroxy, C_{1-4} alkoxy, $-CO_2H$, $-CO_2$ (alkyl), -
- 15 $C(=O)H$, $-C(=O)$ alkyl, $-C(=O)(CH_2)_qNH_2$, phenyl, C_{3-7} cycloalkyl, five to six membered heteroaryl, and/or five to six membered heterocyclo, provided that when R_{16} is attached to a sulfonyl group as in $-SO_2R_{16}$, then R_{16} is not hydrogen; and
- q is 0, 1 or 2.

20

In compounds of formula (Id) as defined above, preferably y is 1 or 2 and z is 0. T_1 is preferably $-CH-$, R_2 is preferably hydrogen or C_{1-4} alkyl, and R_{9a} and R_{9b} are preferably hydrogen.

- 25 Also preferred are compounds of formula (Id), as defined above, where R_{9c} is $-A_1-Q-A_2-R_{16}$, and A_1 , Q , A_2 , and R_{16} are as defined above for compounds of formula (Ic).

- According to another aspect of the invention, preferred compounds are those
- 30 having the formula (Ie),



or an enantiomer, diastereomer, or salt thereof, in which:

R_{1a} is halogen, cyano, nitro, trifluoromethyl, OCF₃, heteroaryl, or heterocyclo;

5 R_{1b} is hydrogen, halogen, C₁₋₄alkyl, cyano, nitro, -CO₂H, -C(=O)H, -CO₂alkyl, or -C(=O)alkyl;

R₂ is hydrogen or C₁₋₄alkyl;

R₉ is selected from hydrogen, C₁₋₁₀alkyl, C₂₋₁₀alkenyl, hydroxy, alkoxy, alkylthio, haloalkyl, haloalkoxy, phenyl, C₃₋₆cycloalkyl, phenyl, pyridyl, pyridazinyl, pyrimidinyl, -(CH₂)_sphenyl, -(CH₂)_stetrazolyl, -(CH₂)_spyridyl, -
 10 (CH₂)_sthienyl, -(CH₂)_scarbazolyl, -(CH₂)_sindolyl, -(CH₂)_sfuryl, -(CH₂)_squinolyl, -(CH₂)_sC₃₋₆cycloalkyl, -(CH₂)_sthiazolyl, -(CH₂)_spyrrolyl, -(CH₂)_simidazolyl, -(CH₂)_sisoxazolyl, -(CH₂)_sbenzofuryl, -(CH₂)_spyrazolyl, -C(=O)H, -C(=O)(alkyl), -C(=O)C₁₋₁₀alkyl, -C(=O)phenyl, -C(=O)piperidyl, -
 15 C(=O)morpholinyl, -C(=O)C₃₋₆cycloalkyl, -C(=O)pyrrolidinyl, -C(=O)quinolyl, -C(=O)imidazolyl, -C(=O)pyrazolyl, -C(=O)thiazolyl, -C(=O)quinoxaliny, -C(=O)pyridyl, -C(=O)-1,2,5,6-tetrahydropyridyl, -C(=O)benzothiazolyl, -C(=O)benzotriazolyl, -C(=O)benzodioxanyl, -C(=O)benzooxadiazolyl, -C(=O)1,2,3,4-tetrahydroquinolyl, -
 20 C(=O)thienopyrazolyl, -C(=O)(CH₂)_stetrazolyl, -C(=O)(CH₂)_spyridyl, -C(=O)(CH₂)_sphenyl, -C(=O)(CH₂)_spyrrolidinyl, -C(=O)(CH₂)_spiperidyl, -C(=O)CH=CH(phenyl), -C(=O)CH=CH(pyridyl), -C(=O)CH₂O(alkyl), -C(=O)CH₂S(alkyl), -C(=O)CH₂S(pyridyl), -C(=O)CH₂SO₂(alkyl), -C(=O)CH₂SO₂(phenyl), -C(=O)CH₂NH(phenyl), -C(=O)CH₂NH(benzyl), -
 25 C(=O)CH₂NH(thiazolyl), -C(=O)CH₂NHC(=O)pyridyl, -C(=O)CH₂NHC(=O)phenyl, -(CH₂)_iSO₂(alkyl), -(CH₂)_iSO₂(phenyl), -

(CH₂)_tSO₂(thienyl), -(CH₂)_tSO₂(imidazolyl), -(CH₂)_tSO₂(furyl),
 (CH₂)_tSO₂(pyrrolyl), SO₂NH(phenyl), -C(=S)NH₂, -C(=S)NH(alkyl), -
 C(=S)NH(phenyl), -(CH₂)C(=O)pyrrolidinyl, -(CH₂)C(=O)piperidyl, -
 (CH₂)C(=O)piperazinyl, -CO₂(alkyl), -CO₂(phenyl), -CO₂(benzyl), -
 5 NHCO₂(alkyl), -(CH₂)_tC(=O)NH(phenyl), -(CH₂)_tC(=O)NH(piperidyl), -
 (CH₂)_tC(=O)NH(thienyl), -(CH₂)_tC(=O)NH(thiazolyl), -(CH₂)_tC(=O)NH(C₅-
 6cycloalkyl), -(CH₂)_tC(=O)NH(benzyl), -(CH₂)_tC(=O)NH(pyrrolidinyl), -
 (CH₂)_tC(=O)NH(piperazinyl), -(CH₂)_tC(=O)NH₂, -(CH₂)_tC(=O)NH(alkyl), -
 (CH₂)_tC(=O)N(alkyl)₂, -(CH₂)_tC(=O)N(C₁₋₄alkyl)(phenyl), -
 10 (CH₂)_tC(=O)N(C₁₋₄alkyl)(thienyl), -(CH₂)_tC(=O)N(C₁₋₄alkyl)(thiazolyl), -
 (CH₂)_tC(=O)N(C₁₋₄alkyl)(benzyl), or -(CH₂)_tC(=O)N(C₁₋₄alkyl)CO₂(alkyl);

wherein each alkyl, alkenyl, or cyclic group of each R₉ in turn is optionally substituted with up to three R₁₈;

R₁₈ is selected from -C₁₋₄alkyl, -S(C₁₋₄alkyl), C₃₋₇cycloalkyl, -SO₂(C₁₋₄alkyl), -O(C₁-
 15 4alkyl), -SO₂-phenyl, halogen, hydroxy, nitro, cyano, -(CH₂)_qCO₂H, -
 (CH₂)_qCO₂C₁₋₄alkyl, -(CH₂)_qNH₂, -O(CH₂)_qCO₂H, -CH=CH-CO₂H, -CH=CH-
 CO₂(alkyl), -(CH₂)_qNH(alkyl), -(CH₂)_qNHCO₂alkyl, -(C=O)NH-SO₂alkyl, -
 (CH₂)_qNH(benzyl), -(CH₂)_qN(alkyl)₂, -O(CH₂)_rN(alkyl)₂, -Obenzyl, -
 C(=O)(CH₂)_qNH₂, -C(=O)(CH₂)_qNH(alkyl), -C(=O)(CH₂)_qN(alkyl)₂, -
 20 O(CH₂)_rNH₂, -O(CH₂)_rNH(alkyl), -O(CH₂)_rN(alkyl)₂, -C(=O)pyridyl, -
 (CH₂)_qphenyl, -(CH₂)_qpyridyl, -(CH₂)_qtriazolyl, -(CH₂)_qtetrazolyl, -
 (CH₂)_qimidazolyl, -(CH₂)_qpyrazolyl, -(CH₂)_qthiamorpholinyl, -
 (CH₂)_qmorpholinyl, -(CH₂)_qthienyl, -(CH₂)_qpyrazinyl, wherein each alkyl or
 25 cyclic group of each R₁₈ in turn is optionally substituted with one to two C₁-
 4alkyl, halogen, hydroxy, trifluoromethyl, trifluoromethoxy, -CO₂H, CO₂C₁-
 4alkyl, C₁₋₄alkoxy, -S(C₁₋₄alkyl), amino, and/or aminoC₁₋₄alkyl;

n is 0, 1 or 2;

q is 0, 1, 2, 3, or 4;

r is 1, 2, 3 or 4.


30 *s* is 1, 2, 3 or 4; and

t is 0, 1, or 2.

Methods of Preparation

The compounds of the invention may be prepared by the exemplary processes described in the following reaction Schemes A-K. Exemplary reagents and procedures for these reactions appear hereinafter. Starting materials are commercially available or can be readily prepared by one of ordinary skill in the art. For all of the schemes, the groups Z, K, L, Ar, J, T, M, R₁, R₂, R₃, R_{4a}, R_{4b}, and R_{4c}, are as described herein for a compound of formula (I), unless otherwise indicated. Groups designated generally as R, R', X, and P as well as solvents, temperatures, pressures, starting materials having the desired groups, and other reaction conditions, may be readily selected as appropriate by one of ordinary skill in the art.

Scheme A:



15


A suitably functionalized amino acid **1** is reacted with an isocyanate **2a** or an isothiocyanate **2b** in water in the presence of a base (such as NaOH, KOH, K₂CO₃, KHCO₃, Na₂CO₃ or NaHCO₃), to yield after acidification the ureidoacid **3a** or the thioureidoacid **3b**, respectively. This intermediate product is then cyclized in an

20

organic or aqueous solvent in the presence of a catalytic amount of acid (such as hydrochloric acid, sulfuric acid, methanesulfonic acid, or toluenesulfonic acid) to give the spirohydantoin having the formula (If) or spiro-2-thiohydantoin having the formula (Ig). *See, e.g.*, Espada *et al.*, Farmaco, Vol. 45 (1990), at pp. 1237-1243, or

5 Nicole *et al.*, Can. J. Chem., Vol. 40 (1962), at pp. 353-366. Alternatively, the ureido or thioureido acid can be cyclized in an organic solvent (such as DMF, THF, DCM) using a dehydrating agent (such as DCC or EDCI) in the presence of an activating agent (such as HOBT or 1-hydroxy-7-azabenzotriazole) and a non-nucleophilic base (such as TEA or DIPEA).

10 **Scheme B:**




Compounds having the formula (If) or (Ig) can also be obtained in one step as depicted in Scheme B. Reaction of a suitably functionalized amino ester **4** with an

15 isocyanate **2a** or isothiocyanate **2b** in an organic solvent (such as THF, methylene chloride or DMF) in the presence of a base (such as TEA, K_2CO_3 or KOH), yields the desired compound having the formula (If) or (Ig) respectively. *See, e.g.*, Park *et al.* J. Org. Chem., Vol. 63 (1998), at pp. 113-117; Johnson *et al.*, J. Am. Chem. Soc., Vol. 40 (1918), at p. 645; and Schöllkopf *et al.*, Liebigs Ann. Chem., (1981), at pp 439-


20 458.

Scheme C:




Treatment of hydantoins (If) with a reagent such as P_2S_5 or 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide (Lawesson's reagent) in an organic solvent such as toluene or dioxane, yields the corresponding dithio-hydantoins having the formula (Ih). See, e.g., Carrington *et al.*, *J. Chem. Soc.*, (1950), at p. 354.

Scheme D:




Dithio-hydantoins (Ii) can be converted into 4-thio-hydantoins by S-alkylating compounds (Ii) with a reagent such as methyl iodide to give intermediate 5, which is hydrolyzed under mild acidic conditions to the 4-thio-hydantoins having the formula (Ij). See, e.g., Carrington *et al.*, *J. Chem. Soc.*, (1950), at p. 354.


Scheme E:




N-acylation of hydantoins having the formula (Ik) can be obtained by treatment with an acylating agent (such as an acyl chloride, an anhydride, a chloroformate or an isocyanate) in an organic solvent (such as THF or acetonitrile) in the presence of a base (such as TEA, DIPEA, DMAP or NaH) to give hydantoins having the formula (II). See, e.g., Link *et al.*, *Eur. J. Med. Chem.*, Vol. 19 (1984), at pp. 261-266, and Ortin *et al.*, *An. R. Soc. Esp. Fis. Quim. Ser.B*, (1958), at p. 69.

Scheme F:

Sulfonylation of hydantoin having the formula (Ik) is obtained by treatment with a sulfonyl chloride in the presence of a base (such as TEA, DIPEA, pyridine or DMAP) in an organic solvent such as toluene to give the desired compounds having the formula (Im). *See, e.g., Takayama et al., Agric. Biol. Chem., Vol. 51 (1987), at pp. 1547-1552.*


Scheme G:

Hydantoin having the formula (Ik) can be *N*-alkylated in an aprotic solvent (such as DMF, THF or DMSO) by treatment with one equivalent of a base (such as NaH, NaHMDS, LDA, LiHMDS, KH, KHMDS or *t*BuOK) followed by addition of a suitable alkylating agent (such as an alkyl iodide, alkyl bromide, alkyl chloride, a tosylate or a mesylate) to yield hydantoin having the formula (In). *See, e.g., Parmee et al., Bioorg. Med. Chem. Lett., Vol. 9 (1999), at pp. 749-754.*

Scheme H:

Spiro hydantoin can also be prepared as depicted in Scheme H. Hydantoin **6** is treated either sequentially or directly with two equivalents of a base (such as NaH, KH, LiHMDS, KHMDS, LDA, tBuOK, KOH, methylmagnesium carbonate or DBU) in an organic solvent (such as THF, DMF, DMSO) and reacted with compound **7** bearing two leaving groups X (such as Cl, Br, I, OMs or OTs) to yield the desired hydantoin having the formula (I). *See, e.g., Collado et al., Tetrahedron Lett., Vol. 37 (1996), at pp. 6193-6196; Fujiwara et al., J. Chem. Soc. Perkin Trans. 2, (1980), at pp. 1573-1577; and Belzecki et al., J. Org. Chem., Vol. 45 (1980), at pp. 2215-2217.*

Scheme I:




10

N-unsubstituted hydantoin having the formula (Ip) can be prepared using the same or similar procedure as for Scheme H, with the addition of a protection/deprotection sequence. Thus hydantoin **8** is protected on the nitrogen with a protecting group P, such as BOC (*see, e.g., Nilsson et al., J. Med. Chem., Vol. 35 (1992), at pp. 3270-3279*) to give the intermediate **9**, which is dialkylated as previously with **7** to yield the compound having the formula (Io). Deprotection gives the desired N-unsubstituted spirohydantoin having the formula (Ip).

15


Scheme J:




20

Bromo spiro hydantoin having the formula (Iq) can be transformed into biaryl compounds having the formula (Ir) by reaction with an aromatic or heteroaromatic boronic acid **10** in the presence of a palladium catalyst (such as Pd(PPh₃)₄) and a base (such as K₂CO₃ or Na₂CO₃) in an appropriate solvent (such as toluene, DMF, DME or water), under conventional Suzuki coupling conditions. *See, e.g., Suzuki et al., Synth. Commun.*, Vol. 11 (1981), at p. 513.


Scheme K:



Hydantoin **9** can be submitted to a Knoevenagel condensation with an aromatic aldehyde **10** under classical conditions (*e.g.*, sodium acetate in refluxing acetic anhydride) to obtain **11**, which is reacted with amine **12** under acidic catalysis (such as trifluoroacetic acid) to yield spiropyrrolo hydantoin having the formula (Is).


Scheme L:

Hydantoins (It) can be debenzylated using, for example, 1-chloroethyl
 5 chloroformate in a solvent such as DCM or DCE, to yield the NH derivatives having
 the formula (Iu). Compounds of formula (Iu) can be alkylated by reaction with an
 alkyl halide RX (*e.g.*, an alkyl iodide), in a solvent such as acetonitrile or acetone at
 temperature ranging from room temperature to reflux. Alternatively, alkylation can be
 achieved by reaction with an aldehyde in the presence of a reducing agent such as
 10 sodium triacetoxo borohydride or sodium cyanoborohydride in a solvent such as
 acetonitrile or DCE to yield compounds of formula (Iv).

Scheme M:


Compounds of formula (Iu) can also be acylated with an acyl halide (for example, an acyl chloride or acyl bromide) in the presence of an organic base (such as triethylamine or diisopropylethylamine) or an inorganic base (such as sodium carbonate) in a solvent such as DCM at a temperature ranging from -15°C to room temperature to yield acylated derivatives of formula (Iw). Compounds (Iw) can also be obtained by reaction with an acid RCO_2H in the presence of a coupling agent such as dicyclohexylcarbodiimide in a solvent such as DCM.

Scheme N:




10

Sulfonamides of formula (Ix) can be obtained from compounds of formula (Iu) by reaction with a sulfonyl halide in the presence of a base (such as triethylamine or sodium carbonate) in a solvent such as DCM or THF at temperature ranging from -15°C to room temperature.

Scheme O:

Compounds of formula (Iu) can also be transformed into the activated
 5 intermediates **13** by sequential reaction with carbonyl diimidazole and methyl iodide.
See R. A. Batey et al. Tetrahedron Lett., Vol. 39 (1998), at p. 6267. Compounds **13**
 can then be reacted with either an alcohol or an amine to give carbamates of formula
 (Iy) or ureas of formula (Iz), respectively.

Scheme P:

5 Compounds of formula (Iu) can be transformed into intermediates **14** by reaction with di *tert*-butyl dicarbonate in a solvent such as THF or DCM. Oxidation of **14** with, for example, sodium periodate in the presence of ruthenium oxide then gives a mixture of lactones **15** and **16**, which can be transformed under standard conditions into compounds of formula (Iaa) and (Iab).

10

Utility

The compounds and compositions of this invention are antagonists and/or inhibitors of LFA-1, Mac-1, and/or ICAMs. They are useful in treating various inflammatory diseases and disorders associated with the action of LFA-1, Mac-1, and/or ICAMs, particularly LFA-1:ICAM-1. The term "Leukointegrin/ICAM-associated condition" is used herein for ease of reference to refer to those diseases or

disorders that are associated with the action or levels of LFA-1, Mac-1 and/or ICAM-1, ICAM-2, or ICAM-3. As used herein, the term "treating" includes prophylactic and therapeutic uses and thus includes the alleviation of symptoms of a

Leukointegrin/ICAM-associated condition in a patient, the improvement of an

5 ascertainable measurement associated with such a condition, or the prevention of such a condition or its symptoms. The term "patient" refers to a mammal, preferably a human.

In view of their inhibition activity, the compounds may be used to treat conditions involving the activation, co-stimulation, or infiltration of T-cells and/or

10 leukocytes, including without limitation conditions involving the influx of leukocytes in the skin, peritoneum, synovium, lung, kidney, and heart. The inventive compounds may be used to treat conditions resulting from a response of the specific or non-specific immune system in a patient.

Leukointegrin/ICAM-associated conditions that may be treated with the

15 inventive compounds include acute or chronic graft vs host reactions (*e.g.*, pancreatic islet allograft); and acute or chronic transplant rejection (*e.g.*, kidney, liver, heart, lung, pancreas, bone marrow, cornea, small bowel, skin allografts, skin homografts, heterografts, and/or cells derived from such organs). Additionally, the compounds may be used to treat inflammatory conditions including, but not limited to, multiple
20 sclerosis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, osteoporosis, diabetes (*e.g.*, insulin dependent diabetes mellitus or juvenile onset diabetes), cystic fibrosis, inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, ulcerative colitis, Alzheimer's disease, shock, ankylosing spondylitis, gastritis, conjunctivitis, pancreatitis (acute or chronic), multiple organ injury syndrome (*e.g.*, secondary to
25 septicemia or trauma), myocardial infarction, atherosclerosis, stroke, reperfusion injury (*e.g.*, due to cardiopulmonary bypass or kidney dialysis), acute glomerulonephritis, vasculitis, thermal injury (*i.e.*, sunburn), necrotizing enterocolitis, granulocyte transfusion associated syndrome, and/or Sjogren's syndrome.

The inventive compounds may be used to treat inflammatory conditions of the
30 skin including eczema, atopic dermatitis, contact dermatitis, urticaria, scleroderma, psoriasis, and dermatosis with acute inflammatory components.

The compounds also may also be used to treat allergies and respiratory conditions, including asthma, pulmonary fibrosis, allergic rhinitis, oxygen toxicity, emphysema, chronic bronchitis, acute respiratory distress syndrome, and any chronic obstructive pulmonary disease (COPD). The compounds may be used to treat chronic hepatitis infection, including hepatitis B and hepatitis C.

Additionally, the compounds of the invention may be used to treat autoimmune diseases and/or inflammation associated with autoimmune diseases such as organ-tissue autoimmune diseases (*e.g.*, Raynaud's syndrome), autoimmune thyroiditis, uveitis, systemic lupus erythematosus, Addison's disease, autoimmune polyglandular disease (also known as autoimmune polyglandular syndrome), and Grave's disease.

The compounds of this invention also may be used to treat metastases or as an adjunct to minimize toxicity with cytokine therapy in the treatment of cancers.

The compounds of this invention further have utility in treating hypogonadism, frailty, sexual dysfunction, wasting, such as wasting syndromes associated with cancer and AIDS, and anemia. The compounds further have utility in treating cancers, including but not limited to cancers of the breast, brain, skin, ovary, endometrium, bladder, prostate, lung, colon, lymphatic system, liver and kidney. The inventive compounds are useful for conditions such as hirsutism, acne, seborrhea, alopecia, fibroids, hyperpilosity, cachexia, polycystic ovarian syndrome, anorexia, contraception, drug withdrawal syndrome, pregnancy termination, and benign prostate hypertrophy. The compounds are further useful as antiangiogenic agents. Additionally, the compounds may be useful as inhibitors of protein prenyltransferases, particularly farnesyltransferase and the prenylation of the oncogene protein Ras. As such, the inventive compounds may potentially be useful for treating and/or preventing the diseases and disorders referred to in WO 01/45704, incorporated herein by reference.

When used as anti-inflammatory agents, the compounds may be administered prior to the onset of, at, or after the initiation of inflammation. When used prophylactically, the compounds are preferably provided in advance of any inflammatory response or symptom (for example, prior to, at, or shortly after the time

of an organ or tissue transplant but in advance of any symptoms of organ rejection). Administration of the compounds may prevent or attenuate inflammatory responses or symptoms.

The present invention thus provides methods for treating such conditions as those listed above, comprising administering to a patient in need thereof an effective amount of at least one compound of formula (I) or a salt thereof. Other therapeutic agents such as those described below may be employed in combination with the compounds of formula (I). In the methods of the present invention, such other therapeutic agent(s) may be administered prior to, simultaneously with, or following the administration of the inventive compounds.

The present invention also provides pharmaceutical compositions capable of treating the above-referenced diseases and disorders. The inventive compositions may contain other therapeutic agents and may be formulated, for example, by employing conventional solid or liquid vehicles or diluents, as well as pharmaceutical additives of a type appropriate to the mode of desired administration (for example, excipients, binders, preservatives, stabilizers, flavors, etc.), according to techniques such as those well known in the art of pharmaceutical formulation.

The compounds of formula (I) may be administered by any means suitable for the condition to be treated, which may depend on the need for site-specific treatment or quantity of drug to be delivered. Topical administration is generally preferred for skin-related diseases, and systematic treatment preferred for cancerous or pre-cancerous conditions, although other modes of delivery are contemplated. For example, the compounds may be delivered orally, such as in the form of tablets, capsules, granules, powders, or liquid formulations including syrups; topically, such as in the form of solutions, suspensions, gels or ointments; sublingually; buccally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intrasternal injection or infusion techniques (*e.g.*, as sterile injectable aqueous or non-aqueous solutions or suspensions); nasally such as by inhalation spray; topically, such as in the form of a cream or ointment; rectally such as in the form of suppositories; or liposomally. Dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents may be administered. The compounds may be administered in a form suitable for immediate release or extended release. Immediate

release or extended release may be achieved with suitable pharmaceutical compositions or particularly in the case of extended release, with devices such as subcutaneous implants or osmotic pumps.

Exemplary compositions for topical administration include a topical carrier
5 such as PLASTIBASE® (mineral oil gelled with polyethylene).

Exemplary compositions for oral administration include suspensions which may contain, for example, microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents such as those known in the art; and immediate release
10 tablets which may contain, for example, microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and/or lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants such as those known in the art. The inventive compounds may also be orally delivered by sublingual and/or buccal administration, *e.g.*, with molded, compressed, or freeze-dried tablets. Exemplary
15 compositions may include fast-dissolving diluents such as mannitol, lactose, sucrose, and/or cyclodextrins. Also included in such formulations may be high molecular weight excipients such as celluloses (AVICEL®) or polyethylene glycols (PEG); an excipient to aid mucosal adhesion such as hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), sodium carboxymethyl cellulose (SCMC),
20 and/or maleic anhydride copolymer (*e.g.*, GANTREZ®); and agents to control release such as polyacrylic copolymer (*e.g.*, CARBOPOL 934®). Lubricants, glidants, flavors, coloring agents and stabilizers may also be added for ease of fabrication and use.

Exemplary compositions for nasal administration via aerosol or inhalation
25 include solutions which may contain, for example, benzyl alcohol or other suitable preservatives, absorption promoters to enhance absorption and/or bioavailability, and/or other solubilizing or dispersing agents such as those known in the art.

Exemplary compositions for parenteral administration include injectable solutions or suspensions which may contain, for example, suitable non-toxic,
30 parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or

wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.

Exemplary compositions for rectal administration include suppositories which may contain, for example, suitable non-irritating excipients, such as cocoa
5 butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures but liquefy and/or dissolve in the rectal cavity to release the drug.

The effective amount of a compound of the present invention may be determined by one of ordinary skill in the art, and includes exemplary dosage amounts for a patient of from about 0.05 to 100 mg/kg of body weight of active compound per
10 day, which may be administered in a single dose or in the form of individual divided doses, such as from 1 to 4 times per day. It will be understood that the specific dose level and frequency of dosage for any particular subject may be varied and will depend upon a variety of factors, including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the species,
15 age, body weight, general health, sex and diet of the subject, the mode and time of administration, rate of excretion, drug combination, and the particular condition sought to be treated and its severity. Preferred subjects for treatment include animals, most preferably mammalian species such as humans, and domestic animals such as dogs, cats, horses, and the like, subject to Leukointegrin/ICAM associated conditions
20 and/or subject to any of the above-referenced diseases and disorders.

The inventive compounds and compositions may be employed alone or in combination with each other and/or other suitable therapeutic agents useful in treating diseases and disorders referenced above, for example, where the second drug has the same or different mechanism of action than the present compounds. Exemplary of
25 such other therapeutic agents include anti-inflammatory agents, antibiotics, anti-viral agents, anti-oxidants, and agents used to treat respiratory conditions such as COPD and asthma.

Examples of suitable other anti-inflammatory agents with which the inventive compounds may be used include aspirin, cromolyn, nedocromil, theophylline,
30 zileuton, zafirlukast, montelukast, pranlukast, indomethacin, and lipoxigenase inhibitors; non-steroidal antiinflammatory drugs (NSAIDs) (such as ibuprofen and

naproxin); TNF- α inhibitors (such as tenidap and rapamycin or derivatives thereof), or TNF- α antagonists (*e.g.*, infliximab, Enbrel®, D2E7, OR1384), cytokine modulators (*e.g.* TNF-alpha converting enzyme [TACE] inhibitors, Interleukin-1 converting enzyme (ICE) inhibitors, Interleukin-1 receptor antagonists), prednisone, 5 dexamethasone, cyclooxygenase inhibitors (*i.e.*, COX-1 and/or COX-2 inhibitors such as Naproxen®, Celebrex®, or Vioxx®), CTLA4-Ig agonists/antagonists (LEA29Y), CD40 ligand antagonists, IMPDH inhibitors (such as mycophenolate [CellCept®] and VX-497), methotrexate (FK506), integrin antagonists (*e.g.*, alpha-4 beta-1, alpha-V-beta-3), cell adhesion inhibitors, interferon gamma antagonists, prostaglandin 10 synthesis inhibitors, budesonide, clofazimine, CNI-1493, CD4 antagonists (*e.g.*, priliximab), p38 mitogen-activated protein kinase inhibitors, protein tyrosine kinase (PTK) inhibitors, IKK inhibitors, therapies for the treatment of irritable bowel syndrome (*e.g.*, Zelmac®, Zelnorm®, and Maxi-K® openers such as those disclosed in U.S. Patent No. 6,184,231 B1), or NF- κ B inhibitors (such calphostin, CSAIDs, and 15 quinoxalines as disclosed in US Pat. No. 4,200,750); disassociated steroids; chemokine receptor modulators (including CCR1, CCR2, CCR3, CCR4, and CXCR2 receptor antagonists); secretory and cytosolic phospholipase A2 inhibitors, glucocorticoids, salicylates, nitric oxide, and other immunosuppressants; and nuclear translocation inhibitors, such as deoxyspergualin (DSG).

20 The inventive compounds may be used in combination with other agents used to treat respiratory conditions such as asthma, COPD, and allergic rhinitis, such as β -adrenergic agonists (such as albuterol, terbutaline, formoterol, salbutamol, salmeterol, bitolterol, pilbuterol, and fenoterol); corticosteroids (such as beclomethasone, triamcinolone, budesonide, fluticasone, flunisolide, dexamethasone, prednisone, and 25 dexamethasone); leukotriene antagonists (*e.g.*, Accolate [Zafirlukast®], and Singulair [Montelukast®]); Muscarinic M3 cholinergic antagonists (*e.g.*, Spiriva®), PDE 4 inhibitors (*e.g.* rolipram, cilomilast [Ariflo®], piclamilast, or roflumilast), histamine H₁ antagonists, Allegra® (fexofenadine), Claritin® (loratidine), and/or Clarinex® (desloratidine).

Examples of suitable antiviral agents for use with the inventive compounds include nucleoside-based inhibitors, protease-based inhibitors, and viral-assembly inhibitors.

5 Examples of suitable anti-osteoporosis agents for use in combination with the compounds of the present invention include alendronate, risedronate, PTH, PTH fragment, raloxifene, calcitonin, RANK ligand antagonists, calcium sensing receptor antagonists, TRAP inhibitors, selective estrogen receptor modulators (SERM) and AP-1 inhibitors.

10 Examples of suitable anti-oxidants for use in combination with the compounds of the present invention include lipid peroxidation inhibitors such as probucol, BO-653, Vitamin A, Vitamin E, AGI-1067, and α -lipoic acid.

The inventive compounds also may be used in combination with anti-diabetic agents, such as biguanides (*e.g.* metformin), glucosidase inhibitors (*e.g.* acarbose), insulins (including insulin secretagogues or insulin sensitizers), meglitinides (*e.g.* repaglinide), sulfonylureas (*e.g.*, glimepiride, glyburide and glipizide),
15 biguanide/glyburide combinations (*e.g.*, glucovance), thiozolidinediones (*e.g.* troglitazone, rosiglitazone and pioglitazone), PPAR-alpha agonists, PPAR-gamma agonists, PPAR alpha/gamma dual agonists, SGLT2 inhibitors, inhibitors of fatty acid binding protein (aP2) such as those disclosed in U.S. Serial No. 09/519,079 filed
20 March 6, 2000 and assigned to the present assignee, glucagon-like peptide-1 (GLP-1), glucagon phosphorylase, and dipeptidyl peptidase IV (DP4) inhibitors.

In addition, the compounds may be used with agents that increase the levels of cAMP or cGMP in cells for a therapeutic benefit. For example, the compounds of the invention may have advantageous effects when used in combination with
25 phosphodiesterase inhibitors, including PDE1 inhibitors (such as those described in Journal of Medicinal Chemistry, Vol. 40, pp. 2196-2210 [1997]), PDE2 inhibitors, PDE3 inhibitors (such as revizinone, pimobendan, or olprinone), PDE4 inhibitors (referenced above), PDE7 inhibitors, or other PDE inhibitors such as dipyridamole, cilostazol, sildenafil, denbutyline, theophylline (1,2-dimethylxanthine), ARIFLO™
30 (*i.e.*, cis-4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic

acid), arofyline, C-11294A, CDC-801, BAY-19-8004, cipamfylline, SCH351591, YM-976, PD-189659, mesiopram, pumafentrine, CDC-998, IC-485, and KW-4490.

In view of their usefulness in treating ischemia, the inventive compounds may be used in combination with agents for inhibiting F_1F_0 -ATPase, including efrapeptin, oligomycin, autovertin B, azide, and compounds described in US patent application Serial No. 60/339,108, filed December 10, 2001 and assigned to the present assignee; -alpha- or beta- adrenergic blockers (such as propranolol, nadolol, carvedilol, and prazosin), antianginal agents such as nitrates, for example, sodium nitrates, nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, and nitrovasodilators; antiarrhythmic agents including Class I agents (such as propafenone); Class II agents (propranolol); Class III agents (such as sotalol, dofetilide, amiodarone, azimilide and ibutilide); Class IV agents (such as diltiazem and verapamil); K^+ channel modulators such as I_{ACh} inhibitors and inhibitors of the K_v1 subfamily of K^+ channel openers such as I_{Kur} inhibitors (*e.g.*, compounds disclosed in U.S. Application Serial No. 09/729,731, filed December 5, 2000); and gap-junction modulators such as connexions; anticoagulant or antithrombotic agents including aspirin, warfarin, ximelagtran, low molecular weight heparins (such as lovenox, enoxaparin, and dalteparin), anti-platelet agents such as GPIIb/GPIIIa blockers, (*e.g.*, abciximab, eptifibatide, and tirofiban), thromboxane receptor antagonists (*e.g.*, ifetroban), $P2Y_1$ and $P2Y_{12}$ antagonists (*e.g.*, clopidogrel, ticlopidine, CS-747, and aspirin/clopidogrel combinations), and Factor Xa inhibitors (*e.g.*, fondaparinux); and diuretics such as sodium-hydrogen exchange inhibitors, chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromethiazide, polythiazide, benzthiazide, ethacrynic acid tricrynafene, chlorthalidone, furosemide, musolimine, bumetanide, triamtrenene, and amiloride.

The inventive compounds may also be useful in combination with antiangiogenic agents, such as compounds that are inhibitors of VEGF receptors, or in conjunction with antitumor agents such as paclitaxel, adriamycin, epithilones, cisplatin, and carboplatin. Examples of anticancer and other cytotoxic agents that may be used in combination with the inventive compounds include the following: epothilone derivatives as found in German Patent No. 4138042.8; WO 97/19086, WO 98/22461, WO 98/25929, WO 98/38192, WO 99/01124, WO 99/02224, WO

99/02514, WO 99/03848, WO 99/07692, WO 99/27890, WO 99/28324, WO
99/43653, WO 99/54330, WO 99/54318, WO 99/54319, WO 99/65913, WO
99/67252, WO 99/67253 and WO 00/00485; cyclin dependent kinase inhibitors as
found in WO 99/24416; and prenyl-protein transferase inhibitors as found in WO
5 97/30992 and WO 98/54966.

The combination of the inventive compounds with other therapeutic agents
may prove to have additive and synergistic effects. The combination may be
advantageous to increase the efficacy of the administration or decrease the dosage to
reduce possible side-effects.

10 The above other therapeutic agents, when employed in combination with
the compounds of the present invention, may be used, for example, in those amounts
indicated in the Physicians' Desk Reference (PDR) or as otherwise determined by one
of ordinary skill in the art. In the methods of the present invention, such other
therapeutic agent(s) may be administered prior to, simultaneously with, or following
15 the administration of the inventive compounds.

Compounds of formula (I), including the compounds described in the
examples hereof, have been tested in assay(s) described below and have shown a
measurable level of activity as inhibitors of LFA-1 and/or ICAM-1.

Assays

20 **H1-HeLa Adhesion assay**

H1-Hela cells were released from their growth flask using versene (Gibco,
Grand Island, NY). Following centrifugation, the cells were resuspended in growth
medium: DMEM (Gibco), 10% fetal calf serum (Hyclone, Logan, UT), 1% Pen-Strep
(Gibco), and 1% L-glutamine (Gibco) and plated for growth at 5,000 cells/well in a
25 96-well plate.

The next day, HSB-2 cells were divided to 2×10^5 /ml in growth medium: RPMI
1640 (Gibco), 10% FCS, 1% Pen-Strep, and 1% L-glutamine. The next day (day #3),
the cells were centrifuged at 534xG for 8 minutes, washed, and resuspended in HBSS
at 5×10^7 /ml. Calcein-AM, 10 μ M (Molecular Probes, Eugene, OR) and 100 nM
30 phorbol myristate acetate (SIGMA, St. Louis, MO) were added to the labeling and

activation mix. Following incubation at 37°C for 30 minutes, ten ml of HBSS was added and the cells centrifuged as above. The cell pellet was then resuspended and counted.

While the HSB-2 cells were labeling, the medium was aspirated from the H1-
5 HeLa cells and the plates washed once with HBSS, followed by the addition of 50 µl of HBSS. An additional 50 µl of HBSS containing compound solution, DMSO, or anti-CD18 antibody was then added to each well. To the H1-HeLa cells were added 200,000 HSB-2 cells/well in 100 µl, followed by incubation in the dark for 30 minutes. The wells were then washed three times to remove the unbound cells. A
10 fluorescence plate reader was then used to determine the number of bound HSB-2 cells. The percent inhibition due to the compound was calculated using the vehicle control as 0% inhibition and the antibody blocked adhesion as 100% inhibition.

HUVEC adhesion assay

On day 1, human umbilical vein endothelial cells (HUVEC) (passage 3,
15 Clonetics, San Diego, CA) were placed into a T-75 flask containing EGM bulletkit media (Clonetics) for growth.

When the HUVEC were 90% confluent (typically day 4), 96-well tissue culture plates were coated with 100 µl/well of 2.5 µg/ml mouse Type IV collagen (Trevigen) diluted in 0.1 M acetic acid. Following incubation for at least three hours,
20 the collagen was removed and the plate washed three times with HBSS (Gibco). The HUVEC flask was trypsinized, and HUVEC were plated on the collagen coated wells at 1250 cells/200 µl/well for use four days later. Twenty hours prior to use, the medium was removed and cells were stimulated with 200 µl of 10nM phorbol myristate acetate (PMA, Sigma, St. Louis, MO) in EGM. When the cells were 90%
25 confluent (typically day 8), the PMA-containing medium was removed, the wells were washed with HBSS, and 50 µl of HBSS was added to the wells. An additional 50 µl containing compound solution, DMSO or blocking anti-CD18 was then added to each well.

On day 7, HSB-2 cells were then divided to 2×10^5 /ml in RPMI 1640 (Gibco),
30 10% FCS (Hyclone, Logan, UT), 1% Pen-Strep (Gibco), and 1% L-glutamine

(Gibco). The following day, the cells were centrifuged at 534xG for 8 minutes, washed, and resuspended in HBSS at 5×10^7 /ml. For activation and labeling, calcein-AM, 10 μ M (Molecular Probes, Eugene, OR) and 100 nM phorbol myristate acetate (Sigma, St. Louis, MO) were added and the cells incubated at 37°C for 30 minutes.

- 5 Following the addition of ten ml of HBSS, the cells were centrifuged, resuspended, and counted.

To the HUVEC cells were added 200,000 labeled and activated HSB-2 cells/well in 100 μ l, followed by incubation in the dark for 30 minutes. To remove unbound cells, the wells were washed three times with HBSS. A fluorescence plate
10 reader was used to determine the number of HSB-2 cells bound. The percent inhibition due to the compound was calculated with the vehicle control set at 0% inhibition and the antibody-blocked adhesion set at 100% inhibition.

15

EXAMPLES

The following Examples illustrate embodiments of the inventive compounds and starting materials, and are not intended to limit the scope of the claims. For ease of reference, the following abbreviations are used herein:

20

Abbreviations

AlCl_3 = aluminum chloride

Ac_2O = acetic anhydride

AcONa = sodium acetate

bp = boiling point

25

CH_3CN = acetonitrile

DCC = dicyclohexylcarbodiimide

DCE = dichloroethane

DCM = dichloromethane

DMAP = 4-dimethylaminopyridine

30

DIPEA or DIEA = *N,N*-diisopropylethylamine

DME = 1,2-dimethoxyethane

DMF = dimethyl formamide

EDCI = 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide

Et_2O = diethyl ether

35


HOBT = 1-hydroxybenzotriazole

EtOAc = ethyl acetate

- EtOH = ethanol
g = gram(s)
HCl = hydrochloric acid
KOH = potassium hydroxide
5 K₂CO₃ = potassium carbonate
l = liter
LiAlH₄ = lithium aluminum hydride
MeCN = acetonitrile
MeOH = methanol
10 MgSO₄ = magnesium sulfate
NaH = sodium hydride
Na₂SO₄ = sodium sulfate
NaOH = sodium hydroxide
NMP = 1-methyl-2-pyrrolidinone
15 PBr₃ = phosphorus tribromide
(Ph₃P)₄Pd = tetrakis(triphenylphosphine)palladium(0)
PS = polystyrene
SOCl₂ = thionyl chloride
TEA = triethylamine
20 mg = milligram(s)
ml = milliliter
μl = microliter
mmol = millimole
μmol = micromole
25 mol = mole
mp = melting point
RT = room temperature

Preparation 1

30 4-(4-Bromophenyl)-4-oxobutyric acid




- AlCl₃ (128.8 g, 0.97 mol) was added by portions within 20 min to a
35 suspension of succinic anhydride (44.3 g, 0.44 mol) and bromobenzene (100 ml, 0.99
mol) in DCM (500 ml) while the reaction flask was cooled in a water bath. After 1h30

min at RT, the reaction mixture was refluxed for 2h. After cooling, the reaction medium was slowly poured into a mixture of ice (1.5 l) and concentrated HCl (100 ml). The precipitate was washed twice with water, with isopropanol, and finally with pentane. After drying 4-(4-bromophenyl)-4-oxobutyric acid was obtained as an off-white solid (86.4 g, mp = 148°C). ¹H NMR (CDCl₃): 7.85 (2H, d, *J* = 8.5 Hz), 7.62 (2H, d, *J* = 8.5 Hz), 3.28 (2H, t, *J* = 6.5 Hz), 2.82 (2H, t, *J* = 6.5 Hz).

Preparation 2

4-(4-Bromophenyl)-4-oxobutyric acid methyl ester

10




4-(4-Bromophenyl)-4-oxobutyric acid (86.4 g, 0.336 mol) (Preparation 1) in MeOH (1.7 l) containing H₂SO₄ (86 ml) was refluxed for 21 h. After cooling, the light precipitate was filtered off and the reaction mixture concentrated to dryness. The obtained solid was placed in water and extracted twice with EtOAc. The organic layer was washed with diluted NaOH and twice with brine, dried over Na₂SO₄ and concentrated to yield the desired 4-(4-bromophenyl)-4-oxobutyric acid methyl ester as a low melting point solid (87.5 g, mp = 50°C). ¹H NMR (CDCl₃): 7.85 (2H, d, *J* = 8.5 Hz), 7.60 (2H, d, *J* = 8.5 Hz), 3.71 (3H, s), 3.28 (2H, t, *J* = 6.5 Hz), 2.76 (2H, t, *J* = 6.5 Hz).

20

Preparation 3

1-(4-Bromophenyl)-butane-1,4-diol


25



A solution of 4-(4-bromophenyl)-4-oxobutyric acid methyl ester (19g, 70 mmol) (Preparation 2) in anhydrous diethyl ether (100 ml) was added dropwise to a suspension of LiAlH_4 (5.3 g, 140 mmol) in ether (100 ml), while the temperature was kept below 5°C with an ice bath. After 2h at RT, the reaction mixture was refluxed for 4h. It was then cooled to 5°C and hydrolyzed with a saturated Na_2SO_4 solution with the temperature kept below 15°C . The suspension was filtered over celite and concentrated to yield a yellow oil (16.1 g) which was chromatographed over silica gel (eluent : DCM/MeOH 90/10) to yield 1-(4-bromophenyl)-butane-1,4-diol as an oil (15 g). ^1H NMR (CDCl_3): 7.40 (2H, d, $J = 8.4$ Hz), 7.12 (2H, d, $J = 8.4$ Hz), 4.65 (1H, br s), 4.50-4.60 (1H, m), 3.97 (1H, br s), 3.4-3.65 (2H, m), 1.6-1.85 (2H, m), 1.45-1.6 (2H, m).

Preparation 4


1-Bromo-4-(1,4-dibromobutyl)benzene



PBr_3 (4 ml, 40 mmol) was added dropwise in 10 min to a solution of 1-(4-bromophenyl)-butane-1,4-diol (15 g, 61 mmol) (Preparation 3) in diethyl ether (300 ml) maintained at -10°C . After 20 h at RT, the reaction mixture was cooled with an ice bath and water (100 ml) was added rapidly. The aqueous layer was extracted twice with ether. The combined organic layers were washed with a diluted aqueous Na_2CO_3 solution then three times with water until neutrality, dried over magnesium sulfate and concentrated to yield 1-bromo-4-(1,4-dibromobutyl)benzene (13 g) as a yellow oil. ^1H NMR (CDCl_3): 7.47 (2H, d, $J = 8.5$ Hz), 7.26 (2H, d, $J = 8.5$ Hz), 4.8-5.0 (1H, m), 3.42 (2H, t, $J = 6.4$ Hz), 2.2-2.45 (2H, m), 1.8-2.2 (2H, m).

Preparation 5


3-Bromo-1-(4-bromophenyl)propan-1-one



AlCl₃ (23.8 g, 178 mmol) was added by portions to bromobenzene (155 ml, 1.47 mol) at 0°C. 3-Bromopropionyl chloride (25g, 146 mmol) was added dropwise to the red solution kept at 0°C over 30 min. After 1h at RT, the reaction mixture was heated to 50°C for 1h. After cooling, the mixture was poured over ice/water and extracted with DCM. The organic layer was dried over Na₂SO₄ and concentrated to yield 3-bromo-1-(4-bromophenyl)propan-1-one (36g) which was crystallized from petroleum ether (mp = 66°C). ¹H NMR (CDCl₃): 7.82 (2H, d, *J* = 8.5 Hz), 7.62 (2H, d, *J* = 8.5 Hz), 3.73 (2H, t, *J* = 6.5 Hz), 3.55 (2H, t, *J* = 6.5 Hz).

Preparation 6

3-Bromo-1-(4-bromophenyl)propan-1-ol




15

NaBH₄ (1.5g, 39.7 mmol) was added by portions to a solution of 3-bromo-1-(4-bromophenyl)propan-1-one (11.7g, 40 mmol) (Preparation 5) in MeOH while keeping the temperature below 10°C. After 1h at RT, 1N aqueous hydrochloric acid was added at 5°C to pH = 1 and the mixture was concentrated in vacuum. The residue was dissolved in water and extracted three times with DCM. The organic layer was dried over Na₂SO₄ and concentrated to yield 3-bromo-1-(4-bromophenyl)propan-1-ol as a yellow oil (11.1 g). ¹H NMR (CDCl₃): 7.47 (2H, d, *J* = 8.3 Hz), 7.22 (2H, d, *J* = 8.3 Hz), 4.87 (1H, br s), 3.50-3.62 (1H, m), 3.31-3.42 (1H, m), 2.35 (1H, OH, br s), 2.31 (2H, m).

25

Preparation 7


1-Bromo-4-(3-bromo-1-chloropropyl)benzene



SOCl₂ (2.8 ml, 38.6 mmol) was added dropwise to a cooled (-20°C) solution
5 of 3-bromo-1-(4-bromophenyl)propan-1-ol (11.1 g, 37.8 mmol) (Preparation 6) in a
mixture of DCM (110 ml) and pyridine (3 ml, 37.6 mmol). After 2h at -20°C, the
reaction mixture was poured over a mixture of ice and 10% HCl. The organic layer
was washed with water, dried over Na₂SO₄ and concentrated to yield a yellow oil
(12.8 g). Distillation under reduced pressure gave 1-bromo-4-(3-bromo-1-
10 chloropropyl)benzene as a colorless oil (5.1 g, bp = 128-130°C/ 0.5 mm Hg). ¹H
NMR (CDCl₃): 7.4-7.55 (2H, m), 7.15-7.3 (2H, m), 5.07 (1H, m), 3.45-3.6 (1H, m),
3.3-3.45 (1H, m), 2.35-2.65 (2H, m).

Preparation 8


15 **3-(3,5-Dichlorophenyl)-2-thioxoimidazolidin-4-one**



3,5-Dichlorophenylisothiocyanate (5g, 24.5 mmol) was added by portion to a
20 suspension of the HCl salt of ethyl glycinate (3.4 g, 24.5 mmol) in a mixture of TEA
(7.5 ml, 53.9 mmol) and dry DCM (40 ml) while cooling the flask in a water bath.
After 60h at RT, the solution was concentrated to dryness and partitioned between
EtOAc and aqueous HCl. The organic layer was washed with water and concentrated.
The obtained amorphous solid was washed with Et₂O to yield 3-(3,5-dichlorophenyl)-
25 2-thioxoimidazolidin-4-one as an orange solid (5.3 g). ¹H NMR (CDCl₃): 7.45 (1H,
m), 7.25 (2H, m), 4.44 (2H, s).

Preparation 9

3-(3,5-Dichlorophenyl)-4-oxo-2-thioxoimidazolidine-1-carboxylic acid *tert*-butyl ester




5

A solution of di-*tert*-butyldicarbonate (1.04 g, 4.6 mmol) in MeCN (1 ml) was added to a suspension of 3-(3,5-dichlorophenyl)-2-thioxoimidazolidin-4-one (1.04 g, 4 mmol) (Preparation 8) and DMAP (73 mg, 0.6 mmol) in MeCN (5 ml). After 2h at RT, the mixture was evaporated, taken into EtOAc, washed twice with aqueous
 10 KHSO₄ and once with water, and finally concentrated to yield 3-(3,5-dichlorophenyl)-4-oxo-2-thioxoimidazolidine-1-carboxylic acid *tert*-butyl ester (1.04 g) as a brown solid. ¹H NMR (CDCl₃): 7.46 (1H, m), 7.18 (2H, m), 4.54 (2H, s), 1.57 (9H, s).

Preparation 10

15 **(5*R**,6*S**)-6-(4-Bromophenyl)-3-(3,5-dichlorophenyl)-4-oxo-2-thioxo-1,3-diazaspiro[4.4]nonane-1-carboxylic acid *tert*-butyl ester**




Using the same procedure as in Example 1 starting from 1-bromo-4-(1,4-dibromobutyl)benzene (423 mg, 1.1 mmol) (Preparation 4) and 3-(3,5-dichlorophenyl)-4-oxo-2-thioxoimidazolidine-1-carboxylic acid *tert*-butyl ester (361 mg, 1 mmol) (Preparation 9), (5*R**,6*S**)-6-(4-bromophenyl)-3-(3,5-dichlorophenyl)-4-oxo-2-thioxo-1,3-diazaspiro[4.4]nonane-1-carboxylic acid *tert*-butyl ester was obtained (54 mg) as a white solid. ¹H NMR (CDCl₃): 7.49 (2H, d, *J* = 8.4 Hz), 7.33

(1H, m), 7.09 (2H, d, $J = 8.4$ Hz), 6.22 (2H, m), 4.17 (1H, dd, $J_1 = 13.2$ Hz, $J_2 = 5.4$ Hz), 2.35-2.6 (3H, m), 2-2.35 (3H, m), 1.69 (9H, s).

Preparation 11


5 **3-(3,5-Dichlorophenyl)-2,4-dioxoimidazolidine-1-carboxylic acid *tert*-butyl ester**



A solution of di-*tert*-butyldicarbonate (7.72 g, 35.4 mmol) in THF (100 ml)
10 was added to a suspension of 3-(3,5-dichlorophenyl)-imidazolidin-2,4-dione (7.5 g, 30.6 mmol, prepared according to Fujinami *et al.*, cited above) and DMAP (560 mg, 4.6 mmol) in THF (150 ml). After 3h at RT, the mixture was evaporated, taken into DCM, washed twice with 1N aqueous HCl and once with brine, and finally concentrated to yield 3-(3,5-dichlorophenyl)-2,4-dioxoimidazolidine-1-carboxylic
15 acid *tert*-butyl ester (10.17 g) as a white solid. ^1H NMR (CDCl_3): 7.40 (1H, m), 7.37 (2H, m), 4.40 (2H, s), 1.58 (9H, s).


Preparation 12

20 **5-(4-Bromophenyl)-5-oxopentanoic acid methyl ester**




Using the procedure described in Preparations 1 and 2, the above above-titled compound was obtained from glutaric anhydride and bromobenzene. ^1H NMR
25 (CDCl_3): 7.83 (2H, d, $J = 8.5$ Hz), 7.60 (2H, d, $J = 8.5$ Hz), 3.68 (3H, s), 3.03 (2H, t, $J = 7.1$ Hz), 2.45 (2H, t, $J = 7.1$ Hz), 2.06 (2H, m).

Preparation 13

1-(4-Bromophenyl)-pentane-1,5-diol

5 Using the procedure described in Preparation 3, 5-(4-bromophenyl)-5-oxopentanoic acid methyl ester (12.8 g, 45 mmol) (Preparation 12) was reduced with LiAlH₄ (3.4 g, 90 mmol) to yield 1-(4-bromophenyl)-pentane-1,5-diol (9.4 g) as a yellow oil. ¹H NMR (CDCl₃): 7.42 (2H, d, *J* = 8.3 Hz), 7.15 (2H, d, *J* = 8.3 Hz), 4.56 (1H, m), 3.63 (1H, br s), 3.45-3.6 (2H, m), 2.96 (1H, br s), 1.25-1.9 (6H, m).

10

Preparation 14**1-Bromo-4-(1,5-dibromopentyl)benzene**


15

 Using the procedure described in Preparation 4, 1-(4-bromophenyl)-pentane-1,5-diol (9.4 g, 36.3 mmol) (Preparation 13) was treated with PBr₃ (3.4 ml, 36.2 mmol) to yield 1-bromo-4-(1,5-dibromopentyl)benzene (6.1 g) as a yellow oil. ¹H NMR (CDCl₃): 7.47 (2H, d, *J* = 8.5 Hz), 7.26 (2H, d, *J* = 8.5 Hz), 4.88 (1H, t, *J* = 7.5 Hz), 3.38 (2H, t, *J* = 6.6 Hz), 2-2.3 (2H, m), 1.8-2.0 (2H, m), 1.55-1.8 (1H, m), 1.4-1.55 (1H, m).

20

Preparation 15**(*E*)-4-[3-Acetyl-1-(3,5-dichlorophenyl)-2,5-dioxoimidazolidin-4-ylidenemethyl]-benzonitrile**


25



A mixture of 3-(3,5-dichlorophenyl)-2,4-dioxoimidazolidine-1-carboxylic acid *tert*-butyl ester (3.45 g, 10 mmol) (Preparation 11), 4-cyanobenzaldehyde (1.31 g, 10 mmol) and NaOAc (0.82 g, 10 mmol) was refluxed for 3 h in Ac₂O (50 ml). The solid obtained after concentration was taken into a mixture of ice/water and DCM. The organic layer was dried and concentrated to yield a solid (4.4 g) which was chromatographed over silica gel (eluent: DCM) to yield 4-[3-acetyl-1-(3,5-dichlorophenyl)-2,5-dioxoimidazolidin-4-ylidenemethyl]-benzonitrile as a white solid (1.25 g). mp = 212°C. ¹H NMR (CDCl₃) : 8.52 (1H, s), 7.6-7.75 (4H, m), 7.43 (1H, m), 7.37 (2H, m), 2.78 (3H, s).

Preparation 16


(*E*)-1-Acetyl-5-(4-bromobenzylidene)-3-(3,5-dichlorophenyl)-imidazolidine-2,4-dione



Using the same procedure as in Preparation 15, but starting with Preparation 11 (34.5 g, 0.1 mol) and 4-bromobenzaldehyde (18.5 g, 0.1 mol), the above-titled compound was obtained as a white solid (16.8 g). mp = 222°C. ¹H NMR (DMSO-*d*₆) : 8.23 (1H, s), 7.79 (1H, m), 7.55-7.75 (6H, m), 2.65 (3H, s).

Preparation 17**(*E*)-4-[1-(3,5-dichlorophenyl)-3-methyl-2,5-dioxoimidazolidin-4-ylidenemethyl]-benzonitrile**

5



Preparation 17 was obtained via three alternative methods:

(1). A solution of 3-(3,5-dichlorophenyl)-1-methyl-imidazole-2,4-dione (70 g, 0.27 mol), 4-cyanobenzaldehyde (53 g, 0.404 mol), and β -alanine (16.1 g, 0.181 mol) in acetic acid (1 l) was heated for 32 h at reflux. The solution was cooled and kept at 50°C for one hour. It was then allowed to cool to 35°C, and the insoluble material was recovered by filtration to yield 35.5 g (0.095 mol) of the above-titled compound.


Yield 35%. mp = 236°C ;

(2). A mixture of 3-(3,5-dichlorophenyl)-1-methyl-imidazole-2,4-dione (1.3 g, 5 mmol), 4-cyanobenzaldehyde (0.98 g, 7.5 mmol, 1.5eq), pyrrolidine (0.3 ml), anhydrous MgSO_4 (0.9 g, 1.5 eq), and EtOH (35 ml) was heated at 78 °C for eighteen hours. The reaction mixture was filtered while hot, and the solid obtained was washed with hot EtOH (2x20 mL), water (2x20 mL), EtOH (2x20 mL) and dried. Yield: 1.58 g;

(3) A mixture of 3-(3,5-dichlorophenyl)-1-methyl-imidazole-2,4-dione (1.3 g, 5 mmol), 4-cyanobenzaldehyde (0.98 g, 7.5 mmol, 1.5 eq), pyrrolidine (0.3 ml) and EtOH (35 ml) was heated at 78 °C for eighteen hours. The reaction mixture was filtered while hot and the solid obtained was washed with hot EtOH (2x20 mL), water (2x20 mL), EtOH (2x20 mL), and dried. Yield: 2.78 g.

Preparation 18

(E)-5-(4-Bromobenzylidene)-3-(3,5-dichlorophenyl)-1-methyl-imidazolidine-2,4-dione




5

The same procedures as for Preparation 17 were followed, using 4-bromobenzaldehyde in place of 4-cyanobenzaldehyde. ¹H NMR (DMSO-*d*₆) : 7.90 (2H, d), 7.72 (1H, m), 7.58 (4H, m), 6.65 (1H, s), 3.24 (3H, s).

10

Preparation 19

3-(2,6-Dichloropyridin-4-yl)-1-methyl-imidazolidine-2,4-dione



15


TEA (7.2 ml, 51 mmol) was added to a suspension of the HCl salt of sarcosine ethyl ester (3.4 g, 24.5 mmol) in dry DCM (80 ml). The formed triethylamine hydrochloride was filtered off and rinsed with DCM (20 ml). The filtrate was transferred into a 3-necked round bottom flask and cooled to 5°C. A solution of 2,6-dichloropyridin-4-yl isocyanate (10 g, 53 mmol) in DCM (25 ml) was added dropwise over 10 min while keeping the inner temperature below 10 °C. After 96h at RT, the reaction mixture was refluxed for 10 h. After cooling to RT, the solution was washed with brine, dried over MgSO₄ and concentrated. The obtained amorphous solid was chromatographed over silica gel (eluent : cyclohexane/EtOAc 80/20 to 50/50) to yield

20

the above titled compound as a white solid (9.9 g). mp = 134°C. ¹H NMR (CDCl₃): 7.75 (2H, s), 4.07 (2H, s), 3.10 (3H, s).

Preparation 20

5 **(*E*)-4-[1-(2,6-Dichloropyridin-4-yl)-3-methyl-2,5-dioxo-imidazolidin-4-ylidenemethyl]-benzonitrile**




10 Using the third method described in Preparation 17, Preparation 19 (5g, 19.2 mmol) was reacted with 4-cyanobenzaldehyde (3.78 g, 28.8 mmol) to yield the above-titled compound as a white solid (5.6 g). mp = 230°C. ¹H NMR (CDCl₃) : 7.91 (2H, d, *J* = 8.1 Hz), 7.65-7.75 (4H, m), 6.40 (1H, s), 3.37 (3H, s).

Preparation 21

15

2-Hydroxymethyl-thiazole-5-carboxylic acid




20 The above-titled compound was synthesized according to the procedure described in DE 2548505 to Roussel-Uclaf (1975) and Chem. Abstr., Vol. 85, #46650. ¹H NMR (DMSO-d₆) 8.27 (1H, s), 4.77 (2H, s).

Preparation 22

25

Ethyl 2-hydroxymethyl-thiazole-5-carboxylate




A solution of crude Preparation 21 (300 mg, 1.9 mmol) and concentrated sulfuric acid (2 ml) in EtOH (30 ml) was refluxed during 5 hours. The solvent was evaporated under reduced pressure and the residue was partitioned between aqueous Na₂CO₃ and EtOAc. The organic layer was washed with water, dried with sodium sulfate, and evaporated under reduced pressure to yield a brown oil (320 mg, 1.7 mmol). ¹H NMR (CDCl₃) : 8.28 (1H, s); 4.94 (2H, s); 4.33 (2H, q); 1.35 (3H, t).

10

Preparation 23

Ethyl 2-bromomethylthiazole 4-carboxylate




A mixture of ethyl-2-methylthiazole 4-carboxylate (500 mg, 2.9 mmol), N-bromosuccinimide (877 mg, 4.9 mmol), and benzoyl peroxide (5-10 mg) in 1,2-DCE (3 mL) was heated at 70° C for 85 h. After cooling to room temperature, DCM (10 ml) was added and washed with water (3 times). The organic layer was dried over Na₂SO₄ and evaporated *in vacuo*. The residue was purified by preparative chromatography to yield the above-titled compound (58 mg). ¹H NMR (CDCl₃) : 8.23 (1H, s), 4.77 (2H, s), 4.43 (2H, q), 1.42 (3H, t).

25

Preparation 24


Ethyl 5-bromomethylisoxazole-3-carboxylate



The above-titled compound was synthesized according to the procedure described in *Heterocycles*, Vol. 23, 3 (1985), at pp. 571-585. ^1H NMR (CDCl_3) 6.74 (1H, s), 4.50 (2H, q), 1.42 (3H, t).

Preparation 25


4-[(5S*, 9R*)-7-(2-Bromo-acetyl)-3-(3,5-dichloro-phenyl)-1-methyl-2,4-dioxo-1,3,7-triaza-spiro[4.4]non-9-yl]-benzonitrile



To a solution of Example 15 (373.5 mg, 0.9 mmol) in 7 ml THF, were added TEA (175 μl , 1.26 mmol) and bromoacetyl bromide (94 μl , 1.08 mmol). After 15 min. at RT, the reaction mixture was evaporated to dryness. The residue was partitioned between DCM (20 ml) and 1N HCl solution (10 ml). The DCM layer was washed with brine, dried over sodium sulfate and concentrated to yield 441.3 mg of crude compound. ^1H NMR (CDCl_3): 7.75 (2H, d), 7.45-7.55 (3H, m), 6.7-6.9 (2H, m), 4.55-3.65 (7H, m), 3.25 (3H, m).

Preparation 26

4-Trifluoromethanesulfonyloxy-benzoic acid *tert*-butyl ester




Trifluoromethanesulfonic anhydride (1.04 ml, 6.2 mmol) was added to a cooled (5°C) solution of *tert*-butyl 4-hydroxybenzoate (1 g, 5.1 mmol) in a mixture of DCM (25 ml) and TEA (1.1 ml, 7.8 mmol). After 4h at 5°C, water was added. The organic layer was separated, dried over MgSO₄ and concentrated *in vacuo*. The residue was chromatographed over silica gel (eluent : cyclohexane/*i*Pr₂O 95/5) to yield the above-titled compound as a colorless oil (1.45 g). ¹H NMR (CDCl₃): 8.09 (2H, d, *J* = 8.6 Hz), 7.32 (2H, d, *J* = 8.6 Hz), 1.60 (9H, s).

10

Preparation 27

4-[(5*S,9*R**)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl]-benzoic acid *tert*-butyl ester**



15


A mixture of Example 15 (300 mg, 0.72 mmol), Cs₂CO₃ (330 mg, 1 mmol), racemic BINAP (33.7 mg, 0.05 mmol), Pd(OAc)₂ (8.1 mg, 0.036 mmol) and Preparation 26 (283 mg, 0.87 mmol) was heated at 80 °C in dioxane (5 ml) for 24h. After cooling to room temperature, the insoluble salts were removed. The filtrate was concentrated *in vacuo* and purified using chromatography on silica gel (eluent : DCM) to yield the above-titled compound (139 mg). ¹H NMR (CDCl₃): 7.94 (2H, d, *J* = 8.5

20

Hz), 7.69 (2H, d, $J = 8.1$ Hz), 7.40 (2H, d, $J = 8.1$ Hz), 6.63 (2H, d, $J = 8.5$ Hz), 3.7-4.2 (6H, m), 3.26 (3H, s), 1.59 (9H, s).

Preparation 28


5-o-Tolyl-1-trityl-1H-tetrazole



A solution of triphenylmethyl chloride (348 mg, 1.25 mmol, 2 ml DCM) was added dropwise to a mixture of 5-(2-methylphenyl)-1H-tetrazole (200.5 mg, 1.25 mmol) and TEA (174 μ l, 1.25 mmol) in 8 ml DCM. The reaction mixture was stirred overnight at RT, then washed with water (10 ml). The organic layer was dried over sodium sulfate and evaporated *in vacuo*. The residue was purified by preparative chromatography (Cyclohexane / EtOAc 95:5) to yield the above-titled compound (159 mg). ^1H NMR (CDCl_3): 8.1 (1H, d), 7.45-7.1 (18H, m), 2.5 (3H, s).

Preparation 29

5-(2-Bromomethyl-phenyl)-1-trityl-1H-tetrazole




A mixture of preparation 28 (96.9 mg, 0.24 mmol), N-bromosuccinimide (42.7 mg, 0.24 mmol) and benzoyl peroxide (5.8 mg, 0.024 mmol) in 5 ml 1,2-dichloromethane was refluxed under nitrogen for 7h. The crude titled compound was

obtained after evaporation *in vacuo* and used without purification. ^1H NMR (CDCl_3): 8.15 (1H, m), 7.45-7.1 (18H, m), 4.9 (2H, s).

Preparation 30


6-Hydroxymethyl-nicotinic acid methyl ester



The above-titled compound was synthesized according to procedures described in the literature (*see*, Y. Langlois and P. Potier, *Tetrahedron*, Vol. 31 (1975), pp. 419-422). ^1H NMR (DMSO-d_6) : 8.98 (1H, s), 8.30 (2H,d), 7.63 (2H,d), 5.64 (1H, t), 4.64 (2H, d), 3.88 (3H, 1H).

Preparation 31


6-Bromomethyl-nicotinic acid methyl ester



Phosphorus tribromide (1.4g; 5.32 mmol) was added slowly to a cooled solution (ice/water/sodium chloride bath) of Preparation 30 (1 g, 5.7 mmol) in toluene (100 ml). The reaction mixture was allowed to warm to RT overnight and then refluxed for one hour. The reaction mixture was cooled to RT and DCM was added. The organic layer was washed with a saturated aqueous solution of sodium bicarbonate, then with water, dried over sodium sulfate, and concentrated under reduced pressure to yield an oil (m = 0.99g, yield 76 %) which was used without further purification. ^1H NMR (CDCl_3) : 9.18 (1H, s); 8.35 (1H, d); 7.56 (1H, d); 4.62 (2H, s); 4.00 (3H,s)


Preparation 32**4-(1H-Tetrazol-5-yl)-thiophene-2-carboxaldehyde**

5



Sodium azide (2.9 g, 44.6 mmol) and TEA hydrochloride (4.13 g, 30 mmol) were added to a solution of 5-formyl-thiophene-3-carbonitrile (2 g, 15 mmol, prepared according to Intern. application WO 02/26718) in DMF (50 ml). The solution was refluxed for 12h. After cooling to RT, water was added and the solution was carefully acidified with HCl. The solution was extracted 3 times with EtOAc. The combined organic layers were dried over Na₂SO₄ and concentrated under reduced pressure to yield the desired product as a brown solid (540 mg) which was used without further purification.

15

EXAMPLE 1**(5*R**,6*S**)-6-(4-Bromophenyl)-3-(3,5-dichlorophenyl)-1-methyl-1,3-diazaspiro[4.4]nonane-2,4-dione**

20


KOH flakes (1.3 g, 23.2 mmol) were added at RT to a solution of 1-bromo-4-(1,4-dibromobutyl)benzene (4.08 g, 10.6 mmol) (Preparation 4) and 3-(3,5-dichlorophenyl)-1-methylimidazolidine-2,4-dione (2.5 g, 9.6 mmol, prepared according to Fujinami *et al.* cited above) in dry DMSO (40 ml). After 30 h at RT, the reaction mixture was poured into water and extracted with EtOAc. The organic layer was dried over Na₂SO₄ and concentrated to yield an orange oil (4.98 g) which was

25

chromatographed over silica gel (DCM/pentane 50/50) to give 6-(4-bromophenyl)-3-(3,5-dichlorophenyl)-1-methyl-1,3-diazaspiro[4.4]nonane-2,4-dione (2.1 g) as a white solid having the relative stereochemistry depicted above. ¹H NMR (CDCl₃): 7.45 (2H, d, *J* = 8.4 Hz), 7.25 (1H, m), 7.03 (2H, d, *J* = 8.4 Hz), 6.65 (2H, m), 3.36 (1H, dd, *J*₁ = 12.9 Hz, *J*₂ = 6.2 Hz), 3.13 (3H, s), 2.4-2.65 (1H, m), 1.8-2.4 (5H, m).

EXAMPLE 2


(1*S**,4*R**)-1-(4-Bromophenyl)-7-(3,5-dichlorophenyl)-5-methyl-5,7-diazaspiro[3.4]octane-6,8-dione



Using the same procedure as in Example 1 starting from 1-bromo-4-(3-bromo-1-chloropropyl)benzene (Preparation 7) and 3-(3,5-dichlorophenyl)-1-methylimidazolidine-2,4-dione, the above titled compound was obtained after reverse phase HPLC purification (gradient from CH₃CN/H₂O/TFA: 5/95/0.05 to CH₃CN/H₂O/TFA : 80/20/0.05). ¹H NMR (CDCl₃): 7.44 (2H, d, *J* = 8.4 Hz), 7.25 (1H, m), 6.95-7 (4H, m), 4.05 (1H, t, *J* = 10.1 Hz), 3.22 (3H, s), 2.65-2.85 (1H, br q), 2.4-2.65 (2H, m), 2.1-2.3 (1H, br q).

EXAMPLE 3


(5*R**,6*S**)-6-(4-Bromophenyl)-3-(3,5-dichlorophenyl)-1-methyl-1,3-diazaspiro[4.5]decane-2,4-dione



Using the same procedure as in Example 1 starting from 1-bromo-4-(1,5-dibromopentyl)benzene (4.2 g, 10.9 mmol) (Preparation 14) and 3-(3,5-dichlorophenyl)-1-methylimidazolidine-2,4-dione (2.59 g, 10 mmol), the above titled compound was obtained as a white solid (3.1 g, mp = 118°C). ¹H NMR (CDCl₃): 7.41 (2H, d, *J* = 8.4 Hz), 7.30 (1H, m), 7.00 (2H, d, *J* = 8.4 Hz), 6.90 (2H, m), 3.03 (3H, s), 2.91 (1H, dd, *J*₁ = 12.9 Hz, *J*₂ = 3.6 Hz), 2.55 (1H, dq), 2.1-2.3 (1H, m), 1.8-2.05 (5H, m), 1.3-1.6 (1H, m).

EXAMPLE 4


(5*R,6*S**)-6-(4-Bromophenyl)-3-(3,5-dichlorophenyl)-2,4-dioxo-1,3-diazaspiro[4.4]nonane-1-carboxylic acid *tert*-butyl ester**



Using the same procedure as in Example 1 starting from 1-bromo-4-(1,4-dibromobutyl)benzene (153 mg, 0.4 mmol) (Preparation 4) and 3-(3,5-dichlorophenyl)-2,4-dioxoimidazolidine-1-carboxylic acid *tert*-butyl ester (113 mg, 0.33 mmol) (Preparation 11), the above-titled compound was obtained (33 mg) as a white solid. ¹H NMR (CDCl₃): 7.48 (2H, d, *J* = 8.3 Hz), 7.30 (1H, m), 7.07 (2H, d, *J* = 8.3 Hz), 6.52 (2H, m), 4.06 (1H, dd, *J*₁ = 13.1 Hz, *J*₂ = 5.5 Hz), 2.35-2.6 (3H, m), 2-2.35 (3H, m), 1.66 (9H, s).

EXAMPLE 5

(5*R,6*S**)-6-(4-Bromophenyl)-3-(3,5-dichlorophenyl)-2-thioxo-1,3-diazaspiro[4.4]nonan-4-one**




6-(4-Bromophenyl)-3-(3,5-dichlorophenyl)-4-oxo-2-thioxo-1,3-diazaspiro[4.4]nonane-1-carboxylic acid *tert*-butyl ester (42 mg, 74 μ mol) (Preparation 10) was added to a TFA/DCM/H₂O (1/1/0.1) solution (1ml) at RT. After 30 min the reaction mixture was concentrated to give a beige solid which was washed with pentane to yield 6-(4-Bromophenyl)-3-(3,5-dichlorophenyl)-2-thioxo-1,3-diazaspiro[4.4]nonan-4-one (21 mg, beige solid). ¹H NMR (CDCl₃) : 8.39 (1H, s), 7.51 (2H, d, *J* = 8.4 Hz), 7.35 (1H, m), 7.19 (2H, d, *J* = 8.4 Hz), 6.44 (2H, m), 3.36 (1H, dd, *J*₁ = 12.9 Hz, *J*₂ = 6.1 Hz), 2.45-2.65 (2H, m), 1.8-2.25 (4H, m).

10

EXAMPLE 6

(5*R,6*S**)-6-(4-Bromophenyl)-3-(3,5-dichlorophenyl)-1,3-diazaspiro[4.4]nonan-2,4-dione**



15

Using the same procedure as in Example 5, (5*R**,6*S**)-6-(4-bromophenyl)-3-(3,5-dichlorophenyl)-2,4-dioxo-1,3-diazaspiro[4.4]nonane-1-carboxylic acid *tert*-butyl ester (80 mg, 0.14 mmol) (Example 4) was converted into (5*R**,6*S**)-6-(4-bromophenyl)-3-(3,5-dichlorophenyl)-1,3-diazaspiro[4.4]nonan-2,4-dione (58 mg).


¹H NMR (CDCl₃): 7.48 (2H, d, *J* = 8.3 Hz), 7.32 (1H, m), 7.18 (2H, d, *J* = 8.3 Hz), 6.68 (2H, m), 6.54 (1H, br s), 3.22 (1H, dd, *J*₁ = 12.7 Hz, *J*₂ = 6.2 Hz), 2.45-2.65 (2H, m), 1.9-2.25 (4H, m).

20

EXAMPLE 7

4-[(5*R,6*S**)-3-(3,5-Dichlorophenyl)-1-methyl-2,4-dioxo-1,3-diazaspiro[4.4]non-6-yl]benzonitrile**


25



A mixture of 6-(4-bromophenyl)-3-(3,5-dichlorophenyl)-1-methyl-1,3-diazaspiro[4.4]nonane-2,4-dione (1g, 2.1 mmol) (Example 1) and CuCN (0.45 g, 5 mmol) in NMP was heated to 180°C for 6 h. After cooling, the reaction mixture was poured on a mixture of ice and ethylene diamine and extracted twice with DCM. The brown residue was chromatographed over silica gel to yield 4-[(5*R**,6*S**)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3-diazaspiro[4.4]non-6-yl]benzonitrile as a beige solid. ¹H NMR (CDCl₃): 7.62 (2H, d, *J* = 8.1 Hz), 7.25-7.3 (3H, m), 6.67 (2H, br s), 3.45 (1H, dd, *J*₁ = 12.8 Hz, *J*₂ = 6.4 Hz), 3.16 (3H, s), 2.4-2.7 (1H, m), 1.8-2.4 (5H, m).

EXAMPLE 8

(5*R**,6*S**)-6-Biphenyl-4-yl-3-(3,5-dichlorophenyl)-1-methyl-1,3-diazaspiro[4.4]nonane-2,4-dione




A solution of (5*R**,6*S**)-6-(4-bromophenyl)-3-(3,5-dichlorophenyl)-1-methyl-1,3-diazaspiro[4.4]nonane-2,4-dione (80 mg, 0.17 mmol) (Example 1), phenylboronic acid (73 mg, 0.6 mmol), (Ph₃P)₄Pd (20 mg, 0.02 mmol) and K₂CO₃ (80 mg, 0.6 mmol) in a mixture of DME (1.5 ml) and water (50 μl) was heated at 80°C for 12 h. The insoluble material was filtered off and the filtrate concentrated. After chromatography, (5*R**,6*S**)-6-biphenyl-4-yl-3-(3,5-dichlorophenyl)-1-methyl-1,3-diazaspiro[4.4]nonane-2,4-dione (20 mg) was obtained as a white solid. ¹H NMR

(CDCl₃) : 7.5-7.6 (4H, m), 7.3-7.5 (3H, m), 7.15-7.3 (3H, m), 6.64 (2H, m), 3.45 (1H, dd, $J_1 = 12.4$ Hz, $J_2 = 6.1$ Hz), 3.18 (3H, s), 2.5-2.75 (1H, m), 1.8-2.45 (5H, m).

EXAMPLE 9

5 **(5*R**,6*S**)-3-(3,5-Dichlorophenyl)-6-(4'-fluorobiphenyl-4-yl)-1-methyl-1,3-diazaspiro[4.4]nonane-2,4-dione**




Using the procedure described in Example 8 (5*R**,6*S**)-6-(4-bromophenyl)-3-(3,5-dichlorophenyl)-1-methyl-1,3-diazaspiro[4.4]nonane-2,4-dione (80 mg, 0.17 mmol) (Example 1) was reacted with 4-fluorophenylboronic acid (71.4 mg, 0.51 mmol) to yield the above-titled compound (12 mg) as a white solid. ¹H NMR (CDCl₃) : 7.45-7.55 (4H, m), 7.05-7.25 (5H, m), 6.62 (2H, m), 3.46 (1H, dd, $J_1 = 12.9$ Hz, $J_2 = 6.3$ Hz), 3.18 (3H, s), 2.5-2.75 (1H, m), 1.85-2.45 (5H, m).

15

EXAMPLE 10

4-[(5*R,6*S**)-3-(3,5-Dichlorophenyl)-1-methyl-2,4-dioxo-1,3-diazaspiro[4.5]dec-6-yl]-benzonitrile**



20


Using the same procedure as in Example 7 starting from (5*R**,6*S**)-6-(4-bromophenyl)-3-(3,5-dichlorophenyl)-1-methyl-1,3-diazaspiro[4.5]decane-2,4-dione (1 g, 2.3 mmol) (Example 3) and CuCN (0.38 g, 4.2 mmol), the above-titled

compound was obtained as a white solid (0.8 g, mp = 192°C). ¹H NMR (CDCl₃): 7.59 (2H, d, *J* = 8.3 Hz), 7.25-7.35 (3H, m), 6.89 (2H, m), 3.04 (3H, s), 3.02 (1H, dd, *J*₁ = 12.9 Hz, *J*₂ = 3.5 Hz), 2.6 (1H, dq), 2.1-2.3 (1H, m), 1.8-2.05 (5H, m), 1.3-1.6 (1H, m).

5

EXAMPLE 11

4-[(5*S**,9*R**)-1-Acetyl-7-benzyl-3-(3,5-dichlorophenyl)-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile



10


TFA (72μl, 0.9 mmol) was added to a cooled solution (5°C) of Preparation 15 (4.15 g, 10.4 mmol) and *N*-(methoxymethyl)-*N*-(trimethylsilylmethyl)benzylamine (2.9 g, 11.9 mmol) in DCM (200 ml). After 20 h at RT, the solution was washed with diluted ammonium hydroxide and water. The organic layer was dried over Na₂SO₄ and concentrated to yield a solid (7.5 g) which was chromatographed over silica gel (eluent: DCM/acetone 95/5) to yield the above-titled compound as a white solid (3.3 g). mp = 224°C. ¹H NMR (CDCl₃) : 7.65 (2H, d, *J* = 8.3 Hz), 7.45 (2H, d, *J* = 6.9 Hz), 7.25-7.40 (6H, m), 6.53 (2H, d, *J* = 1.5 Hz), 4.62 (1H, dd, *J*₁ = 10.3 Hz, *J*₂ = 7 Hz), 4.04 (1H, d, *J* = 13.1 Hz), 3.79 (1H, d, *J* = 1 Hz), 3.70 (1H, d, *J* = 10.2 Hz), 3.40-3.50 (2H, m), 3.02 (1H, d, *J* = 10.2 Hz), 2.71 (3H, s).

20

EXAMPLE 12

4-[(5*S**,9*R**)-7-Benzyl-3-(3,5-dichlorophenyl)-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile


25




A mixture of Example 11 (8.9 g, 16.7 mmol), TEA (3.8 ml) and pyrrolidine (2.2 ml) in THF (270 ml) was refluxed for 2 h 30 min. The mixture was concentrated *in vacuo* and taken into DCM, then washed with water. The organic layer was dried over MgSO_4 and concentrated. The resulting solid was chromatographed over silica gel (eluent : DCM/MeOH 95/5) to yield the above-titled compound (9.3 g) as a white solid (mp = 200°C). ^1H NMR ($\text{DMSO}-d_6$) : 9.32 (1H, br s), 7.84 (2H, d, $J = 8.2$ Hz), 7.60 (1H, m), 7.25-7.45 (7H, m), 6.74 (2H, d, $J = 1.9$ Hz), 3.65-3.9 (3H, m), 3-3.3 (4H, m).

EXAMPLE 13

(5S*,9R*)-7-Benzyl-9-(4-bromophenyl)-3-(3,5-dichlorophenyl)-1,3,7-triazaspiro[4.4]nonane-2,4-dione




Using the same procedure as in Examples 11 and 12, but using Preparation 16 instead of Preparation 15, the above-titled compound was obtained as a white solid. ^1H NMR ($\text{DMSO}-d_6$) : 10.3 (1H, br s), 7.79 (2H, d), 7.62 (3H, m), 7.35-7.55 (3H, m), 7.20 (2H, d, $J = 8.4$ Hz), 6.73 (2H, d, $J = 1.9$ Hz), 4.6-4.9 (3H, m), 4.2-4.4 (2H, m), 3.65-3.8 (1H, m), 3.25-3.5 (1H, m).

EXAMPLE 14**4-[(5*S**,9*R**)-7-Benzyl-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile**

5

Example 12 (6.25 g, 12.7 mmol) was added to a suspension of NaH (60% in oil, 0.75 g, 18.8 mmol) in dry DMF (60 ml). After 2 h at RT, methyl iodide (1.2 ml, 19.2 mmol) was added. After 48 h, the mixture was concentrated *in vacuo* and taken into DCM and water. The organic layer was dried over MgSO₄ and concentrated to dryness. The residue was chromatographed over silica gel (DCM/acetone 95/5) to yield the above-titled compound (5.1 g) as a white solid (mp = 164°C). ¹H NMR (CDCl₃) : 7.61 (2H, d, *J* = 8.1 Hz), 7.25-7.4 (8H, m), 6.65 (2H, d, *J* = 1.6 Hz), 3.7-3.9 (3H, m), 3.1-3.35 (2H, m), 3.22 (3H, s), 2.98 (2H, d, *J* = 10.9 Hz).

15

EXAMPLE 15**4-[(5*S**,9*R**)-3-(3,5-Dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile**

20

1-Chloroethyl chloroformate (4.4 ml, 40.3 mmol) was added to a cooled (5°C) solution of Example 14 (5.1 g, 10.1 mmol) in DCM (250 ml). After 1 h at 5°C, the reaction mixture was stirred at RT for 20 h. The solution was concentrated to dryness and then refluxed in MeOH (350 ml) for 3 h. After concentration *in vacuo*, the oily

25


residue was triturated in Et₂O to give the hydrochloride of the desired compound (4.9 g). After basification, the product was chromatographed over silica gel (DCM/MeOH 90/10) to yield the above-titled compound (3.35 g) as an amorphous solid. ¹H NMR (CDCl₃) : 7.64 (2H, d, *J* = 8.4 Hz), 7.25-7.32 (3H, m), 6.72 (2H, d, *J* = 2 Hz), 3.6-3.75 (2H, m), 3.35-3.55 (3H, m), 3.20 (3H, s), 2.16 (1H, br s).

EXAMPLES 15A AND 15B

Compound 15 was resolved into its enantiomers Examples 15A and 15B, below, using HPLC, a Chiralpak-AD column, and solvent system of hexane: MeOH:EtOH or carbondioxide : MeOH. There are numerous alternative ways of resolving compounds of the present invention into their enantiomers.

Example 15a


4-[(5*S*,9*R*)-3-(3,5-Dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile



Retention time on a Chiralpak-AD column using carbondioxide: MeOH as eluent is 5.74 minutes. $[\alpha]_D = +95.2$ (*c* = 1, MeOH)


Example 15b

4-[(5*R*,9*S*)-3-(3,5-Dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile



Retention time on a Chiralpak-AD column using carbondioxide: MeOH as eluent is 13.31 minutes. $[\alpha]_D = -96.5$ ($c = 1$, MeOH)

5

EXAMPLES 16-21







10 A solution of Example 15 (12.4 mg, 0.03 mmol) in 1 ml THF was added to the acid or sulfonyl chlorides (0.045 mmol). After addition of the supported base PS-DIEA (Argonaut, 3.56 mmol/g, 15 mg, 0.05 mmol), the suspensions were agitated overnight at RT. The scavenger PS-trisamine (Argonaut, 3.65 mmol/g, 36 mg, 0.13 mmol) was then added and the mixtures were filtered after overnight agitation. When

15 necessary, the resulting solutions were treated with PS-Isocyanate (Argonaut, 1.44 mmol/g, 90 mg, 0.13 mmol) overnight. Compounds having the above formula (Iac), wherein R_9 has the values listed in Table 1, were obtained after filtration and evaporation to dryness. For each compound the purity and the LC Mass results are reported (LCMS conditions : LC Micromass platform (APCI +, DAD (210-400 nm)),


20 Column : TSK gel Super ODS 4.6 mm ID x 5 cm, Flow rate : 2.75 mL / min, Gradient : from 100% eluent A to 100% eluent B in 2 min., with a plateau with 100% eluent B during 1 min. Eluent A : H_2O (0.05% TFA), Eluent B : $\text{CH}_3\text{CN} / \text{H}_2\text{O} / \text{TFA}$ (80/20/0.05)).

25

TABLE 1

| Ex. | R ₉ | Quan. (mg) | Purity (%) | Ret. time | Other |
|-----|---|---------------|---------------|--------------|--|
| 16 |  | 4.3 | 90 | 2.09 | 688 (M+1) |
| 17 |  | 13.7 | 100 | 2.24 | ¹ H NMR (CDCl ₃): 7.9 (2H,d), 7.7-7.5 (5H, m), 7.3-7.1 (3H, m), 6.6 (2H, s), 4.0-3.65 (5H, m), 3.15 (3H, s) |
| 18 |  | 9.9 | 87 | 2.07 | |
| 19 |  | 11.7 | 74 | 2.08 | |
| 20 |  | 1.8 | 95 | 2.1 | |
| 21 |  | 11.3 | 100 | 1.96 | 573 (M+1) |


EXAMPLES 22-24



A solution of Example 15 (18.7 mg, 0.045 mmol) in 1 ml THF was added to the sulfonyl chlorides (0.03 mmol). After addition of the supported base PS-DIEA (Argonaut, 3.56 mmol/g, 15 mg, 0.05 mmol), the suspensions were agitated overnight at RT. The scavenger PS-isocyanate (Argonaut, 1.44 mmol/g, 90 mg, 0.13 mmol) was then added and the mixtures were agitated overnight at RT. The desired compounds having formula (Iad), wherein R_{18a} and R_{18b} have the values listed in Table 2, were obtained after filtration and evaporation to dryness. For each compound, the purity and the LC Mass results are reported (LCMS conditions : LC Micromass platform (APCI +, DAD (210-400 nm)), Column : TSK gel Super ODS 4.6 mm ID x 5 cm, Flow rate : 2.75 mL / min, Gradient : from 100% eluent A to 100% eluent B in 2 min., with a plateau with 100% eluent B during 1 min. Eluent A : H_2O (0.05% TFA), Eluent B : CH_3CN / H_2O / TFA (80/20/0.05)).

TABLE 2


| Ex. | R_{18a} | R_{18b} | Quan. (mg) | Purity (%) | Ret. time | Other |
|-----|-----------|-----------|---------------|---------------|--------------|--|
| 22 | $-CO_2H$ | $-OH$ | 7.3 | 80 | 1.72 | |
| 23 | $-H$ | $-CO_2H$ | 15.1 | 80 | 2.15 | |
| 24 | $-CO_2H$ | $-H$ | 10.8 | 88 | 2.07 | 1H NMR ($CDCl_3$): 8.6 (1H, s), 8.36 (1H, d), 8.1 (1H, d), 7.7 (1H, t), 7.6 (2H, d), 7.3-7.12 (3H, m), 6.7 (2H, s), 4.1-3.5 (5H, m), 3.2 (3H, s) |

Example 24a**3-[(5S,9R)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonane-7-sulfonyl]-benzoic acid**

5 To a mixture of 4-[(5S,9R)-3-(3,5-Dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile (Example 15a) (0.11 g, 0.26 mmol) and (3-(Chlorosulfonyl)benzoic acid (0.058 g, 0.26 mmol) in acetone and water (1 : 1 mL) was added sodium bicarbonate at room temperature. The reaction mixture was stirred at room temperature for forty minutes, quenched by the slow addition of 1N


10 hydrochloric acid (1 mL) and partitioned between DCM (2x20 mL) and brine (25 mL). The DCM layer was dried over sodium sulfate, concentrated and column purified using silica gel chromatography using DCM and MeOH to yield the titled compound (0.12 g). Retention time: 3.39 min. YMC S5 Combiscreen ODS 4.6 x 50 mm (4 minute gradient). Solvent A = 10% MeOH, 90% water and 0.2% phosphoric acid.

15 acid. Solvent B = 90% MeOH, 10% water and 0.2% phosphoric acid.

Example 24b**3-[(5R,9S)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonane-7-sulfonyl]-benzoic acid**

Example 24b was made in a similar fashion to what is described in Example 24a starting from 4-[(5*R*,9*S*)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile (0.404 g, 0.97 mmol) (Example 15b) to yield 0.331 g of the titled compound. Retention time: 3.36 min. YMC S5 ODS 4.6 x 50 mm (4 minute gradient). Solvent A = 10% MeOH, 90% water and 0.2% phosphoric acid. Solvent B = 90% MeOH, 10% water and 0.2% phosphoric acid.

10

EXAMPLES 25-36

To a suspension of PS-carbodiimide (Argonaut, 0.96 mmol/g, 74 mg, 0.071 mmol) in 0.33 ml of hydroxyazabenzotriazole solution (150 mM DCM {25% DMF}, 0.05 mmol), were added 0.5 ml of the acid solutions (66 mM DCM {20% DMF}, 0.033 mmol) and 0.25 ml of a solution of Example 15 (120 mM DCM {20% DMF}, 0.03 mmol). After 24 h at RT, the mixtures were treated with PS-trisamine (Argonaut, 3.65 mmol/g, 65 mg, 0.24 mmol) overnight. After evaporation to dryness of the filtered off solutions, compounds having the formula (Iae), wherein R_{16} has the values listed in Table 3, were obtained by SCX cartridge purification. For the N-Boc and/or CO_2tBu protected acids, the compounds were first treated with DCM/TFA (1:1) solution for 2 h at RT.

25


TABLE 3

| Ex. | R_{16} | Quantity (mg) | Purity (%) | Retention time | MS (M+1) |
|-----|----------|---------------|------------|----------------|----------|
|-----|----------|---------------|------------|----------------|----------|

| | | | | | |
|----|--|------|----|------|-----|
| 25 | | 14.3 | 95 | 1.83 | 534 |
| 26 | | 15.7 | 95 | 1.88 | 534 |
| 27 | | 14.8 | 95 | 1.73 | 528 |
| 28 | | 15.6 | 96 | 1.76 | 548 |
| 29 | | 15 | 95 | 1.75 | 548 |
| 30 | | 16 | 90 | 1.75 | 569 |
| 31 | | 15.5 | 97 | 1.76 | 540 |
| 32 | | 14.4 | 97 | 1.73 | 540 |
| 33 | | 9.7 | 81 | 1.75 | 538 |
| 34 | | 14.1 | 95 | 1.87 | 570 |
| 35 | | 21 | 90 | 1.97 | 562 |
| 36 | | 19.4 | 94 | 2.11 | 562 |

EXAMPLE 37


5-[(5*S,9*R**)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-thiophene-3-carboxylic acid**



5-Formyl-3-thiophenecarboxylic acid (45 mg, 0.29 mmol) was added to a suspension of sodium sulfate (100 mg) and Example 15 (100 mg, 0.24 mmol) in 1,2-DCE (4 ml). After 20h at room temperature, sodium triacetoxyborohydride (75 mg, 0.34 mmol) was added, and the reaction mixture was stirred at room temperature for 24h. Water was then added, and the reaction mixture was acidified by bubbling SO₂ through it. The organic layer was separated and the aqueous layer extracted twice with DCM. The combined organic layers were washed with water, dried over sodium sulfate, and concentrated. The obtained solid was crystallized in MeOH to yield the desired compound as white crystals (120 mg). mp = 188°C.

Example 37a

5-[(5S,9R)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-thiophene-3-carboxylic acid




To a solution of 4-[(5S,9R)-3-(3,5-Dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile (0.1 g, 0.24 mmol) (Example 15a) in 1,2-DCE (4 mL) were sequentially added 5-Formyl-3-thiophenecarboxylic acid (0.045 g, 0.29 mmol) and sodium sulfate (150 mgs) under a nitrogen atmosphere at room temperature. The contents were stirred at room temperature for twenty hours and

sodium triacetoxyborohydride (0.075 g, 0.336 mmol) was added. The reaction was allowed to continue at room temperature for six hours and quenched by the addition of water (15 mL). DCM (15 mL) was added, and sulfurdioxide gas was bubbled through the reaction mixture for ten minutes and the contents transferred into a separating funnel. The organic layer was separated, washed with brine (2 x 20 mL), dried over sodium sulfate, concentrated under reduced pressure and purified by silica gel column chromatography using DCM and MeOH to yield 0.1 g of the titled compound. Retention time: 3.09 min. YMC S5 Combiscreen 4.6 x 50 mm (4 minute gradient). Solvent A = 10% MeOH, 90% water and 0.2% phosphoric acid. Solvent B = 90% MeOH, 10% water and 0.2% phosphoric acid.


Example 37b

5-[(5*R*,9*S*)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-thiophene-3-carboxylic acid



Example 37b was made in a similar fashion to what is described for Example 37a, starting from 4-[(5*R*,9*S*)-3-(3,5-Dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile (0.1 g, 0.24 mmol) (Example 15b). Yield = 0.091 g. Retention time: 3.68 min. YMC S5 ODS 4.6 x 50 mm (4 minute gradient). Solvent A = 10% MeOH, 90% water and 0.2% phosphoric acid. Solvent B = 90% MeOH, 10% water and 0.2% phosphoric acid.

EXAMPLES 38-48









Compounds having the formula (Iac) were prepared, wherein R₉ has the values listed in Table 4A, using the same procedure as for Example 37, starting from Example 15 and the appropriate aldehydes or ketones.

5

TABLE 4A


| Ex. # | R ₉ | Compound Name | Data |
|-------|----------------|---|-----------------------------|
| 38 | | 2-[(5 <i>S</i> *,9 <i>R</i> *)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-5-methyl-thiophene-3-carboxylic acid | White solid. mp = 150°C |
| 39 | | 2-[(5 <i>S</i> *,9 <i>R</i> *)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-thiophene-3-carboxylic acid | White solid. mp = 160°C |
| 40 | | 4-[(5 <i>S</i> *,9 <i>R</i> *)-3-(3,5-Dichlorophenyl)-1-methyl-7-(2-morpholin-4-yl-benzyl)-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile | White solid. mp = 207°C |
| 41 | | 4-[(5 <i>S</i> *,9 <i>R</i> *)-3-(3,5-Dichlorophenyl)-1-methyl-7-(6-methyl-pyridin-2-ylmethyl)-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile | Beige solid. mp = 80-84°C |
| 42 | | 5-[(5 <i>S</i> *,9 <i>R</i> *)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-thiophene-2-carboxylic acid | Off-white solid. mp = 270°C |
| 43 | | {4-[(5 <i>S</i> *,9 <i>R</i> *)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]- | Off-white solid. mp = 246°C |

| | | | |
|----|---|---|------------------------------------|
| |  | phenoxy}-acetic acid | |
| 44 |  | 5-[(5 <i>S</i> *,9 <i>R</i> *)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-furan-2-carboxylic acid | Off-white solid. mp = 179-182°C |
| 45 |  | 4-[(5 <i>S</i> *,9 <i>R</i> *)-3-(3,5-Dichlorophenyl)-1-methyl-2,4-dioxo-7-thiophen-3-ylmethyl]-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile | Beige solid. mp = 206°C |
| 46 |  | 5-[(5 <i>S</i> *,9 <i>R</i> *)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-1H-pyrrole-2-carboxylic acid | Off-white solid. mp = 166°C |
| 47 |  | 4-[(5 <i>S</i> *,9 <i>R</i> *)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-1H-pyrrole-2-carboxylic acid | White solid. mp = 180°C |
| 48 |  | 4-[(5 <i>S</i> *,9 <i>R</i> *)-7-Cyclobutyl-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile | White solid. mp = 194°C |

EXAMPLE 49

4-[(5*S,9*R**)-7-Benzyl-3-(3,5-dichlorophenyl)-1-ethyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile**


5



Using the same procedure as in Example 14, by reaction of Example 12 (100 mg, 0.2 mmol) with ethyl iodide (25 μ l, 0.31 mmol), the above-titled compound was obtained (70 mg) as a white solid (mp = 216°C after crystallization from isopropyl ether). ^1H NMR (CDCl_3) : 7.61 (2H, d, J = 8.3 Hz), 7.25-7.4 (8H, m), 6.67 (2H, d, J = 1.5 Hz), 3.5-4 (5H, m), 3.25-3.35 (2H, m), 2.95-3.2 (2H, m), 1.48 (3H, t, J = 7.2 Hz).

EXAMPLE 50

4-[(5*S,9*R**)-3-(3,5-Dichlorophenyl)-1-ethyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile**




10

Using the procedure described in Example 15, Example 49 (3.5 g, 6.74 mmol) was reacted with 1-chloroethyl chloroformate (7.3 ml, 66.9 mmol) to yield the above-titled compound (1.8 g) as an amorphous white solid. ^1H NMR (CDCl_3) : 7.63 (2H, d, J = 8.3 Hz), 7.25-7.35 (3H, m), 6.73 (2H, d, J = 1.5 Hz), 3.35-3.85 (7H, m), 1.17 (1H, br s), 1.45 (3H, t, J = 7.1 Hz).

15

EXAMPLE 51

4-[(5*S,9*R**)-3-(3,5-Dichlorophenyl)-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile**



Using the procedure described in Example 15, Example 12 (5 g, 10.17 mmol) was reacted with 1-chloroethyl chloroformate (11.1 ml, 101.7 mmol) to yield the


25

above-titled compound (2 g) as white crystals, mp = 198 °C. ^1H NMR (DMSO- d_6) : 9.08 (1H, br s), 7.84 (2H, d, J = 8.2 Hz), 7.61 (1H, m), 7.45 (2H, d, J = 8.2 Hz), 6.79 (2H, d, J = 1.9 Hz), 3.1-3.85 (5H, m).

5

EXAMPLE 52

5-[(5*S,9*R**)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-ethyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-thiophene-3-carboxylic acid**




10

Using the procedure described for Example 37 by reaction of 5-Formyl-3-thiophenecarboxylic acid (40 mg, 0.26 mmol) with Example 50 (100 mg, 0.23 mmol), the above-titled compound was obtained as a white solid (93 mg) after crystallization from MeOH. mp = 182°C.

15

EXAMPLE 53

5-[(5*S,9*R**)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-thiophene-3-carboxylic acid**




20

Using the procedure described for Example 37 by reaction of 5-Formyl-3-thiophenecarboxylic acid (43 mg, 0.27 mmol) with Example 51 (100 mg, 0.25 mmol), the above-titled compound was obtained as a white solid (92 mg), mp = 260°C.

5

EXAMPLE 54

3-[(5*S,9*R**)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-ethyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonane-7-sulfonyl]-benzoic acid**




To a mixture of Example 50 (100 mg, 0.23 mmol) and 3-(chlorosulfonyl) benzoic acid (57 mg, 0.26 mmol) in THF (5 ml) was added DIEA (45 μ l, 0.26 mmol) at room temperature. The reaction mixture was stirred at room temperature for 24 hours then concentrated under vacuum. The residue was partitioned between EtOAc and water. The pH was adjusted to pH=2. The aqueous layer was extracted twice with EtOAc. The combined organic layers were washed with brine, dried over Na₂SO₄ and concentrated. The obtained solid was chromatographed over silica gel using DCM/MeOH (80/20) to yield the above-titled compound (63 mg), mp = 145 °C. ¹H NMR (CDCl₃) : 8.63 (1H, s), 8.41 (1H, d, *J* = 7.5 Hz), 8.17 (1H, d, *J* = 7.4 Hz), 7.77 (1H, t, *J* = 7.7 Hz), 7.62 (2H, d, *J* = 7.7 Hz), 7.18-7.26 (3H, m), 6.60 (2H, s), 3.4-4.2 (7H, m), 1.45 (3H, t, *J* = 6.8 Hz).

20

EXAMPLE 55

3-[(5*S,9*R**)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-2,4-dioxo-1,3,7-triazaspiro[4.4]nonane-7-sulfonyl]-benzoic acid**




Using the procedure of Example 54, Example 51 (100 mg, 0.25 mmol) was reacted with 3-(chlorosulfonyl) benzoic acid (61 mg, 0.27 mmol) in THF (5 ml) in the presence of DIEA (48 μ l, 0.27 mmol) at room temperature to yield the above-titled compound (84 mg), mp = 150 °C. ^1H NMR (DMSO- d_6) : 9.14 (1H, br s), 8.35 (1H, s), 8.29 (1H, d, J = 7.7 Hz), 8.18 (1H, d, J = 7.7 Hz), 7.83 (3H, m), 7.61 (1H, s), 7.38 (2H, d, J = 8.1 Hz), 6.69 (2H, d, J = 1.5 Hz), 3.65-4.05 (4H, m), 3.5-3.6 (1H, m).

10

EXAMPLE 56

4-[(5*S,9*R**)-7-Benzyl-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-2,4-dioxo-1,3,7-triazaspiro[4.4]non-1-yl]-butyric acid ethyl ester hydrochloride**



15

Using the procedure described for Example 14, Example 12 (100 mg, 0.2 mmol) was deprotonated with NaH (60% in oil, 12 mg, 0.3 mmol) in DMF (1 ml) and reacted with ethyl 4-bromobutyrate (44 μ l, 0.3 mmol) to yield the above-titled compound which was converted into its hydrochloride by precipitation in Et₂O/HCl gas (86 mg). LC Mass : retention time = 2.27 min, M_{obs} = 604 (M-1) (LCMS

20

conditions : LC Micromass platform (APCI +, DAD (210-400 nm)), Column : TSK gel Super ODS 4.6 mm ID x 5 cm, Flow rate : 2.75 mL / min, Gradient : from 100% eluent A to 100% eluent B in 2 min., with a plateau with 100% eluent B during 1 min. Eluent A : H₂O (0.05% TFA), Eluent B : CH₃CN / H₂O / TFA (80/20/0.05)).

5

EXAMPLES 57-58


Using the procedure described for Example 56, the following two Examples were prepared by reaction of Example 12 (100 mg) with ethyl 5-bromo-valerate and ethyl 6-bromo-caproate, respectively.

10

EXAMPLE 57

5-[(5*S,9*R**)-7-Benzyl-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-2,4-dioxo-1,3,7-triazaspiro[4.4]non-1-yl]-pentanoic acid ethyl ester hydrochloride**

15




Yield : 55 mg. LC Mass : retention time = 2.40 min, $M_{\text{obs}} = 618$ (M-1) (LCMS conditions : LC Micromass platform (APCI +, DAD (210-400 nm)), Column : TSK gel Super ODS 4.6 mm ID x 5 cm, Flow rate : 2.75 mL / min, Gradient : from 100% eluent A to 100% eluent B in 2 min., with a plateau with 100% eluent B during 1 min. Eluent A : H₂O (0.05% TFA), Eluent B : CH₃CN / H₂O / TFA (80/20/0.05)).

20

EXAMPLE 58

6-[(5*S,9*R**)-7-Benzyl-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-2,4-dioxo-1,3,7-triazaspiro[4.4]non-1-yl]-hexanoic acid ethyl ester hydrochloride**


25



Yield : 54 mg. LC Mass : retention time = 2.29 min, $M_{\text{obs}} = 632$ (M-1) (LCMS conditions : LC Micromass platform (APCI +, DAD (210-400 nm)), Column : TSK gel Super ODS 4.6 mm ID x 5 cm, Flow rate : 2.75 mL / min, Gradient : from 100% eluent A to 100% eluent B in 2 min., with a plateau with 100% eluent B during 1 min.
 5 Eluent A : H₂O (0.05% TFA), Eluent B : CH₃CN / H₂O / TFA (80/20/0.05)).

EXAMPLES 59-61

ω -[(5*S**,9*R**)-7-Benzyl-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-2,4-dioxo-
 10 1,3,7-triazaspiro[4.4]non-1-yl]-alkanoic acids




To prepare Example 59 [the compound of formula (Iaf) wherein e is 1], LiOH
 15 (1N, 600 μ l) was added to a suspension of Example 56 (60.3 mg, 0.1 mmol) in THF (2.5 ml). The solution was heated at 50 °C for 3h. After concentration *in vacuo*, the resulting product was taken into water which was acidified by bubbling gaseous SO₂. Example 59 precipitated out of the solution, was collected by filtration, and dried.
 Yield : 17 mg, mp = 148 °C. Example 60 ($e=2$), and Example 61 ($e=3$), were prepared

using the same method, starting from Examples 57 and 58, respectively. For Example 60: (35.4 mg). Yield : 22 mg, white crystals, mp = 250 °C.; for Example 61: (32.5 mg). Yield : 17.4 mg. ¹H NMR (CDCl₃) : 7.61 (2H, d, *J* = 8 Hz), 7.25-7.40 (8H, m), 6.64 (2H, s), 3.8-4.0 (3H, m), 3.5-3.8 (2H, m), 3.3-3.5 (2H, m), 3-3.3 (2H, m), 2.3-2.45 (2H, m), 1.7-1.9 (4H, m), 1.45-1.55 (2H, m).

EXAMPLE 62


[(5*S,9*R**)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl]-acetic acid ethyl ester**



A mixture of Example 15 (100 mg, 0.24 mmol), ethyl bromo acetate (29 μ l, 0.26 mmol) and K₂CO₃ (36.6 mg, 0.26 mmol) in toluene (2ml) was heated to 100 °C for 5h. After cooling to room temperature, the precipitate (unreacted starting material) was removed by filtration. The filtrate was concentrated and purified by chromatography over silica gel (eluent : DCM then acetone) to yield the above-titled compound as an oil (47.2 mg). ¹H NMR (CDCl₃) : 7.63 (2H, d, *J* = 8.3 Hz), 7.25-7.30 (3H, m), 6.68 (2H, d, *J* = 1.5 Hz), 4.23 (2H, q, *J* = 7.1 Hz), 3.89 (1H, dd, *J*₁ = 11.7 Hz, *J*₂ = 6.3 Hz), 3.55-3.65 (2H, m), 3.3-3.5 (3H, m), 3.26 (3H, s), 3.05 (1H, d, *J* = 10.8 Hz), 1.31 (3H, t, *J* = 7.1 Hz).

EXAMPLE 63


[(5*S,9*R**)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl]-acetic acid *tert*-butyl ester**



A mixture of Example 15 (2 g, 4.81 mmol), *tert*-butyl bromo acetate (2.4 ml, 16.3 mmol) and K₂CO₃ (2.4 g, 17.4 mmol) in dioxane (40 ml) was refluxed for 24h. After cooling to room temperature, the solution was concentrated and partitioned
 5 between DCM/water. The aqueous layer was extracted twice with DCM. The combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated to an oil which was purified by chromatography over silica gel (eluent : DCM/acetone 95/5) to yield the above-titled compound as an amorphous solid (1.56 g). ¹H NMR (CDCl₃) : 7.62 (2H, d, *J* = 8.3 Hz), 7.25-7.30 (3H, m), 6.67 (2H, d, *J* =
 10 1.5 Hz), 3.80-3.95 (1H, dd), 3.55-3.65 (2H, m), 3.3-3.5 (3H, m), 3.26 (3H, s), 3.02 (1H, d, *J* = 10.9 Hz), 1.50 (9H, s).

EXAMPLE 64

15 [(5*S**,9*R**)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl]-acetic acid




Trifluoroacetic acid (4.8 ml, 59 mmol) was added to a solution of Example 63 (1.56 g, 2.95 mmol) in DCM (40 ml). The solution was refluxed for 3h. It was then
 20 concentrated *in vacuo* and partitioned between EtOAc/aqueous NH₄OH. The aqueous layer was acidified to pH=2 with SO₂. The white precipitate was separated by filtration. The aqueous layer was extracted with DCM and concentrated to give white crystals which were combined with the precipitated solid to give, after drying, the above-titled compound (1.04 g), mp = 220 °C.

25

EXAMPLE 65


(5*S,9*R**)-7-Benzyl-9-(4-bromophenyl)-3-(3,5-dichlorophenyl)-1-methyl-1,3,7-triazaspiro[4.4]nonane-2,4-dione**



Using the procedure described for Example 14, Example 13 (5.45 g, 10 mmol) was reacted with methyl iodide (0.93 ml, 14.9 mmol) to yield the above-titled compound as a white solid (4.15 g), mp = 204 °C.

EXAMPLE 66

(5*S,9*R**)-7-Benzyl-3-(3,5-dichlorophenyl)-1-methyl-9-(4-pyrimidin-5-yl-phenyl)-1,3,7-triazaspiro[4.4]nonane-2,4-dione**




A mixture of Example 65 (2g, 3.58 mmol), 5-trimethylstannyl-pyrimidine (1.3 g, 5.35 mmol, prepared according to patent WO 95/06636) and tetrakis(triphenylphosphine)palladium(0) (620 mg, 0.54 mmol) in toluene (50 ml) was refluxed for 10h under a nitrogen atmosphere. After cooling to room temperature, the insoluble material was filtered off and washed twice with toluene. The toluene layers were concentrated *in vacuo*. The resulting orange oil (3.1 g) was chromatographed

over silica gel (eluent : EtOAc) to yield the above-titled compound as a white solid after crystallization from MeOH (430 mg), mp = 228 °C.

EXAMPLE 67

5 **(5*S**,9*R**)-3-(3,5-Dichlorophenyl)-1-methyl-9-(4-pyrimidin-5-yl-phenyl)-1,3,7-triazaspiro[4.4]nonane-2,4-dione**




10 Using the procedure described for Example 15, Example 66 (358 mg, 0.64 mmol) was reacted with 1-chloroethyl chloroformate (0.28 ml, 2.6 mmol) in DCM (3 ml) to yield the above-titled compound as an amorphous solid (88 mg). ¹H NMR (CDCl₃) : 9.22 (1H, s), 8.94 (2H, s), 7.58 (2H, d, *J* = 8.2 Hz), 7.35 (2H, d, *J* = 8.2 Hz), 7.21 (1H, m), 6.66 (2H, d, *J* = 1.6 Hz), 3.3-3.9 (5H, m), 3.23 (3H, s), 2.63 (1H, br s).

15

EXAMPLE 68

5-[(5*S,9*R**)-3-(3,5-Dichlorophenyl)-1-methyl-2,4-dioxo-9-(4-pyrimidin-5-yl-phenyl)-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-thiophene-3-carboxylic acid**



20


Using the procedure described for Example 37, Example 67 (37.3 mg, 0.08 mmol) was reacted with 5-formyl-3-thiophenecarboxylic acid (15 mg, 0.096 mmol) in DCE (3 ml) to yield the above-titled compound as an amorphous solid (43 mg). ¹H

NMR (CDCl₃) : 9.23 (1H, s), 8.96 (2H, s), 8.16 (1H, s), 7.45-7.65 (3H, m), 7.29 (2H, d, *J* = 8.1 Hz), 7.20 (1H, m), 6.65 (2H, d, *J* = 1.4 Hz), 3.9-4.2 (3H, m), 3.2-3.5 (3H, m), 3.23 (3H, s), 3.10 (1H, d, *J* = 11.1 Hz).

5

EXAMPLE 69

(5*S,9*R**)-3-(3,5-Dichlorophenyl)-1-methyl-7-(1-methylethyl)-9-(4-pyrimidin-5-yl-phenyl)-1,3,7-triazaspiro[4.4]nonane-2,4-dione**




10

A mixture of Example 67 (49.7 mg, 0.11 mmol), 2-iodo propane (26 μ l, 0.26 mmol) and K₂CO₃ (36 mg, 0.26 mmol) was heated at 80°C for 25h in acetonitrile (2 ml). After cooling to room temperature, the insoluble salts were removed and the filtrate concentrated to dryness. The residue was partitioned between DCM/water. The organic layer was concentrated *in vacuo* and chromatographed over silica gel (eluent : DCM/MeOH 95/5) to yield the above-titled compound as an amorphous white solid (38.1 mg). ¹H NMR (CDCl₃) : 9.21 (1H, s), 8.92 (2H, s), 7.56 (2H, d, *J* = 8.0 Hz), 7.33 (2H, d, *J* = 8.0 Hz), 7.20 (1H, m), 6.61 (2H, d, *J* = 1.5 Hz), 3.90 (1H, dd, *J*₁ = 12 Hz, *J*₂ = 6 Hz), 3.4-3.5 (2H, m), 3.2-3.4 (1H, m), 3.28 (3H, s), 3.09 (1H, d, *J* = 11 Hz), 2.79 (1H, m), 1.23 (6H, m).

20

EXAMPLES 70-74



Compounds having the formula (Iac) were prepared, wherein R₉ has the values listed in Table 4B, using the same procedure as for Example 69, starting from Example 15 and the appropriate iodo compound.


5

TABLE 4B


| Ex. # | R ₉ | Compound Name | Data |
|-------|----------------|--|---|
| 70 | | 4-[(5 <i>S</i> *,9 <i>R</i> *)-3-(3,5-Dichlorophenyl)-1-methyl-7-(1-methylethyl)-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile | White solid (180 mg), mp = 208 °C. |
| 71 | | 4-[(5 <i>S</i> *,9 <i>R</i> *)-7-Cyclopentyl-3-(3,5-Dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile | White solid (132 mg), mp = 178 °C. |
| 72 | | 4-[(5 <i>S</i> *,9 <i>R</i> *)-3-(3,5-Dichlorophenyl)-1-methyl-7-(2-methylpropyl)-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile | White solid recrystallized from MeOH (105 mg), mp = 170 °C. |
| 73 | | 4-[(5 <i>S</i> *,9 <i>R</i> *)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl]-butyric acid methyl ester | Yellow oil (199 mg). |
| 74 | | 5-[(5 <i>S</i> *,9 <i>R</i> *)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl]-pentanoic acid methyl ester | Yellow oil (192 mg). |

EXAMPLE 75

4-[(5*S,9*R**)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-**


1,3,7-triazaspiro[4.4]non-7-yl]-butyric acid

NaOH (2ml, 1N) was added to a solution of Example 73 (199 mg, 0.48 mmol) in THF (2ml). After 3h at room temperature the solution was acidified with SO₂ and concentrated *in vacuo*. The resulting solid was partitioned between water and EtOAc. The organic layer was dried over Na₂SO₄ and concentrated to yield the above-titled compound which was crystallized from MeOH (23 mg), mp = 228 °C.

EXAMPLE 76**5-[(5S*,9R*)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl]-pentanoic acid**

Using the same procedure as for Example 75, Example 74 (190 mg, 0.36 mmol) was converted into the above-titled compound (152 mg). White solid, mp = 240 °C.

EXAMPLE 77**[(5S*,9R*)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl]-acetamide**




Isobutyl chloroformate (27 μ l, 0.21 mmol) was added to a cooled (5 $^{\circ}$ C) suspension of Example 64 (90 mg, 0.19 mmol) and N-methyl morpholine (23 μ l, 0.2 mmol) in DCM (4 ml). After 1h, ammonia (420 μ l, 0.5 M in dioxane, 0.21 mmol) was added. After 1 h at 5 $^{\circ}$ C and 3h at RT, water (2 ml) was added. The organic layer was separated and the aqueous layer extracted with DCM. The combined organic layers were concentrated *in vacuo* and the resulting material was purified by chromatography over silica gel (eluent : DCM/MeOH 95/5) to yield the above-titled compound as a solid (49.6 mg). ^1H NMR (CDCl_3) : 7.64 (2H, d, J = 8.2 Hz), 7.25-7.30 (3H, m), 6.84 (1H, br s), 6.65 (2H, d, J = 1.5 Hz), 6.18 (1H, br s), 3.87 (1H, t), 3.4-3.5 (5H, m), 3.24 (3H, s), 3.15 (1H, d, J = 10.9 Hz).

EXAMPLES 78-79

Using the experimental procedure described in Example 77, the following Examples were prepared.

EXAMPLE 78

[(5S*,9R*)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl]-N-methyl-acetamide




Using Example 64 (90 mg, 0.19 mmol) and methylamine (105 μ l, 2 M in THF, 0.21 mmol), the above-titled compound was obtained as a solid (47.1 mg). ^1H NMR

(CDCl₃) : 7.64 (2H, d, $J = 8.1$ Hz), 7.27-7.31 (3H, m), 6.95 (1H, br s), 6.65 (2H, d, $J = 1.3$ Hz), 3.87 (1H, t), 3.35-3.5 (5H, m), 3.25 (3H, s), 3.16 (1H, d, $J = 10.9$ Hz), 2.89 (3H, d, $J = 4.9$ Hz).

5

EXAMPLE 79

[(5*S,9*R**)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl]-*N,N*-dimethyl-acetamide**



10


Using Example 64 (90 mg, 0.19 mmol) and dimethylamine (105 μ l, 2 M in THF, 0.21 mmol), the above-titled compound was obtained as a solid (78.8 mg). ¹H NMR (CDCl₃) : 7.62 (2H, d, $J = 8$ Hz), 7.15-7.3 (3H, m), 6.68 (2H, d, $J = 1.8$ Hz), 3.92 (1H, dd, $J_1 = 11.4$ Hz, $J_2 = 6.2$ Hz), 3.6-3.75 (2H, m), 3.35-3.5 (3H, m), 3.26 (3H, s), 3.05 (3H, s), 2.99 (3H, s), 2.95-3.0 (1H, m).

15

EXAMPLE 80

***N*-{5-[(5*S**,9*R**)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-thiophene-3-carbonyl}-methanesulfonamide**

20




EDCI (84 mg, 0.44 mmol) was added to a solution of Example 37 (100 mg, 0.18 mmol), methanesulfonamide (38 mg, 0.38 mmol), triethylamine (62 μ l, 0.43 mmol) and a trace of DMAP in DCM (5 ml) at room temperature. After 48h, water was added and the mixture was acidified by bubbling SO_2 . The organic layer was separated and the aqueous layer extracted twice with DCM. The combined organic layers were washed with brine and concentrated *in vacuo*. The resulting product was chromatographed over silica gel to yield the above-titled compound (38.9 mg) as an amorphous solid along with 55.6 mg of unreacted starting material. ^1H NMR (CDCl_3) : 8.04 (1H, s), 7.62 (2H, d, J = 8 Hz), 7.40 (1H, s), 7.25-7.3 (3H, m), 6.65 (2H, d, J = 1.5 Hz), 3.8-4.1 (3H, m), 3.86 (3H, s), 3.3-3.4 (2H, m), 3.3.25 (3H, s), 3.15-3.3 (1H, m), 3.01 (1H, d, J = 11 Hz).

15

EXAMPLE 81

***N*-{4-[(5*S**,9*R**)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-benzoyl}-methanesulfonamide**




20

Using the same procedure as in Example 80 by reaction of Example 185 (200 mg, 0.36 mmol) with methanesulfonamide (38.1 mg, 0.4 mmol), the above-titled compound was obtained (64 mg). ¹H NMR (CDCl₃) : 7.86 (2H, d, *J* = 8.1 Hz), 7.63 (2H, d, *J* = 8 Hz), 7.55 (2H, d, *J* = 8 Hz), 7.25-7.3 (3H, m), 6.65 (2H, d, *J* = 1.3 Hz), 3.85-4.05 (3H, m), 3.2-3.45 (3H, m), 3.44 (3H, s), 3.24 (3H, s), 3.05 (1H, *J* = 11.1 Hz).

EXAMPLE 82


4-[(5*S**,9*R**)-3-(3,5-Dichlorophenyl)-1-methyl-2,4-dioxo-7-pyrimidin-2-yl-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile



A mixture of Example 15 (100 mg, 0.24 mmol), K₂CO₃ (37 mg, 0.27 mmol) and 2-bromo-pyrimidine (42 mg, 0.27 mmol) was heated at 100 °C in DMF (1 ml) for 20h. After cooling to room temperature, the insoluble salts were removed and the filtrate was partitioned between water and EtOAc. The aqueous layer was extracted twice with EtOAc. The combined organic layers were washed with brine, concentrated *in vacuo* and purified using chromatography on silica gel (eluent : DCM/acetone 95/5) to yield the above-titled compound (36.1 mg). White crystals from MeOH, mp = 234 °C.

EXAMPLE 83

4-[(5*S**,9*R**)-7-(6-Chloropyridazin-3-yl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile




Using the same experimental procedure as in Example 82, Example 15 (100 mg, 0.24 mmol) was reacted with 3,6-dichloropyridazine (39 mg, 0.26 mmol) to yield
 5 the above-titled compound (27.1 mg), mp = 125 °C.

EXAMPLE 84

4-[(5*S,9*R**)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-7-pyridin-2-yl-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile**


10



Using the same experimental procedure as in Example 82, Example 15 (100 mg, 0.24 mmol) was reacted with 2-bromopyridine (25 μ l, 0.26 mmol) to yield the
 15 above-titled compound (30 mg). ^1H NMR (CDCl_3) : 8.22 (1H, m), 7.7 (2H, m), 7.55 (1H, m), 7.39 (2H, m), 7.1 (1H, m), 6.79 (2H, d), 6.70 (1H, m), 6.5 (1H, d), 3.95-4.3 (5H, m), 3.24 (3H, s).

EXAMPLE 85


20 **4-[(5*S**,9*R**)-1-Acetyl-3-(3,5-dichlorophenyl)-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile**



Using the same experimental procedure as in Example 15, Example 11 (533 mg, 1 mmol) was reacted with 1-chloroethyl chloroformate to yield the above-titled compound (76 mg), mp = 125 °C. ¹H NMR (CDCl₃) : 7.66 (2H, d, *J* = 8.3 Hz), 7.25-7.35 (3H, m), 6.52 (2H, d, *J* = 1.5 Hz), 4.10 (1H, dd, *J*₁ = 11.3 Hz, *J*₂ = 7.1 Hz), 3.74 (1H, d, *J* = 13.1 Hz), 3.45-3.60 (3H, m), 2.78 (1H, br s), 2.73 (3H, s).

EXAMPLE 86


4-[(5*S**,9*R**)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl]-4-oxo-butanoic acid



A solution of Example 15 (100 mg, 0.24 mmol) and succinic anhydride (24.1 mg, 0.24 mmol) in DCM (2 ml) was stirred at room temperature for 24h. After concentration to dryness the above-titled compound was obtained as an amorphous solid (128 mg). LC Mass : retention time = 1.87 min, *M*_{obs} = 514 (M-1) (LCMS conditions : LC Micromass platform (APCI +, DAD (210-400 nm)), Column : TSK gel Super ODS 4.6 mm ID x 5 cm, Flow rate : 2.75 mL / min, Gradient : from 100% eluent A to 100% eluent B in 2 min., with a plateau with 100% eluent B during 1 min. Eluent A : H₂O (0.05% TFA), Eluent B : CH₃CN / H₂O / TFA (80/20/0.05)).

EXAMPLE 87

5-[(5*S,9*R**)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl]-5-oxo-pentanoic acid**




5

Using the same experimental conditions as in Example 86, Example 15 (100 mg, 0.24 mmol) was reacted with glutaric anhydride (41.5 mg, 0.36 mmol) to yield the above-titled compound as an amorphous solid (132 mg). LC Mass : retention time = 1.89 min, $M_{obs} = 528$ (M-1) (LCMS conditions : LC Micromass platform (APCI +, DAD (210-400 nm)), Column : TSK gel Super ODS 4.6 mm ID x 5 cm, Flow rate : 2.75 mL / min, Gradient : from 100% eluent A to 100% eluent B in 2 min., with a plateau with 100% eluent B during 1 min. Eluent A : H₂O (0.05% TFA), Eluent B : CH₃CN / H₂O / TFA (80/20/0.05)).

15


EXAMPLE 88

4-[(5*S,9*R**)-7-Cyclopropyl-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile**



Sodium cyanoborohydride (202 mg, 3.25 mmol) was added to a methanolic solution (10 ml) of 1-ethoxy-1-trimethylsilyloxy-cyclopropane (871 μ l, 4.33 mmol), Example 15 (300 mg, 0.72 mmol) and acetic acid (413 μ l, 7.2 mmol). The solution was refluxed for 2.5h, concentrated *in vacuo* and partitioned between DCM and brine. The aqueous layer was extracted twice with DCM. The combined organic layers were dried over Na₂SO₄ and concentrated. The resulting product was crystallized from MeOH to yield the above-titled compound as a white solid (107 mg), mp = 216 °C.

25


EXAMPLE 89**4-[(5*S**,9*R**)-3-(3,5-Dichlorophenyl)-1,7-dimethyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile**

5

Formaldehyde (80 μ l, 37% in water, 1.1 mmol) was added to a solution of Example 15 (300 mg, 0.72 mmol) in formic acid (1 ml). After 4h at 90°C, the solution was cooled to 0°C, basified with NaOH 2N, and extracted with EtOAc. After concentration, the compound was purified by crystallization of its TFA salt in ether.

10 After basification, the above-titled compound was obtained as a white solid (123 mg). ^1H NMR (CDCl_3) : 7.63 (2H, d, $J = 8.0$ Hz), 7.25-7.35 (3H, m), 6.67 (2H, m), 3.83 (1H, dd, $J_1 = 11.7$ Hz, $J_2 = 6.0$ Hz), 3.2-3.4 (2H, m), 3.24 (3H, s), 3.09 (1H, m), 2.94 (1H, d, $J = 10.9$ Hz), 2.52 (3H, s).

15

EXAMPLES 90-101

20 Using the same procedure as described for Examples 16-21 (**Method A**) or Examples 22-24 (**Method B**), the compounds having the above formula (Iac), listed in Table 5, were obtained after filtration and evaporation to dryness. Some compounds were further purified by reverse phase HPLC (gradient from $\text{CH}_3\text{CN}/\text{H}_2\text{O}/\text{TFA}$: 5/95/0.05 to $\text{CH}_3\text{CN}/\text{H}_2\text{O}/\text{TFA}$: 80/20/0.05). Examples 99 and 100 were obtained

- after hydrolysis of their corresponding esters following the general **Method C** (0.06 mmol in 3 ml THF, with a 2N solution of LiOH (240 μ l, 0.48 mmol)). These compounds were then purified by reverse phase HPLC (gradient from CH₃CN/H₂O/TFA: 5/95/0.05 to CH₃CN/H₂O/TFA : 80/20/0.05). For each compound
- 5 LC Mass results are reported (LCMS conditions : LC Micromass platform (APCI +, DAD (210-400 nm)), Column : TSK gel Super ODS 4.6 mm ID x 5 cm, Flow rate : 2.75 mL / min, Gradient : from 100% eluent A to 100% eluent B in 2 min., with a plateau with 100% eluent B during 1 min. Eluent A : H₂O (0.05% TFA), Eluent B : CH₃CN / H₂O / TFA (80/20/0.05)).

TABLE 5













| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|---|--------|---------------|----------------|--|
| 90 |  | A | 23.9 | 2.31 | 649 (M+1) |
| 91 |  | A | 20.3 | 2.28 | 619 (M+1) |
| 92 |  | A | 4.2 | 2.4 | 644 (M+1) |
| 93 |  | A | 4.7 | 2.48 | ¹ H NMR (CDCl ₃): 7.69-7.58 (3H, m), 7.29-7.19 (3H, m), 6.62 (2H, s), 4.17-3.69 (8H, m), 3.20 (3H, s), 2.58 (3H, s) |
| 94 |  | A | 4.7 | 2.47 | 631 (M+1) |
| 95 |  | A | 3.2 | 2.43 | ¹ H NMR (CDCl ₃): 7.67 (2H, d), 7.41 (1H, s), 7.29-7.18 (3H, m), 6.69 (2H, s), 4.11-3.9 (7H, m), 3.19 (3H, s), 2.65 (3H, s) |
| 96 |  | A | 3.8 | 2.34 | 616 (M+1) |
| 97 |  | A | 3.8 | 1.71 | 500 (M+1) |

Table 5 (continued)


| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|--|--------|---------------|----------------|------------|
| 98 |  | A | 5.2 | 2.11 | 618 (M+1) |
| 99 |  | A & C | 2.4 | 2.11 | 650 (M+1) |
| 100 |  | A & C | 5.9 | 1.45* | 562 (M-1)* |
| 101 |  | B | 3 | 2.33* | 651 (M-1)* |

*(APCI -) as in Example 152

5

EXAMPLE 102


4-[(5S*, 9R*)-3-(3,5-Dichloro-phenyl)-1-methyl-2,4-dioxo-7-(quinoxaline-6-carbonyl)-1,3,7-triaza-spiro[4.4]non-9-yl]-benzonitrile



10

To a solution of quinoxaline-6-carboxylic acid (56.2 mg, 0.318 mmol) in 7 ml DMF were added EDCI (62 mg, 0.32 mmol), TEA (53.9 μ l, 0.38 mmol) and HOBt (49.3 mg, 0.36 mmol). After 30 min, a solution of Example 15 (103.4 mg, 0.249 mmol) in 1 ml DMF was added. The reaction mixture was then stirred overnight at RT before evaporation to dryness. The residue was partitioned between DCM (50 ml) and 1N solution of HCl (20 ml). The DCM layer was washed with 10% solution of sodium carbonate (2 x 20 ml), dried over sodium sulfate, concentrated and purified by reverse phase HPLC (gradient from CH₃CN/H₂O/TFA: 5/95/0.05 to CH₃CN/H₂O/TFA : 80/20/0.05) to yield the titled compound (35 mg). Retention time: 2.16 min., 571 (M+1) (LCMS conditions : LC Micromass platform (APCI +, DAD (210-400 nm)), Column : TSK gel Super ODS 4.6 mm ID x 5 cm, Flow rate : 2.75 mL / min, Gradient : from 100% eluent A to 100% eluent B in 2 min., with a plateau with 100% eluent B during 1 min. Eluent A : H₂O (0.05% TFA), Eluent B : CH₃CN / H₂O / TFA (80/20/0.05)).

EXAMPLES 103-134



Using the same procedure as described for Examples 25-36 (**Method D**), the compounds having the above formula (Iae), listed in Table 6, were obtained after filtration and evaporation to dryness. For the N-Boc and/or CO₂tBu protected R, the compounds were treated with DCM/TFA (1:1) solution for 2 h at RT, and the resulting basic or acidic compounds were further purified by SCX or SAX cartridge, respectively (**Method L**).

Some compounds were further purified by reverse phase HPLC (gradient from CH₃CN/H₂O/TFA: 5/95/0.05 to CH₃CN/H₂O/TFA : 80/20/0.05). For each compound, the LC Mass results are reported (LCMS conditions : LC Micromass platform (APCI +, DAD (210-400 nm)), Column : TSK gel Super ODS 4.6 mm ID x 5 cm, Flow rate : 2.75 mL / min, Gradient : from 100% eluent A to 100% eluent B in

2 min., with a plateau with 100% eluent B during 1 min. Eluent A : H₂O (0.05% TFA), Eluent B : CH₃CN / H₂O / TFA (80/20/0.05)).

TABLE 6








| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|---|--------|---------------|----------------|---|
| 103 |  | D | 14.9 | 10.802* | 586 (M+1)* |
| 104 |  | D | 9.6 | 9.768* | 588 (M+1)* |
| 105 |  | D | 16.1 | 1.77 | 548 (M+1); ¹ H NMR (CDCl ₃): 8.6-8.4 (2H, m), 7.75-7.55 (3H, m), 7.4-7.15 (4H, m), 6.85-6.7 (2H, m), 4.45-4.15 (1H, m), 4.15-3.65 (4H, m), 3.2 (3H, s), 3.15-3.0 (2H, m), 2.8-2.55 (2H, m) |
| 106 |  | D & L | 15.1 | 1.76 | 554 (M+1) |
| 107 |  | D & L | 14.6 | 1.74 | 558 (M+1) |
| 108 |  | D & L | 15.4 | 1.74 | 558 (M+1) |
| 109 |  | D & L | 15 | 1.76 | 526 |

Table 6 (continued)








| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|---|--------|---------------|----------------|-----------|
| 110 |  | D & L | 14.7 | 1.76 | 526 (M+1) |
| 111 |  | D & L | 13.4 | 1.72 | 514 (M+1) |
| 112 |  | D & L | 15 | 1.8 | 556 (M+1) |
| 113 |  | D & L | 17 | 1.93 | 598 (M+1) |
| 114 |  | D | 13.2 | 1.75 | 534 (M+1) |
| 115 |  | D | 14.5 | 1.73 | 534 (M+1) |
| 116 |  | D | 11.7 | 1.74 | 534 (M+1) |

Table 6 (continued)








| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|---|--------|---------------|----------------|-----------|
| 117 |  | D | 11.7 | 1.81 | 546 (M+1) |
| 118 |  | D | 5.2 | 1.79 | 566 (M+1) |
| 119 |  | D | 11.6 | 1.77 | 577 (M+1) |
| 120 |  | D | 12.7 | 1.79 | 546 (M+1) |
| 121 |  | D | 16.9 | 1.79 | 554 (M+1) |
| 122 |  | D | 21.4 | 1.82 | 576 (M+1) |
| 123 |  | D | 15.5 | 1.99 | 501 (M+1) |

Table 6 (continued)













| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|---|--------|---------------|----------------|---|
| 124 |  | D | 12 | 2.17 | 611 (M+1) |
| 125 |  | D | 4.6 | 1.75 | 542 (M+1) |
| 126 |  | D | 10.8 | 1.93 | ¹ H NMR (CDCl ₃): 7.69 (2H, d), 7.39-7.24 (3H, m), 6.78 (2H, d), 4.6-3.78 (7H, m), 3.27-3.15 (6H, m) |
| 127 |  | D | 12.7 | 1.87 | 586 (M+1) |
| 128 |  | D | 10.3 | 2.06 | 578 (M+1) |
| 129 |  | D | 9.5 | 1.92 | 560 (M+1) |
| 130 |  | D | 17.1 | 2.13 | 577 (M+1) |

Table 6 (continued)

| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|--|--------|---------------|----------------|-----------|
| 131 |  | D | 10.7 | 2 | 586 (M+1) |
| 132 |  | D | 19.6 | 2.13 | 593 (M+1) |
| 133 |  | D | 16.2 | 2.03 | 574 (M+1) |
| 134 |  | D' | 4 | 2.1 | 587 (M+1) |







*: (APCI -) as in Example 152

D' : Method D without PS-Trisamine treatment


EXAMPLES 135-140

- 5 To di-carboxylic acid reagents (0.24 mmol) were added 1 ml of a mixture of EDCI (95.9 mg, 0.5 mmol) and TEA (84 μl , 0.6 mmol) in DMF (7 ml) and 0.1 ml of HOBT solution (78 mg, 0.57 mmol in 0.7 ml DMF). After 15 min., 0.3 ml of Example 15 solution (174.5 mg, 0.42 mmol, in 2.1 ml DMF), was added. The reaction mixtures were then stirred overnight at RT before evaporation to dryness (**Method E**). The
- 10 residues were purified by reverse phase HPLC (gradient from $\text{CH}_3\text{CN}/\text{H}_2\text{O}/\text{TFA}$: 5/95/0.05 to $\text{CH}_3\text{CN}/\text{H}_2\text{O}/\text{TFA}$: 80/20/0.05), to provide compounds having the above formula (Iae), listed in Table 7. LC Mass results are reported (LCMS conditions : LC Micromass platform (APCI +, DAD (210-400 nm)), Column : TSK gel Super ODS 4.6 mm ID x 5 cm, Flow rate : 2.75 mL / min, Gradient : from 100% eluent A to
- 15 100% eluent B in 2 min., with a plateau with 100% eluent B during 1 min. Eluent A : H_2O (0.05% TFA), Eluent B : CH_3CN / H_2O / TFA (80/20/0.05)).

TABLE 7

| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|---|--------|---------------|----------------|------------|
| 135 |  | E | 8.1 | 1.489 | 562 (M-1)* |
| 136 |  | E | 13.8 | 2.06 | 591 (M+1) |
| 137 |  | E | 20.1 | 1.89 | 553 (M+1) |
| 138 |  | E | 13.5 | 1.95 | 564 (M+1) |
| 139 |  | E | 8.4 | 2.03 | 641 (M+1) |
| 140 |  | E | 10 | 2.15 | 553 (M+1) |

*: (APCI -) as in Example 152

EXAMPLES 141-151

- 5 To solutions of anhydride carboxylic acid reagents (0.072 mmol) in 1.5 ml THF, was added 0.5 ml of a solution of Example 15 (448.5 mg, 1.08 mmol, in 9 ml THF). The reaction mixtures were stirred overnight at RT before evaporation to dryness (**Method F**). The compounds were then purified by SAX cartridge and some further purified by reverse phase HPLC (gradient from CH₃CN/H₂O/TFA: 5/95/0.05
- 10 to CH₃CN/H₂O/TFA : 80/20/0.05), to provide compounds having the above formula (Iag), listed in Table 8. LC Mass results are reported (LCMS conditions : LC Micromass platform (APCI +, DAD (210-400 nm)), Column : TSK gel Super ODS 4.6 mm ID x 5 cm, Flow rate : 2.75 mL / min, Gradient : from 100% eluent A to 100% eluent B in 2 min., with a plateau with 100% eluent B during 1 min. Eluent A :
- 15 H₂O (0.05% TFA), Eluent B : CH₃CN / H₂O / TFA (80/20/0.05)).

TABLE 8













| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|---|--------|---------------|----------------|-----------|
| 141 |  | F | 4.9 | 2.01 | 579 (M+1) |
| 142 |  | F | 3.1 | 2.01 | 563 (M+1) |
| 143 |  | F | 0.6 | 1.85 | 607 (M+1) |
| 144 |  | F | 1 | 1.89 | 607 (M+1) |
| 145 |  | F | 1.2 | 2.1 | 569 (M+1) |
| 146 |  | F | 2 | 2.04 | 567 (M+1) |
| 147 |  | F | 2.8 | 2.03 | 567 (M+1) |

Table 8 (continued)

| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|--|--------|---------------|----------------|------------|
| 148 |  | F | 8.2 | 1.84 | 564 (M+1) |
| 149 |  | F | 7.6 | 1.98 | 553 (M+1) |
| 150 |  | F | 8.7 | 2.09 | 581 (M-18) |
| 151 |  | F | 4.5 | 2.06 | 551 (M-18) |


EXAMPLE 152**4-[(5*S**, 9*R**)-7-(2-Benzylamino-acetyl)-3-(3,5-dichloro-phenyl)-1-methyl-2,4-dioxo-1,3,7-triaza-spiro[4.4]non-9-yl]-benzonitrile**

5

To a solution of Example 15 (41.5 mg, 0.1 mmol) in 1 ml THF, were added TEA (0.0194 ml, 0.14 mmol) and chloroacetyl chloride (0.0095 ml, 0.12 mmol). After 15 min. at RT, the reaction mixture was evaporated to dryness to yield 47.8 mg of crude intermediate. To this intermediate (37.7 mg, 0.077 mmol) in 1 ml THF, were added PS-DIEA (Argonaut, 21 mg, 0.06 mmol), benzylamine (4.9 μ l, 0.045 mmol) and PS-DMAP (Argonaut, 20 mg, 0.06 mmol). The reaction mixture was stirred for 24h at RT before evaporation to dryness. The residue was purified by reverse phase HPLC (gradient from CH₃CN/H₂O/TFA: 5/95/0.05 to CH₃CN/H₂O/TFA : 80/20/0.05) to yield the titled compound (4.2 mg). Retention time: 10.65 min., 563 (M+1);

(LCMS conditions : HP 1100 MSD platform (APCI -, DAD (210-400 nm)), Column : TSK gel Super ODS 4.6 mm ID x 10 cm, Flow rate : 1 mL / min, Gradient : from 5% to 95% eluent B in 15 min., with a plateau with 95% eluent B during 5 min. Eluent A : H₂O (0.1% ammonium formate), Eluent B : CH₃CN). ¹H NMR (CDCl₃): 7.75-7.6 (2H, d), 7.6-7.15 (8H, m), 7.75 (2H, d), 4.25 (2H, s), 4.2-3.6 (7H,m), 3.3-3.05 (3H, m).

20

EXAMPLES 153-162

Compounds having the above formula (Iah), listed in Table 9, were obtained by adding Example 15 (10.9 mg, 0.045 mmol) and TEA (6.74 μ l, 0.048 mmol) to solutions of appropriate alkyl, aryl or heteroaryl bromide reagents (RR'CHBr) (0.03 mmol) in 1 ml dioxane. The reaction mixtures were stirred overnight at RT before evaporation to dryness (**Method G**). The compounds were purified by SCX cartridge and PS-Isocyanate (Argonaut, 0.06 mmol) when desired; some compounds were also purified by reverse phase HPLC (gradient from CH₃CN/H₂O/TFA: 5/95/0.05 to CH₃CN/H₂O/TFA : 80/20/0.05). Examples 162-164 were obtained after hydrolysis of their corresponding esters following the general **Method C** as in Examples 90-101. These compounds were then purified by reverse phase HPLC (gradient from CH₃CN/H₂O/TFA: 5/95/0.05 to CH₃CN/H₂O/TFA : 80/20/0.05).

LC Mass results are reported (LCMS conditions : LC Micromass platform (APCI +, DAD (210-400 nm)), Column : TSK gel Super ODS 4.6 mm ID x 5 cm, Flow rate : 2.75 mL / min, Gradient : from 100% eluent A to 100% eluent B in 2 min., with a plateau with 100% eluent B during 1 min. Eluent A : H₂O (0.05% TFA), Eluent B : CH₃CN / H₂O / TFA (80/20/0.05)).

TABLE 9












| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|---|--------|---------------|----------------|--|
| 153 |  | G | 3.2 | 1.98 | 549 (M+1) |
| 154 |  | G | 4.4 | 1.96 | ¹ H NMR (CDCl ₃): 7.62 (4H,d), 7.41-7.1 (5H,m), 6.62 (2H,s), 4.62-4.31 (3H,m), 4.10-3.75 (3H,m), 3.62-3.58 (5H,m), 3.51-3.38 (1H,m), 3.34 (3H,s) |
| 155 |  | G | 12.9 | 2.03 | 641 (M+1) |
| 156 |  | G | 3.3 | 1.82 | 563 |
| 157 |  | G | 9.9 | 2.11 | 594 (M+1) |
| 158 |  | G | 7.3 | 2.14 | 584 (M+1) |
| 159 |  | G | 11.7 | | ¹ H NMR (CDCl ₃): 7.6 (2H,d), 7.3 (2H,d), 7.2 (1H,s), 6.8 (1H,s), 6.7 (2H,s), 6.2 (1H,s), 4.45 (2H,q), 4.2 (2H,s), 3.93-4.03 (1H,m), 3.5-3.7 (3H,m), 3.3 (1H,d), 3.2 (3H,s), 1.4 (3H,t) |

Table 9 (continued)

| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|---|--------|---------------|----------------|-----------|
| 160 |  | G & C | 8.5 | 1.71 | 543 (M+1) |
| 161 |  | G & C | 1.6 | 1.86 | 613 (M+1) |
| 162 |  | G & C | 6 | 1.83 | 556 (M+1) |

EXAMPLES 163-181

5 To a solution of Example 15 (873.1 mg, 2.1 mmol) and TEA (408 μ l, 2.94 mmol) in 5 ml THF was added dropwise a solution of 1,1'-carbonyldiimidazole (479.3 mg, 2.94 mmol, in 6 ml THF). The reaction mixture was stirred at RT for 24h before evaporation to dryness. The residue was partitioned between DCM (50 ml) and brine (20 ml). The DCM layer was dried over sodium sulfate and concentrated. This
10 residue was stirred at 60°C overnight with methyl iodide (523 μ l, 8.4 mmol) in 20 ml ACN, and the reaction mixture was evaporated to dryness, furnishing the crude reactive intermediate.

To solutions of appropriately-substituted amine or alcohol reagents (RXH) (0.072 mmol) in 1.8 ml (DCM/DMF: 8/2), was added 0.5 ml of a solution of the
15 reactive intermediate (1.62 mmol), with TEA (0.5 ml, 3.56 mmol), in 13 ml DCM. The reaction mixtures were stirred overnight at RT before evaporation to dryness (**Method H**). The compounds were purified by reverse phase HPLC (gradient from CH₃CN/H₂O/TFA: 5/95/0.05 to CH₃CN/H₂O/TFA : 80/20/0.05), to provide compounds having the above formula (Iai), listed in Table 10. Examples 174-179
20 were obtained after hydrolysis of their corresponding esters following the general **Method C** as in Examples 90-101. These compounds were then purified by reverse phase HPLC (gradient from CH₃CN/H₂O/TFA: 5/95/0.05 to CH₃CN/H₂O/TFA : 80/20/0.05). LC Mass results are reported (LCMS conditions : LC Micromass platform (APCI +, DAD (210-400 nm)), Column : TSK gel Super ODS 4.6 mm ID x
25 5 cm, Flow rate : 2.75 mL / min, Gradient : from 100% eluent A to 100% eluent B in 2 min., with a plateau with 100% eluent B during 1 min. Eluent A : H₂O (0.05% TFA), Eluent B : CH₃CN / H₂O / TFA (80/20/0.05)).

TABLE 10








| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|---|--------|---------------|----------------|-----------|
| 163 |  | H | 2.2 | 2.01 | 558 (M+1) |
| 164 |  | H | 2.5 | 1.95 | 558 (M+1) |
| 165 |  | H | 4.5 | 2.22 | 598 (M+1) |
| 166 |  | H | 1.7 | 1.89 | 586 (M+1) |
| 167 |  | H | 2.7 | 1.86 | 586 (M+1) |
| 168 |  | H | 2.9 | 2.19 | 598 (M+1) |
| 169 |  | H | 3.7 | 2.07 | 570 (M+1) |

Table 10 (continued)













| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|---|--------|---------------|----------------|---|
| 170 |  | H | 1.7 | 2.18 | 622 (M+1) |
| 171 |  | H | 4 | 1.87 | 534 (M-44) |
| 172 |  | H | 7.2 | 1.89 | ¹ H NMR (CDCl ₃): 7.71 (2H,d), 7.57-7.25 (4H,m), 7.14 (2H,d), 7.00 (1H,d), 6.75 (2H,d), 4.6-3.88 (5H,m), 3.24 (3H,s) |
| 173 |  | H | 6.9 | 2.05 | 534 (M-44) |
| 174 |  | H & C | 8.2 | 1.83 | 530 (M+1) |
| 175 |  | H & C | 4.8 | 1.85 | 544 (M+1) |
| 176 |  | H & C | 1.1 | 2.04 | 570 (M+1) |


Table 10 (continued)

| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|---|--------|---------------|----------------|--|
| 177 |  | H & C | 3.2 | 1.81 | 572 (M+1) |
| 178 |  | H & C | 3.8 | 1.98 | 570 (M+1) |
| 179 |  | H & C | 2.4 | 1.94 | 556 (M+1) |
| 180 |  | H | 3.8 | 1.95 | ¹ H NMR (CDCl ₃): 7.7 (2H,d), 7.5-7.3 (3H,m), 6.8 (2H,d), 4.8 (1H,d), 4.57 (1H,d), 4.1-3.89 (5H,m), 3.24 (3H,s) |
| 181 |  | H | 2.5 | 2.28 | ¹ H NMR (CDCl ₃): 8.05 (2H,d), 7.7 (2H,d), 7.45 (2H,d), 7.4-7.2 (3H,m), 6.8 (2H,d), 5.3 (2H,d), 4.5 4.2 (1H,m), 4.2-3.75 (8H,m), 3.2 (3H,s) |


EXAMPLE 182

[[[(5*S, 9*R**)-9-(4-Cyano-phenyl)-3-(3,5-dichloro-phenyl)-1-methyl-2,4-dioxo-1,3,7-triaza-spiro[4.4]nonane-7-carbonyl]-amino}-acetic acid ethyl ester**

5



To a solution of Example 15 (24.9 mg, 0.06 mmol) in 1 ml THF/DMF (9/1), was added ethyl isocyanatoacetate (11.6 mg, 0.089 mmol), and the reaction mixture was stirred overnight at RT. The titled compound was obtained (33.3 mg) after treatment with PS-Trisamine (Argonaut, 73 mg, 0.267 mmol) and PS-Isocyanate (Argonaut, 85 mg, 0.122 mmol). Retention time: 1.99 min., 544 (M+1); (LCMS conditions : LC Micromass platform (APCI +, DAD (210-400 nm)), Column : TSK gel Super ODS 4.6 mm ID x 5 cm, Flow rate : 2.75 mL / min, Gradient : from 100% eluent A to 100% eluent B in 2 min., with a plateau with 100% eluent B during 1 min. Eluent A : H₂O (0.05% TFA), Eluent B : CH₃CN / H₂O / TFA (80/20/0.05)).

EXAMPLES 183-216

(Iaj)

20

Compounds having the above formula (Iaj), listed in Table 11, were obtained either by **Method I** or **Method J**, below, after SCX cartridge purification. Some compounds were further purified by reverse phase HPLC (gradient from

CH₃CN/H₂O/TFA: 5/95/0.05 to CH₃CN/H₂O/TFA : 80/20/0.05). Example 207 was obtained after hydrolysis of its corresponding ethyl ester following the general **Method C** as in Examples 90-101, and purified by reverse phase HPLC (gradient from CH₃CN/H₂O/TFA: 5/95/0.05 to CH₃CN/H₂O/TFA : 80/20/0.05).

5 **Method I:** To solutions of aldehyde reagents (0.12 mmol) in 1.2 ml 1,2-DCE, were added sodium sulfate (12.8 mg) and 0.5 ml of Example 15 solution (0.797 mg, 1.92 mmol, in 16 ml 1,2-DCE). The reaction mixtures were then stirred 24 h at RT before addition of sodium triacetoxyborohydride (20 mg, 0.084 mmol). The reactions were allowed to continue at RT for 24 h.

10 **Method J:** To solutions of aldehyde reagents (0.135 mmol) and triacetoxyborohydride (19 mg, 0.09 mmol) in 1.5 ml of 1,2-DCE, were added 0.4 ml of a mixture trimethyl orthoformate / acetic acid: (10.5 ml / 0.225 ml) and 0.5 ml of Example 15 solution (0.486 mg, 1.17 mmol, in 75 ml 1,2-DCE). The reaction mixtures were then stirred 24 h at RT, before treatment by PS-TsNHNH₂ (Argonaut,
15 159 mg, 0.405 mmol).

For each compound, LC Mass results are reported in Table 11 (LCMS conditions : LC Micromass platform (APCI +, DAD (210-400 nm)), Column : TSK gel Super ODS 4.6 mm ID x 5 cm, Flow rate : 2.75 mL / min, Gradient : from 100% eluent A to 100% eluent B in 2 min., with a plateau with 100% eluent B during 1 min.
20 Eluent A : H₂O (0.05% TFA), Eluent B : CH₃CN / H₂O / TFA (80/20/0.05)).

TABLE 11








| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|---|--------|---------------|----------------|---|
| 183 |  | I | 12.7 | 2.24 | 545 (M+1) |
| 184 |  | J | 6.6 | 1.87 | 548 (M+1); ¹ H NMR (CDCl ₃): 7.6 (2H, d), 7.4-7.15 (5H, m), 6.85-6.6 (4H, m), 3.9-3.55 (3H, m), 3.45-2.85 (13H, m) |
| 185 |  | J | 4 | 1.85 | 549 (M+1) |
| 186 |  | J | 4.5 | 1.91 | 579 (M+1) |
| 187 |  | J | 4.5 | 1.88 | 575 (M+1) |
| 188 |  | J | 2.8 | 1.72 | 606 (M+1) |
| 189 |  | J | 3.6 | 1.89 | 471 (M+1) |

Table 11 (continued)








| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|---|--------|---------------|----------------|-----------------------|
| 190 |  | J | 3.2 | 2.32 | 512 (M+1) |
| 191 |  | J | 3.2 | 2.16 | 611 (M+1) |
| 192 |  | J | 3 | 1.99 | 580 (M+41); 540 (M+1) |
| 193 |  | J | 2.5 | 1.84 | 549 (M+1); 590 (M+41) |
| 194 |  | J | 6.4 | 1.69 | 568 (M+41) |
| 195 |  | J | 9.5 | 1.75 | 495 (M+1) |
| 196 |  | J | 1.3 | 1.82 | 579 (M+1) |

Table 11 (continued)








| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|---|--------|---------------|----------------|------------|
| 197 |  | J | 13.6 | 1.84 | 555 (M+1) |
| 198 |  | J | 7.4 | 1.97 | 556 (M+1) |
| 199 |  | J | 1.9 | 1.83 | 471 (M+1) |
| 200 |  | J | 3.3 | 10.734* | 650 (M-1)* |
| 201 |  | J | 14.6 | 2.02 | 560 (M+1) |
| 202 |  | J | 16.8 | 1.92 | 541 (M+1) |
| 203 |  | J | 20.1 | 1.92 | 485 (M+1) |

Table 11 (continued)















| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|---|--------|---------------|----------------|-----------|
| 204 |  | J | 18.3 | 1.79 | 457 (M+1) |
| 205 |  | J | 9.6 | 2.02 | 519 (M+1) |
| 206 |  | J | 3.7 | 1.75 | 513 (M+1) |
| 207 |  | J & C | 12.5 | 1.75 | 513 (M+1) |
| 208 |  | J | 12.6 | 2.17 | 533 (M+1) |
| 209 |  | J | 7.4 | 2.34 | 622 (M+1) |
| 210 |  | J | 7.8 | 1.9 | 571 (M+1) |

Table 11 (continued)

| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|---|--------|---------------|----------------|-----------|
| 211 |  | J | 5.8 | 2.09 | 499 (M+1) |
| 212 |  | J | 7 | 2.11 | 544 (M+1) |
| 213 |  | J | 6.5 | 2.12 | 485 (M+1) |
| 214 |  | J | 4 | 1.69 | 571 (M+1) |
| 215 |  | J | 9 | 2.01 | 495 (M+1) |
| 216 |  | J | 20 | 1.85 | 556 (M+1) |

*(APCI-) as in Example 152

EXAMPLES 217-250

- 5 To a suspension of PS-carbodiimide (Argonaut, 0.96 mmol/g, 74 mg, 0.071 mmol) in 0.33 ml of hydroxyazabenzotriazole solution (153 mM DCM {25% DMF}, 0.05 mmol), were added 0.5 ml of a solution of Example 64 (60 mM DCM {20% DMF}, 0.03 mmol) and 0.5 ml of solution having the desired amine reagent RR'NH (54 mM DCM {20% DMF}, 0.027 mmol). After 24 h at RT, the mixtures were
- 10 treated with PS-trisamine (Argonaut, 3.65 mmol/g, 65 mg, 0.24 mmol) overnight. After evaporation to dryness of the filtered solutions, compounds having the formula (Iak), listed in Table 12, were obtained. For N-Boc and/or CO₂tBu protected acids (Examples 245-250), the compounds were treated with DCM/TFA (1:1) solution for 2 h at RT, following respectively by SCX or SAX cartridge purification (**Method L**).
- 15 Examples 242-244 were obtained after hydrolysis of their corresponding esters following the general **Method C** as in Examples 90-101. These compounds were then purified by SAX cartridge. Some compounds were obtained after purification by reverse phase HPLC (gradient from CH₃CN/H₂O/TFA: 5/95/0.05 to CH₃CN/H₂O/TFA : 80/20/0.05).
- 20 For each compound, LC Mass results are reported in Table 12 (LCMS conditions : LC Micromass platform (APCI +, DAD (210-400 nm)), Column : TSK gel Super ODS 4.6 mm ID x 5 cm, Flow rate : 2.75 mL / min, Gradient : from 100% eluent A to 100% eluent B in 2 min., with a plateau with 100% eluent B during 1 min. Eluent A : H₂O (0.05% TFA), Eluent B : CH₃CN / H₂O / TFA (80/20/0.05)).

TABLE 12








| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|---|--------|---------------|----------------|-----------|
| 217 |  | K | 2 | 2.25 | 620 (M+1) |
| 218 |  | K | 1.6 | 1.97 | 572 (M+1) |
| 219 |  | K | 1.9 | 2.26 | 620 (M+1) |
| 220 |  | K | 1.3 | 2.59 | 610 (M+1) |
| 221 |  | K | 2.1 | 1.83 | 624 (M+1) |
| 222 |  | K | 1.9 | 2.05 | 612 (M+1) |
| 223 |  | K | 1.9 | 2.07 | 612 (M+1) |

Table 12 (continued)








| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|---|--------|---------------|----------------|-----------|
| 224 |  | K | 1.7 | 2.27 | 646 (M+1) |
| 225 |  | K | 1.2 | 2.14 | 586 (M+1) |
| 226 |  | K | 1.7 | 2.16 | 626 (M+1) |
| 227 |  | K | 1.9 | 2.4 | 676 (M+1) |
| 228 |  | K | 1.7 | 2.47 | 686 (M+1) |
| 229 |  | K | 1.8 | 2.15 | 600 (M+1) |
| 230 |  | K | 1.6 | 2.23 | 692 (M+1) |

Table 12 (continued)








| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|---|--------|---------------|----------------|-----------|
| 231 |  | K | 1.7 | 2.29 | 660 (M+1) |
| 232 |  | K | 1.5 | 2.46 | 700 (M+1) |
| 233 |  | K | 1.7 | 2.13 | 641 (M+1) |
| 234 |  | K | 1.8 | 2.11 | 629 (M+1) |
| 235 |  | K | 1.9 | 2.09 | 641 (M+1) |
| 236 |  | K | 5.5 | 2.08 | 528 (M+1) |
| 237 |  | K | 7 | 1.77 | 528 (M+1) |

Table 12 (continued)















| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|---|----------|---------------|----------------|-----------|
| 238 |  | K | 12.2 | 1.97 | 514 (M+1) |
| 239 |  | K | 16.7 | 1.8 | 516 (M+1) |
| 240 |  | K | 14.8 | 1.94 | 526 (M+1) |
| 241 |  | K' (SCX) | 13.6 | 2.12 | 562 (M+1) |
| 242 |  | K & C | 1.1 | 2.13 | 592 (M+1) |
| 243 |  | K & C | 1.3 | 1.8 | 584 (M+1) |
| 244 |  | K & C | 1.5 | 1.81 | 584 (M+1) |

Table 12 (continued)

| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|---|--------|---------------|----------------|-----------|
| 245 |  | K & L | 1.5 | 1.71 | 574 (M+1) |
| 246 |  | K & L | 4.7 | 1.71 | 544 (M+1) |
| 247 |  | K & L | 4.5 | 1.81 | 636 (M+1) |
| 248 |  | K & L | 16.7 | 1.57 | 541 (M+1) |
| 249 |  | K & L | 17.7 | 1.59 | 529 (M+1) |
| 250 |  | K & L | 17.5 | 1.57 | 541 (M+1) |

EXAMPLES 251-268

5 Compounds having the formula (Iaj), listed in Table 13, were obtained using
Method G or **I**, as described for Examples 153-162 and 183-216, after SCX cartridge
purification. Some compounds were further purified by reverse phase HPLC (gradient
from CH₃CN/H₂O/TFA: 5/95/0.05 to CH₃CN/H₂O/TFA : 80/20/0.05). Example 268
was obtained after hydrolysis of its corresponding ethyl ester (example 267) following
10 the general **Method C** as in Examples 90-101. For each compound, LC Mass results
are reported in Table 13 (LCMS conditions : LC Micromass platform (APCI +, DAD
(210-400 nm)), Column : TSK gel Super ODS 4.6 mm ID x 5 cm, Flow rate : 2.75 mL
/ min, Gradient : from 100% eluent A to 100% eluent B in 2 min., with a plateau with
100% eluent B during 1 min. Eluent A : H₂O (0.05% TFA), Eluent B : CH₃CN / H₂O
15 / TFA (80/20/0.05)).

TABLE 13




















| Ex. | Structure | Method | Quantity (mg) | Retention Time | Analysis |
|-----|---|--------|---------------|----------------|-----------|
| 251 |  | I | 4.5 | 1.9 | 523 (M+1) |
| 252 |  | I | 9.6 | 2.04 | 593 (M+1) |
| 253 |  | I | 7.6 | 1.97 | 557 (M+1) |
| 254 |  | I | 8.5 | 1.92 | 577 (M+1) |
| 255 |  | I | 10.3 | 1.82 | 566 (M+1) |
| 256 |  | I | 11.2 | 1.81 | 543 (M+1) |
| 257 |  | I | 18.1 | 1.72 | 523 (M+1) |
| 258 |  | I | 9.3 | 1.74 | 523 (M+1) |
| 259 |  | I | 16.5 | 1.7 | 509 (M+1) |

Table 13 (continued)











| Ex. | Structure | Method | Quantity (mg) | Retention Time | Analysis |
|-----|---|--------|---------------|----------------|-----------|
| 260 |  | I | 11.5 | 1.9 | 523 (M+1) |
| 261 |  | I | 14.8 | 1.85 | 509 (M+1) |
| 262 |  | I | 8 | 1.82 | 508 (M+1) |
| 263 |  | I | 6.1 | 1.89 | 525 (M+1) |
| 264 |  | I | 12.8 | 1.77 | 494 (M+1) |
| 265 |  | I | 3.9 | 1.85 | 511 (M+1) |
| 266 |  | I | 7.6 | 2 | 591 (M+1) |
| 267 |  | G | 2.5 | 1.97 | 584 (M+1) |
| 268 |  | G + C | 2 | 1.76 | 557 (M+1) |

EXAMPLES 269-278

5


Compounds having the above formula (Ial), listed in Table 14, were obtained by adding 0.1 ml of TEA solution (720 mM in THF, 0.072 mmol), 0.1 ml of DMAP solution (60 mM in THF, 0.006 mmol) and 1 ml of Preparation 25 solution (60 mM in THF, 0.06 mmol), to a solution of an appropriately-substituted amine RR'NH (0.5 ml, 18 mM in THF, 0.09 mmol). The reaction mixtures were stirred at RT overnight and concentrated to dryness (**Method M**). The residues were purified by reverse phase HPLC (gradient from CH₃CN/H₂O/TFA: 5/95/0.05 to CH₃CN/H₂O/TFA : 80/20/0.05). N-Boc and/or CO₂tBu protected compounds were treated with DCM/TFA (1:1) solution for 2 h at RT, followed respectively by SCX or SAX cartridge purification for the resulting basic or acidic compounds (**Method L**). LC Mass results are reported (APCI +, DAD (210-400 nm)), Column : TSK gel Super ODS 4.6 mm ID x 5 cm, Flow rate : 2.75 mL / min, Gradient : from 100% eluent A to 100% eluent B in 2 min., with a plateau with 100% eluent B during 1 min. Eluent A : H₂O (0.05% TFA), Eluent B : CH₃CN / H₂O / TFA (80/20/0.05)).

TABLE 14

| Ex. | Structure | Method | Quantity (mg) | Retention time | Analysis |
|-----|---|--------|---------------|----------------|-----------|
| 269 |  | M | 5.3 | 1.86 | 572 (M+1) |
| 270 |  | M | 3.5 | 1.86 | 612 (M+1) |
| 271 |  | M | 7.8 | 1.89 | 612 (M+1) |
| 272 |  | M | 9.1 | 1.86 | 528 (M+1) |
| 273 |  | M | 11.2 | 1.7 | 516 (M+1) |
| 274 |  | M | 8.8 | 1.78 | 526 (M+1) |
| 275 |  | M + L | 13.2 | 1.64 | 541 (M+1) |
| 276 |  | M + L | 6.8 | 1.59 | 529 (M+1) |
| 277 |  | M + L | 10.7 | 1.58 | 541 (M+1) |
| 278 |  | M | 3.7 | 1.86 | 572 (M+1) |

EXAMPLE 279

4-[(5*S,9*R**)-7-Benzyl-3-(2,6-dichloro-pyridin-4-yl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile**



5


Using the experimental procedure described for Example 11, Preparation 20 (5.6 g, 15 mmol) was converted into the above-titled compound as a white solid (7.5 g), mp = 174-176°C. ¹H NMR (CDCl₃) : 7.60 (2H, d, *J* = 8 Hz), 7.25-7.35 (7H, m), 7.11 (2H, m), 3.65-4.0 (4H, m), 3.0-3.4 (2H, m), 3.23 (3H, s), 2.97 (1H, d, *J* = 10.9 Hz).

10

EXAMPLE 280

4-[(5*S,9*R**)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl]-benzoic acid**

15




Trifluoroacetic acid (122 μl, 1.6 mmol) was added to a cooled (5°C) solution of Preparation 27 (97 mg, 0.16 mmol) in DCM (3ml). After 24 h at RT, water was added and the pH was brought to 10 with NH₄OH. SO₂ was then bubbled into the solution until pH=6. The organic layer was separated. The aqueous layer was

20

extracted twice with DCM. The combined organic layers were dried over MgSO_4 and concentrated *in vacuo*. The resulting compound was crystallized by addition of acetonitrile. The solid was washed with ether and pentane to yield the above-titled compound as an off-white solid (7.5 mg). Retention time: 8.1 min., 533 (M-1); LCMS conditions : HP 1100 MSD platform (APCI -, DAD (210-400 nm), Column : TSK gel Super ODS 4.6 mm ID x 10 cm, Flow rate : 1 mL / min, Gradient : from 5% to 95% eluent B in 15 min., with a plateau with 95% eluent B during 5 min. Eluent A : H_2O (0.1% ammonium formate), Eluent B : CH_3CN .

EXAMPLE 281


4-[(5*S,9*R**)-3-(3,5-Dichlorophenyl)-1-methyl-2,4-dioxo-7-(2-1*H*-tetrazol-5-yl-acetyl)-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile**



Using the same procedure as in Example 102, the above titled compound was obtained (33.3 mg) after purification by reverse phase HPLC (gradient from $\text{CH}_3\text{CN}/\text{H}_2\text{O}/\text{TFA}$: 5/95/0.05 to $\text{CH}_3\text{CN}/\text{H}_2\text{O}/\text{TFA}$: 80/20/0.05) from Example 15 (41.3mg, 0.1 mmol) and tetrazole-5-acetic acid (22 mg, 0.17 mmol). ^1H NMR (CDCl_3): 7.65-7.5 (2H, m), 7.35-7.1 (3H, m), 6.67 (2H, d), 4.5-3.7 (7H, m), 3.1 (3H, d).

EXAMPLE 282


4-[(5*S,9*R**)-3-(3,5-Dichlorophenyl)-1-methyl-2,4-dioxo-7-[2-(1*H*-tetrazol-5-yl)-ethyl]-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile**



To Example 15 (24.9 mg, 0.06 mmol) in 1 ml CH₃CN, were added sodium iodide (8.4 mg, 0.084 mmol), potassium carbonate (5.5 mg, 0.06 mmol) and 5-(2-chloroethyl)-1*H*-tetrazole (5.3 mg, 0.04 mmol). The reaction mixture was stirred at 70°C overnight. The above titled compound was obtained (1.3 mg) after SCX cartridge purification and PS-isocyanate treatment (Argonaut, 83 mg). Retention time: 1.36 min., $M_{obs} = 511$ (M+1) (LCMS conditions : LC Micromass platform (APCI +, DAD (210-400 nm)), Column : TSK gel Super ODS 4.6 mm ID x 5 cm, Flow rate : 2.75 mL / min, Gradient : from 100% eluent A to 100% eluent B in 2 min., with a plateau with 100% eluent B during 1 min. Eluent A : H₂O (0.05% TFA), Eluent B : CH₃CN / H₂O / TFA (80/20/0.05)).

EXAMPLE 283

4-((5*S,9*R**)-3-(3,5-Dichlorophenyl)-1-methyl-2,4-dioxo-7-[2-(1*H*-tetrazol-5-yl)-benzyl]-1,3,7-triazaspiro[4.4]non-9-yl)-benzonitrile**



20


A mixture of Example 15 (33 mg, 0.08 mmol), Preparation 29 (57.8 mg, 0.12 mmol), TEA (16.7 μ l, 0.12 mmol) and PS-DMAP (Argonaut, 5 mg) was stirred at RT overnight. The above titled compound was obtained (4.1 mg) after purification by reverse phase HPLC (gradient from CH₃CN/H₂O/TFA: 5/95/0.05 to

CH₃CN/H₂O/TFA : 80/20/0.05). Retention time: 1.49 min., 573 (M+1) (LCMS conditions : LC Micromass platform (APCI +, DAD (210-400 nm)), Column : TSK gel Super ODS 4.6 mm ID x 5 cm, Flow rate : 2.75 mL/min, Gradient : from 100% eluent A to 100% eluent B).

5

EXAMPLE 284

6-[(5*S,9*R**)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-nicotinic acid methyl ester**




10

The above titled compound was obtained using the procedure described for Example 283 from Example 15 and Preparation 31. Retention time: 1.47 min., M_{obs} = 564/566 (M and M+2) (LCMS conditions : LC Micromass platform (APCI +, DAD (210-400 nm)), Column : TSK gel Super ODS 4.6 mm ID x 5 cm, Flow rate : 2.75 mL/min, Gradient : from 100% eluent A to 100% eluent B).

15

EXAMPLE 285

6-[(5*S,9*R**)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-nicotinic acid**




20

The above titled compound was obtained from Example 284 using the procedure described for Example 59. Retention time: 1.38 min., $M_{\text{obs}} = 550/552$ (M and M+2) (LCMS conditions : LC Micromass platform (APCI +, DAD (210-400 nm)), Column : TSK gel Super ODS 4.6 mm ID x 5 cm, Flow rate : 2.75 mL/min, Gradient : from 100% eluent A to 100% eluent B).

EXAMPLE 286


4-[(5*S,9*R**)-3-(2,6-Dichloro-pyridin-4-yl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile**



The above titled compound was obtained from Example 279 using the procedure described for Example 15. White solid, mp = 202 °C.

EXAMPLE 287

4-[(5*S,9*R**)-3-(3,5-Dichlorophenyl)-1-methyl-2,4-dioxo-7-[4-(1*H*-tetrazol-5-yl)-thiophen-2-ylmethyl]-1,3,7-triazaspiro[4.4]non-9-yl]-benzonitrile**




Example 287 was prepared from Example 15 and Preparation 32 by the reductive amination procedure described for Example 37. Retention time: 8.40 min., $M_{\text{obs}} = 580$ (M+1); (LCMS conditions : HP 1100 MSD platform (APCI +, DAD (210-400 nm)), Column : TSK gel Super ODS 4.6 mm ID x 10 cm, Flow rate : 1 mL / min,

Gradient : from 5% to 95% eluent B in 15 min., with a plateau with 95% eluent B during 5 min. Eluent A : H₂O (0.1% ammonium formate), Eluent B : CH₃CN).

EXAMPLE 288

5 **5-[(5*S**,9*R**)-9-(4-Cyanophenyl)-3-(2,6-Dichloro-pyridin-4-yl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-thiophene-3-carboxylic acid**




10

Example 288 was prepared as described for Example 287, using the appropriate aldehyde. White solid, mp = 230-232 °C.

EXAMPLE 289

15 **5-[(5*S**,9*R**)-9-(4-Cyanophenyl)-3-(2,6-Dichloro-pyridin-4-yl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-thiophene-2-carboxylic acid**




Example 289 was prepared as described for Example 287, using the appropriate aldehyde. Off-white solid, mp = 252 °C.

20

EXAMPLE 290

5-[(5*S,9*R**)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-thiophene-3-carboxylic acid methyl ester**




To a solution of 5-[(5*S**,9*R**)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-thiophene-3-carboxylic acid (example 37) (0.150 g, 0.27 mmol) in DCM/MeOH (5:1 mL) was added trimethylsilyldiazomethane (2.0 M solution in hexane, 0.33 mL, 0.67 mmol) over a period of three minutes at RT. The reaction mixture was stirred at RT for twenty minutes, quenched by the slow addition of acetic acid (approximately ten drops) and partitioned between DCM (20 mL) and saturated aqueous sodium bicarbonate (15 mL). The DCM layer was washed with brine (20 mL), dried over sodium sulfate and concentrated to yield a thick oil. LC retention time = 3.34 min. Column used: YMC S5 combiscreen ODS 4.6 x 50 mm (4 min. gradient); Solvent A = 10% MeOH, 90% H₂O and 0.2% H₃PO₄; solvent B = 90% MeOH, 10% H₂O, 0.2% H₃PO₄.

15

CLAIMS:

We claim:

1. A compound according to formula (I),



its enantiomers, diastereomers, or a pharmaceutically-acceptable salt, hydrate, solvate, or prodrug thereof, in which:

L and K, taken independently, are O or S;

Z is N or CR_{4b};

10 Ar is aryl or heteroaryl;

G is attached to ring A at T or M; and (i) when attached to a carbon atom of ring A, G is selected from a bond, -O-, -N-, -S-, C₁₋₄alkylene, C₁₋₄substituted alkylene, or bivalent alkoxy, alkylthio, aminoalkyl, sulfonyl, sulfonamidyl, acyl, or alkoxycarbonyl; or (ii) when attached to a nitrogen atom of ring A, G is
 15 selected from a bond, C₁₋₄alkylene, C₁₋₄substituted alkylene, and bivalent acyl or alkoxycarbonyl, and a bivalent alkoxy, alkylthio, aminoalkyl, sulfonyl, or sulfonamidyl wherein in (ii), each of said G groups have at least one carbon atom directly attached to ring A;

J is -O-, -S-, -NR₃-, -N=, -S(=O)-, -SO₂-, -NHSO₂-, a substituted or unsubstituted C₁₋₃alkylene, a substituted or unsubstituted C₂₋₃alkenylene, an unsubstituted C₁₋₂heteroalkylene, a substituted heteroalkylene having from one to two carbon atoms in the heteroalkylene straight chain, or J is absent so that ring A is a three-membered ring;

T is T₁ when G-Ar is attached to T, and T₂ when G-Ar is attached to M;

25 M is M₁ when G-Ar is attached to M, and M₂ when G-Ar is attached to T;

T₁ and M₁ are selected from -N- and -C(R₅)-;

T₂ and M₂ are selected from -O-, -S-, -N(R₆)-, -N=, -S(=O)-, -SO₂-, -NHSO₂-, and -C(R₇R₈)-, provided that J, M, and T are selected so that ring A defines a three to six membered saturated or partially unsaturated cycloalkyl or heterocyclic ring having 1 to 4 heteroatoms, wherein no two adjacent heteroatoms of said heterocyclic ring A are simultaneously selected from -O- and -S-;

R₂ is selected from hydrogen, alkyl, substituted alkyl, OR₁₂, NR₁₂R₁₃, C(=O)R₁₂, CO₂R₁₂, C(=O)NR₁₂R₁₃, NR₁₂C(=O)R₁₃, NR₁₂C(=O)OR₁₃, S(O)_pR_{13a}, NR₁₂SO₂R_{13a}, SO₂NR₁₂R₁₃, cycloalkyl, heterocyclo, aryl, and heteroaryl;

R_{4a}, R_{4b} and R_{4c} are independently selected from hydrogen, halogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, nitro, cyano, SR₁₄, OR₁₄, NR₁₄R₁₅, NR₁₄C(=O)R₁₅, CO₂R₁₄, C(=O)R₁₄, -C(=O)NR₁₄R₁₅, aryl, heterocyclo, cycloalkyl, and heteroaryl;

R₃ and R₆ are independently selected from hydrogen, alkyl, substituted alkyl, hydroxy, alkoxy, alkenyl, substituted alkenyl, aminoalkyl, alkylthio, C(=O)H, acyl, amide, alkoxycarbonyl, sulfonyl, sulfonamidyl, cycloalkyl, heterocyclo, aryl, and heteroaryl;

R₅, R₇, and R₈ are (i) independently selected from hydrogen, alkyl, substituted alkyl, halogen, nitro, cyano, hydroxy, alkoxy, alkenyl, substituted alkenyl, aminoalkyl, alkylthio, C(=O)H, acyl, CO₂H, amide, alkoxycarbonyl, sulfonyl, sulfonamidyl, cycloalkyl, heterocyclo, aryl, and heteroaryl; or (ii) R₇ with R₈ may form a cycloalkyl or heterocyclic ring or a double bond to an oxygen atom to define a keto (=O) group; or (iii) one of R₅ or R₈ may be a bond so that there is a double bond between T and M, or between M and J, respectively, so that ring A is partially unsaturated;

R₁₂, R₁₃, R₁₄ and R₁₅ (i) are selected independently of each other from hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclo; or (ii) R₁₂ is taken together with R₁₃, and/or R₁₄ is taken together with R₁₅ to form a heteroaryl or heterocyclo ring;

R_{13a} is selected from alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclo; and

p is 1 or 2.

- 5 2. A compound according to claim 1, or a pharmaceutically-acceptable salt, hydrate, prodrug, or enantiomer thereof, wherein:

G is a bond;

Ar is an aryl or heteroaryl substituted with one to three R₁;

10 R₁ is selected from alkyl, substituted alkyl, halogen, cyano, nitro, OR₁₀, NR₁₀R₁₁, C(=O)R₁₀, CO₂R₁₀, C(=O)NR₁₀R₁₁, NR₁₀C(=O)R₁₁, NR₁₀C(=O)OR₁₁, SR₁₀, S(O)_oR_{10a}, NR₁₀SO₂R_{10a}, NHCH(alkyl)CO₂R₁₀, SO₂NR₁₀R₁₁, cycloalkyl, heterocyclo, aryl, and heteroaryl;

15 R₁₀ and R₁₁ (i) are selected independently of each other from hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclo; or (ii) R₁₀ is taken together with R₁₁ to form a heteroaryl or heterocyclo;

R_{10a} is alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclo; and
o is 1 or 2.

- 20 3. A compound according to claim 1, or a pharmaceutically-acceptable salt, hydrate, prodrug, or enantiomer thereof, in which:

J is selected from -O-, -S-, -S(=O)-, -SO₂-, or -NHSO₂-; or J is C₁₋₃alkylene, C₂₋₃alkenylene, or C₁₋₂heteroalkylene optionally substituted with one to two R₉;

R₉ is -A₁-Q-A₂-R₁₆;

A₁ is a bond, C₁₋₂alkylene, or C₂₋₃alkenylene;

25 Q is a bond, -C(=O)-, -C(=O)NR₁₇-, -C(=S)NR₁₇-, -SO₂-, -SO₂NR₁₇-, -CO₂-, or -NR₁₇CO₂-;

A₂ is a bond, C₁₋₃alkylene, C₂₋₃alkenylene, -C₁₋₄alkylene-NR₁₇-, -C₁₋₄alkylene-NR₁₇C(=O)-, -C₁₋₄alkylene-S-, -C₁₋₄alkylene-SO₂-, or -C₁₋₄alkylene-O-, wherein said A₂ alkylene groups are branched or straight chain and optionally

substituted with a group selected from $-\text{CO}_2\text{H}$, $-\text{CO}_2(\text{C}_{1-4}\text{alkyl})$, $-\text{S}(\text{C}_{1-4}\text{alkyl})$, NH_2 , $-\text{NH}(\text{C}_{1-4}\text{alkyl})$, or $-\text{N}(\text{C}_{1-4}\text{alkyl})_2$;

R_{16} is selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, heteroaryl, cycloalkyl, and heterocyclo; and

R_{17} is hydrogen or alkyl.

5

4. A compound according to claim 3, or a pharmaceutically-acceptable salt, hydrate, prodrug, or enantiomer thereof, in which:

R_{16} is selected from cycloalkyl, heterocyclo, aryl or heteroaryl optionally substituted with one to three R_{18} ;

10

R_{18} is selected from $\text{C}_{1-6}\text{alkyl}$, substituted $\text{C}_{1-6}\text{alkyl}$, halogen, cyano, nitro, OR_{20} , $\text{NR}_{20}\text{R}_{21}$, $\text{C}(=\text{O})\text{R}_{20}$, CO_2R_{20} , $\text{C}(=\text{O})\text{NR}_{20}\text{R}_{21}$, $\text{C}(=\text{O})\text{NR}_{20}\text{SO}_2\text{R}_{20a}$, $\text{NR}_{20}\text{C}(=\text{O})\text{R}_{21}$, $\text{NR}_{20}\text{C}(=\text{O})\text{OR}_{21}$, SR_{20} , $\text{S}(\text{O})_u\text{R}_{20a}$, $\text{NR}_{20}\text{SO}_2\text{R}_{20a}$, $\text{NHCH}(\text{alkyl})\text{CO}_2\text{R}_{20}$, $\text{SO}_2\text{NR}_{20}\text{R}_{21}$, $\text{C}_{3-7}\text{cycloalkyl}$, phenyl, four to seven membered heterocyclo, or five or six membered heteroaryl, said $\text{C}_{3-7}\text{cycloalkyl}$, phenyl, four to seven membered heterocyclo, or five or six membered heteroaryl groups in turn being optionally substituted with one to two R_{22} ;

15

R_{20} and R_{21} are selected from hydrogen, alkyl, alkenyl, $\text{C}_{3-7}\text{cycloalkyl}$, phenyl, benzyl, phenylethyl, naphthyl, a four to seven membered heterocyclo, or a five to six membered heteroaryl, or when attached to the same nitrogen atom may join to form a heterocyclo or heteroaryl; wherein each of R_{20} and R_{21} in turn is optionally substituted with one to two R_{22} ;

20

R_{20a} is selected from hydrogen, alkyl, alkenyl, CO_2H , $\text{CO}_2(\text{alkyl})$, $\text{C}_{3-7}\text{cycloalkyl}$, phenyl, benzyl, phenylethyl, naphthyl, a four to seven membered heterocyclo, or a five to six membered heteroaryl; wherein each R_{20a} in turn is optionally substituted with one to two R_{22} ; and


25

R_{22} is selected from the group consisting of $(\text{C}_{1-4})\text{alkyl}$, $(\text{C}_{2-4})\text{alkenyl}$, hydroxy, cyano, CF_3 , $\text{O}(\text{C}_{1-4}\text{alkyl})$, OCF_3 , $\text{C}(=\text{O})\text{H}$, $\text{C}(=\text{O})(\text{C}_{1-4}\text{alkyl})$, CO_2H , $\text{CO}_2(\text{C}_{1-4}\text{alkyl})$, $\text{NHCO}_2(\text{C}_{1-4}\text{alkyl})$, $-\text{S}(\text{C}_{1-4}\text{alkyl})$, $-\text{NH}_2$, $\text{NH}(\text{C}_{1-4}\text{alkyl})$, $\text{N}(\text{C}_{1-4}\text{alkyl})_2$,

30

$N(CH_3)_3^+$, $SO_2(C_{1-4}alkyl)$, $C(=O)(C_{1-4}alkylene)NH_2$, $C(=O)(C_{1-4}alkylene)NH(alkyl)$, and $C(=O)(C_{1-4}alkylene)N(C_{1-4}alkyl)_2$.

5. A compound according to claim 4, or a pharmaceutically-acceptable salt, hydrate, prodrug, or enantiomer thereof, in which:



T_1 and M_1 are selected from $-N-$ and $-CH-$, and T_2 and M_2 are selected from O, S, NH, $S(=O)$, SO_2 , $NHSO_2$, $-C(=O)-$ and $-CH_2-$;

J is a $-C_{2-3}alkylene$ optionally substituted with one to two R_9 , $-(CH_2)_y-NH-$, or $-(CH_2)_y-NR_9-$;

R_{1a} and R_{1b} are independently selected from halogen, $C_{1-4}alkyl$, hydroxy, alkoxy, haloalkyl, haloalkoxy, cyano, nitro, $-CO_2H$, $-C(=O)H$, $-CO_2alkyl$, $-C(=O)alkyl$, $-C(=O)NH(CH_2)_{1-4}CO_2H$, $-C(=O)NH(CH_2)_{1-4}CO_2(alkyl)$, and $S(O)_2alkyl$; or from phenyl, benzyl, phenyloxy, benzyloxy and heteroaryl in turn optionally substituted with halogen, $C_{1-4}alkyl$, hydroxy, alkoxy, haloalkyl, haloalkoxy, cyano, nitro, $-CO_2H$, $-C(=O)H$, $-CO_2alkyl$, and/or $-C(=O)alkyl$; or alternatively, two R_{1b} groups join together with each other or one R_{1b} joins together with R_{1a} to form a fused benzo ring;


R_{4a} and R_{4c} are selected from halogen, alkyl, cyano, haloalkyl, haloalkoxy, nitro, aryloxy, and arylthio;

R_{4b} is hydrogen, halogen, alkyl, substituted alkyl, nitro, cyano, hydroxy, alkoxy, haloalkoxy, phenyloxy, $-CO_2H$, $-C(=O)H$, $-NH(alkyl)$, $-N(alkyl)_2$, $-CO_2alkyl$, $-C(=O)alkyl$, alkylthio, $-C(=O)NH(CH_2)_{1-4}CO_2H$, $-C(=O)NH(CH_2)_{1-4}CO_2(alkyl)$, aryl, heteroaryl, or heterocyclo, wherein each of the aryl, heteroaryl, and heterocyclo groups are optionally substituted with one to two halogen, $C_{1-4}alkyl$, OMe, CF_3 , CN, OCF_3 , CO_2H , $C(=O)H$, CO_2alkyl , and/or $C(=O)alkyl$;

n is 0, 1, or 2; and


y is 0, 1 or 2.

6. A compound according to claim 1, or a pharmaceutically-acceptable salt, hydrate, prodrug, or enantiomer thereof, having the formula:



7. A compound according to claim 6, or a pharmaceutically-acceptable salt, hydrate, prodrug, or enantiomer thereof, in which R_{1a} is halogen or cyano, and R_{4a} and R_{4c} are independently selected from halogen, alkyl, cyano, trifluoromethyl, and nitro.

8. A compound according to claim 3, having the formula (Ie),



or a pharmaceutically-acceptable salt, hydrate, prodrug, or enantiomer thereof, in which:

R_{1a} and R_{1b} are independently selected from halogen, C_{1-4} alkyl, hydroxy, alkoxy, haloalkyl, haloalkoxy, cyano, nitro, $-CO_2H$, $-C(=O)H$, $-CO_2$ alkyl, $-C(=O)$ alkyl, $-C(=O)NH(CH_2)_{1-4}CO_2H$, $-C(=O)NH(CH_2)_{1-4}CO_2$ (alkyl), and $S(O)_2$ alkyl; or from phenyl, benzyl, phenyloxy, benzyloxy and heteroaryl in turn optionally substituted with halogen, C_{1-4} alkyl, hydroxy, alkoxy, haloalkyl, haloalkoxy, cyano, nitro, $-CO_2H$, $-C(=O)H$, $-CO_2$ alkyl, and/or $-C(=O)$ alkyl; or alternatively, two R_{1b} groups join together with each other or one R_{1b} joins together with R_{1a} to form a fused benzo ring; and

n is 0, 1 or 2.

10

9. A compound according to claim 8, or a pharmaceutically-acceptable salt, hydrate, prodrug, or enantiomer thereof, in which:

R_{1a} is halogen, cyano, nitro, trifluoromethyl, OCF_3 , aryl or heteroaryl;

R_{1b} is halogen, C_{1-4} alkyl, cyano, nitro, $-CO_2H$, $-C(=O)H$, $-CO_2$ alkyl, or $-C(=O)$ alkyl;

R_2 is hydrogen, C_{1-6} alkyl, or C_{1-6} alkyl substituted with CO_2H or $CO_2(C_{1-4}alkyl)$;

15

R_9 is selected from hydrogen, C_{1-10} alkyl, substituted C_{1-10} alkyl, C_{2-10} alkenyl, substituted C_{2-10} alkenyl, C_{3-6} cycloalkyl, phenyl, pyridyl, pyridazinyl, pyrimidinyl, $-(CH_2)_s$ phenyl, $-(CH_2)_s$ tetrazolyl, $-(CH_2)_s$ pyridyl, $-(CH_2)_s$ thienyl, $-(CH_2)_s$ carbazolyl, $-(CH_2)_s$ indolyl, $-(CH_2)_s$ furyl, $-(CH_2)_s$ quinolyl, $-(CH_2)_s$ C_{3-6} cycloalkyl, $-(CH_2)_s$ thiazolyl, $-(CH_2)_s$ pyrrolyl, $-(CH_2)_s$ imidazolyl, $-(CH_2)_s$ isoxazolyl, $-(CH_2)_s$ benzofuryl, $-(CH_2)_s$ pyrazolyl, $-C(=O)H$, $-C(=O)$ (alkyl), $-C(=O)C_{1-10}$ alkyl, $-C(=O)$ phenyl, $-C(=O)$ piperidyl, $-C(=O)$ morpholinyl, $-C(=O)C_{3-6}$ cycloalkyl, $-C(=O)$ pyrrolidinyl, $-C(=O)$ quinolyl, $-C(=O)$ imidazolyl, $-C(=O)$ pyrazolyl, $-C(=O)$ thiazolyl, $-C(=O)$ quinoxalinyl, $-C(=O)$ pyridyl, $-C(=O)$ -1,2,5,6-tetrahydropyridyl, $-C(=O)$ benzothiazolyl, $-C(=O)$ benzotriazolyl, $-C(=O)$ benzodioxanyl, $-C(=O)$ benzooxadiazolyl, $-C(=O)$ 1,2,3,4-tetrahydroquinolyl, $-C(=O)$ thienopyrazolyl, $-C(=O)(CH_2)_s$ tetrazolyl, $-C(=O)(CH_2)_s$ pyridyl, $-C(=O)(CH_2)_s$ phenyl, $-C(=O)(CH_2)_s$ pyrrolidinyl, $-C(=O)(CH_2)_s$ piperidyl, $-C(=O)CH=CH$ (phenyl), $-C(=O)CH=CH$ (pyridyl), $-C(=O)CH_2O$ (alkyl), $-$

30

$C(=O)CH_2S(alkyl)$, $-C(=O)CH_2S(pyridyl)$, $-C(=O)CH_2SO_2(alkyl)$, $-$
 $C(=O)CH_2SO_2(phenyl)$, $-C(=O)CH_2NH(phenyl)$, $-C(=O)CH_2NH(benzyl)$, $-$
 $C(=O)CH_2NH(thiazolyl)$, $-C(=O)CH_2NHC(=O)pyridyl$, $-$
 $C(=O)CH_2NHC(=O)phenyl$, $-(CH_2)_tSO_2(alkyl)$, $-(CH_2)_tSO_2(phenyl)$, $-$
5 $(CH_2)_tSO_2(thienyl)$, $-(CH_2)_tSO_2(imidazolyl)$, $-(CH_2)_tSO_2(furyl)$,
 $(CH_2)_tSO_2(pyrrolyl)$, $SO_2NH(phenyl)$, $-C(=S)NH_2$, $-C(=S)NH(alkyl)$, $-$
 $C(=S)NH(phenyl)$, $-(CH_2)C(=O)pyrrolidinyl$, $-(CH_2)C(=O)piperidyl$, $-$
 $(CH_2)C(=O)piperazinyl$, $-CO_2(alkyl)$, $-CO_2(phenyl)$, $-CO_2(benzyl)$,
 $NHCO_2(alkyl)$, $-(CH_2)_tC(=O)NH(phenyl)$, $-(CH_2)_tC(=O)NH(piperidyl)$, $-$
10 $(CH_2)_tC(=O)NH(thienyl)$, $-(CH_2)_tC(=O)NH(thiazolyl)$, $-$
 $(CH_2)_tC(=O)NH(cyclopentyl)$, $-(CH_2)_tC(=O)NH(cyclopentenyl)$, $-$
 $(CH_2)_tC(=O)NH(benzyl)$, $-(CH_2)_tC(=O)NH(pyrrolidinyl)$, $-$
 $(CH_2)_tC(=O)NH(piperazinyl)$, $-(CH_2)_tC(=O)NH_2$, $-(CH_2)_tC(=O)NH(alkyl)$, $-$
 $(CH_2)_tC(=O)N(alkyl)_2$, $-(CH_2)_tC(=O)N(C_{1-4}alkyl)(phenyl)$, $-$
15 $(CH_2)_tC(=O)N(C_{1-4}alkyl)(thienyl)$, $-(CH_2)_tC(=O)N(C_{1-4}alkyl)(thiazolyl)$, $-$
 $(CH_2)_tC(=O)N(C_{1-4}alkyl)(benzyl)$, $-(CH_2)_tC(=O)N(C_{1-4}alkyl)CO_2(alkyl)$,
wherein each R_9 is optionally substituted with one to two R_{18} ;

R_{18} is selected from $-(CH_2)_q$ halogen, $-(CH_2)_q$ nitro, $-(CH_2)_q$ cyano, $-(CH_2)_q$ haloalkyl, $-$
 $(CH_2)_q$ haloalkoxy, $-(CH_2)_qSR_{24}$, C_{3-7} cycloalkyl, $-SO_2R_{24}$, $-OR_{24}$, $-$
20 $(CH_2)_qCO_2R_{24}$, $-(CH_2)_qNR_{24}R_{25}$, $-(CH_2)_qNHCO_2R_{24}$, $-C(=O)NH-SO_2R_{24}$, $-$
 $C(=O)(CH_2)_qNR_{24}R_{25}$, $-O(CH_2)_rNR_{24}R_{25}$, $-C(=O)R_{24}$, $-(CH_2)_qR_{24}$ and $-C_{1-4}$
alkyl or $-C_{2-4}$ alkenyl optionally substituted with CO_2R_{24} ;

R_{24} is selected from hydrogen, alkyl, phenyl, benzyl, C_{3-7} cycloalkyl, five or six
membered heteroaryl, and four to seven membered heterocyclo, in turn
25 optionally substituted with one to two C_{1-4} alkyl, halogen, hydroxy,
trifluoromethyl, trifluoromethoxy, $-CO_2H$, $CO_2C_{1-4}alkyl$, $C_{1-4}alkoxy$, $-S(C_{1-4}alkyl)$,
amino, and/or amino $C_{1-4}alkyl$, provided that when R_{24} is attached to a
sulfonyl group as in $-SO_2R_{24}$, then R_{24} is not hydrogen;

R_{25} is selected from hydrogen and alkyl; and

30 n is 0, 1, or 2;

p is 1 or 2;

q is 0, 1, 2, 3, or 4;


r is 1, 2, 3, or 4;


s is 0, 1, 2, 3, or 4; and

t is 1, 2, 3, or 4.

5

10. A compound according to claim 1, or a pharmaceutically-acceptable salt, hydrate, prodrug, or enantiomer thereof, wherein J is selected from:





A_1 is a bond, C_{1-2} alkylene, or C_{2-3} alkenylene;

Q is a bond, $-C(=O)-$, $-C(=O)NR_{17}-$, $-SO_2-$, $-CO_2-$, or $-NR_{17}CO_2-$;

A_2 is a bond, C_{1-3} alkylene, C_{2-3} alkenylene, $-C_{1-4}$ alkylene- $NR_{17}-$, $-C_{1-4}$ alkylene- $NR_{17}C(=O)-$, $-C_{1-4}$ alkylene- $S-$, $-C_{1-4}$ alkylene- SO_2- , or $-C_{1-4}$ alkylene- $O-$,
 10 wherein said A_2 alkylene groups are branched or straight chain and optionally substituted with a group selected from $-CO_2H$, $-CO_2(C_{1-4}alkyl)$, $-S(C_{1-4}alkyl)$, NH_2 , $-NH(C_{1-4}alkyl)$, or $-N(C_{1-4}alkyl)_2$;

R_{17} is hydrogen or alkyl;

15 R_{18} and R_{19} are selected from hydrogen, (C_{1-6}) alkyl, (C_{2-6}) alkenyl, CO_2H , $CO_2(C_{1-6}alkyl)$, $C(=O)H$, $C(=O)(C_{1-6}alkyl)$, halogen, cyano, hydroxy, (C_{1-4}) alkoxy, (C_{1-4}) haloalkyl, (C_{1-4}) haloalkoxy, NH_2 , $NH(C_{1-4}alkyl)$, $N(C_{1-4}alkyl)_2$, $N(C_{1-4}alkyl)_3^+$, $-C(=O)(CH_2)NH_2$, $-NHCO_2(C_{1-4}alkyl)$, $-C(=O)NH SO_2(C_{1-4}alkyl)$, $SO_2(C_{1-4}alkyl)$, phenyl, C_{3-7} cycloalkyl, five to six membered heteroaryl, and
 20 four to seven membered heterocyclo, wherein each group R_{18} and R_{19} in turn is optionally substituted with one to two of (C_{1-4}) alkyl, (C_{2-4}) alkenyl, CO_2H ,


CO₂(C₁₋₄alkyl), C(=O)H, C(=O)(C₁₋₄alkyl), halogen, cyano, hydroxy, (C₁₋₄)alkoxy, trifluoromethyl, trifluoromethoxy, NH₂, NH(C₁₋₄alkyl), N(C₁₋₄alkyl)₂, N(C₁₋₄alkyl)₃⁺, -C(=O)(CH₂)NH₂, -NHCO₂(C₁₋₄alkyl), and/or SO₂(C₁₋₄alkyl);

f is 0, 1, 2 or 3; and


g is -1, 0, 1, or 2.





11. A compound according to claim 1, or a pharmaceutically-acceptable salt, hydrate, prodrug, or enantiomer thereof, wherein Z is CR_{4b}.


12. A compound according to claim 3, having the formula,








or a pharmaceutically-acceptable salt, hydrate, prodrug, or enantiomer thereof, wherein J is selected from one of:














5







5












5









5







10









5




10





5

13. A compound according to claim 1, having the formula,



10

or a pharmaceutically-acceptable salt, hydrate, prodrug, or enantiomer thereof, in which:

R_{1a} is halogen, cyano, nitro, trifluoromethyl, OCF_3 , aryl or heteroaryl;

15 R_{1b} is halogen, C_{1-4} alkyl, cyano, nitro, $-CO_2H$, $-C(=O)H$, $-CO_2$ alkyl, or $-C(=O)$ alkyl;


R_2 is hydrogen, C_{1-6} alkyl, or C_{1-6} alkyl substituted with CO_2H or $CO_2(C_{1-4})$ alkyl;

20 R_{18} is selected from (C_{1-4}) alkyl, CO_2H , $CO_2(C_{1-4})$ alkyl, $C(=O)H$, $C(=O)(C_{1-4})$ alkyl, halogen, cyano, hydroxy, (C_{1-4}) alkoxy, (C_{1-4}) haloalkyl, (C_{1-4}) haloalkoxy, NH_2 , $NH(C_{1-4})$ alkyl, $N(C_{1-4})$ alkyl₂, $N(C_{1-4})$ alkyl₃⁺, $-C(=O)(CH_2)NH_2$, $-NHCO_2(C_{1-4})$ alkyl, $-C(=O)NHSO_2(C_{1-4})$ alkyl, $SO_2(C_{1-4})$ alkyl, thienyl, tetrazolyl, triazolyl, pyrazolyl, and imidazolyl;

f is 0, 1, 2 or 3; and

n is 0 or 1.

14. A compound according to claim 1, having the formula,



5 or a pharmaceutically-acceptable salt, hydrate, prodrug, or enantiomer thereof, in which:

R_{1a} is halogen, cyano, nitro, trifluoromethyl, OCF_3 , aryl or heteroaryl;

R_{1b} is halogen, C_{1-4} alkyl, cyano, nitro, $-CO_2H$, $-C(=O)H$, $-CO_2$ alkyl, or $-C(=O)$ alkyl;


R_2 is hydrogen, C_{1-6} alkyl, or C_{1-6} alkyl substituted with CO_2H or $CO_2(C_{1-4}$ alkyl);

10 R_{18} is selected from (C_{1-4}) alkyl, CO_2H , $CO_2(C_{1-4}$ alkyl), $C(=O)H$, $C(=O)(C_{1-4}$ alkyl), halogen, cyano, hydroxy, (C_{1-4}) alkoxy, (C_{1-4}) haloalkyl, (C_{1-4}) haloalkoxy, NH_2 , $NH(C_{1-4}$ alkyl), $N(C_{1-4}$ alkyl) $_2$, $N(C_{1-4}$ alkyl) $_3^+$, $-C(=O)(CH_2)NH_2$, $-NHCO_2(C_{1-4}$ alkyl), $-C(=O)NHSO_2(C_{1-4}$ alkyl), $SO_2(C_{1-4}$ alkyl), thienyl, tetrazolyl, triazolyl, pyrazolyl, and imidazolyl;

15 f is 0, 1, 2 or 3; and

n is 0 or 1.

20 15. A compound having the formula,



or a pharmaceutically-acceptable salt, hydrate, prodrug, or enantiomer thereof,
in which:

5 L and K, taken independently, are O or S;

Z is N or CR_{4b};

J is selected from $-(\text{CR}_{9a}\text{R}_{9c})_x-$ and $-(\text{CR}_{9a}\text{R}_{9b})_y-\text{NR}_{9c}-(\text{CR}_{9a}\text{R}_{9b})_z-$, wherein x is 1, 2 or 3, y is 0, 1 or 2, and z is 0, 1 or 2, provided that y and z together are not greater than 2;

10 T₁ is $-\text{N}-$ or $-\text{CH}-$;

R_{1a} and R_{1b} are independently selected from alkyl, substituted alkyl, halogen, cyano, nitro, OR₁₀, NR₁₀R₁₁, C(=O)R₁₀, CO₂R₁₀, C(=O)NR₁₀R₁₁, NR₁₀C(=O)R₁₁, NR₁₀C(=O)OR₁₁, SR₁₀, S(O)₀R_{10a}, NR₁₀SO₂R_{10a}, NHCH(alkyl)CO₂R₁₀, SO₂NR₁₀R₁₁, cycloalkyl, heterocyclo, aryl, and heteroaryl; or alternatively, two
15 R_{1b} groups join together with each other or one R_{1b} joins together with R_{1a} to form a fused benzo ring;

R₂ is selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, heterocyclo, and heteraryl;

R_{4a}, R_{4b}, and R_{4c} are selected from halogen, alkyl, cyano, haloalkyl, haloalkoxy, aryloxy, arylthio, and nitro;
20

R_{9a} and R_{9b} at each occurrence are independently selected from hydrogen, halogen, C₁₋₄alkyl, hydroxy, C₁₋₄alkoxy, C₁₋₄haloalkyl, C₁₋₄haloalkoxy, or cyano, or R_{9a} and R_{9b} together form keto (=O);

R_{9c} is selected from hydrogen and A₁-Q-A₂-R₁₆;

25 A₁ is a bond, C₁₋₂alkylene, or C₂₋₃alkenylene;

Q is a bond, $-C(=O)-$, $-C(=O)NR_{17}-$, $-SO_2-$, $-CO_2-$, or $-NR_{17}CO_2-$;

A₂ is a bond, C₁₋₃alkylene, C₂₋₃alkenylene, $-C_{1-4}alkylene-NR_{17}-$, $-C_{1-4}alkylene-NR_{17}C(=O)-$, $-C_{1-4}alkylene-S-$, $-C_{1-4}alkylene-SO_2-$, or $-C_{1-4}alkylene-O-$,
 wherein said A₂ alkylene groups are branched or straight chain and optionally
 5 substituted with a group selected from $-CO_2H$, $-CO_2(C_{1-4}alkyl)$, $-S(C_{1-4}alkyl)$,
 NH_2 , $-NH(C_{1-4}alkyl)$, or $-N(C_{1-4}alkyl)_2$;

R₁₀ and R₁₁ (i) are selected independently of each other from hydrogen, alkyl,
 substituted alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclo; or (ii) R₁₀ is
 taken together with R₁₂ to form a heteroaryl or heterocyclo;

10 R_{10a} is alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclo;

R₁₆ is selected from alkyl, alkenyl, aryl, heteroaryl, cycloalkyl, or heterocyclo,
 wherein each R₁₆ is optionally substituted with one to three R₁₈;

R₁₇ is hydrogen or alkyl; -

R₁₈ is selected from C₁₋₆alkyl, substituted C₁₋₆alkyl, halogen, cyano, nitro, OR₂₀,
 15 NR₂₀R₂₁, C(=O)R₂₀, CO₂R₂₀, C(=O)NR₂₀R₂₁, C(=O)NR₂₀SO₂R_{20a},
 NR₂₀C(=O)R₂₁, NR₂₀C(=O)OR₂₁, SR₂₀, S(O)_uR_{20a}, NR₂₀SO₂R_{20a},
 NHCH(alkyl)CO₂R₂₀, NH-(CH₂)₁₋₄-CO₂R₂₀, SO₂NR₂₀R₂₁, C₃₋₇cycloalkyl,
 phenyl, four to seven membered heterocyclo, or five or six membered
 heteroaryl, said C₃₋₇cycloalkyl, phenyl, four to seven membered heterocyclo,
 20 or five or six membered heteroaryl groups in turn being optionally substituted
 with one to two R₂₂;

R₂₀ and R₂₁ are selected from hydrogen, alkyl, alkenyl, C₃₋₇cycloalkyl, phenyl, benzyl,
 phenylethyl, naphthyl, a four to seven membered heterocyclo, or a five to six
 membered heteroaryl, or when attached to the same nitrogen atom may join to
 25 form a heterocyclo or heteroaryl; wherein each of R₂₀ and R₂₁ in turn is
 optionally substituted with one to two R₂₂;

R_{20a} is selected from alkyl, alkenyl, CO₂H, CO₂(alkyl), C₃₋₇cycloalkyl, phenyl, benzyl,
 phenylethyl, naphthyl, a four to seven membered heterocyclo, or a five to six
 membered heteroaryl; wherein each R_{20a} in turn is optionally substituted with
 30 one to two R₂₂;

R_{22} is selected from the group consisting of (C_{1-6}) alkyl, (C_{2-6}) alkenyl, hydroxy, cyano, CF_3 , $O(C_{1-6})$ alkyl, OCF_3 , $C(=O)H$, $C(=O)(C_{1-6})$ alkyl, CO_2H , $CO_2(C_{1-6})$ alkyl, $NHCO_2(C_{1-6})$ alkyl, $-S(C_{1-6})$ alkyl, $-NH_2$, $NH(C_{1-6})$ alkyl, $N(C_{1-6})$ alkyl) $_2$, $N(CH_3)_3^+$, $SO_2(C_{1-6})$ alkyl, $C(=O)(C_{1-4})$ alkylene) NH_2 , $C(=O)(C_{1-4})$ alkylene) $NH(alkyl)$, and $C(=O)(C_{1-4})$ alkylene) $N(C_{1-4})$ alkyl) $_2$;


o and u are independently 1 or 2; and

n is 0, 1 or 2.

16. A compound according to claim 15, or a pharmaceutically-acceptable salt, hydrate, prodrug, or enantiomer thereof, wherein R_{4a} and R_{4c} are chloro.

17. A compound according to claim 15, or a pharmaceutically-acceptable salt, hydrate, prodrug, or enantiomer thereof, wherein R_{1a} is cyano or halogen.

18. A compound according to claim 15, having the formula,



or a pharmaceutically-acceptable salt, hydrate, prodrug, or enantiomer thereof.

19. A compound according to claim 18, or a pharmaceutically-acceptable salt, hydrate, prodrug, or enantiomer thereof, in which:

R_2 is selected from hydrogen, C_{1-6} alkyl, and C_{1-6} alkyl substituted with amino, $NH(C_{1-4})$ alkyl, $N(alkyl)_2$, $C(=O)H$, $C(=O)C_{1-4}$ alkyl, CO_2H , $CO_2(C_{1-4})$ alkyl, SO_2C_{1-4} alkyl, SO_3H , and/or $PO(OH)_2$;

R_{4a} and R_{4b} are selected from halogen, C₁₋₄alkyl, cyano, halo C₁₋₄alkyl, and haloC₁₋₄alkoxy;

J is $-(\text{CHR}_{9c})_x-$ or $-(\text{CH}_2)_y-\text{NR}_{9c}-$;


R_{9c} is A₁-Q-A₂-R₁₆;

- 5 R₁₆ is selected from (a) hydrogen and C₁₋₆alkyl or C₂₋₆alkenyl optionally substituted with one to two of OH, O(C₁₋₄alkyl), -CO₂H, -CO₂(C₁₋₄alkyl), NH₂, -NH(C₁₋₄alkyl), and/or N(C₁₋₄alkyl)₂, or from (b) furanyl, indolyl, carbazolyl, pyrazolyl, pyrrolyl, thienyl, pyridyl, pyrimidinyl, benzofuranyl, isoxazolyl, imidazolyl, triazolyl, tetrazolyl, phenyl, piperidyl, pyrrolidinyl, pyridazinyl, 10 C₃₋₇cycloalkyl, piperazinyl, thiazolyl, morpholinyl, 1,2,5,6-tetrahydropyridyl, quinoxaliny, benzothiazolyl, benzotriazolyl, benzodioxanyl, benzooxadiazolyl, thienopyrazolyl, tetrahydroquinolinyl, and quinolinyl, wherein each of said cyclic R₁₆ groups in turn is optionally substituted with up to three R₁₈;

R₁₇ is hydrogen or alkyl; and

- 15 R₁₈ is selected from hydrogen, (C₁₋₆)alkyl, (C₂₋₆)alkenyl, CO₂H, CO₂(C₁₋₆alkyl), C(=O)H, C(=O)(C₁₋₆alkyl), halogen, cyano, hydroxy, (C₁₋₄)alkoxy, (C₁₋₄)haloalkyl, (C₁₋₄)haloalkoxy, NH₂, NH(C₁₋₄alkyl), N(C₁₋₄alkyl)₂, N(C₁₋₄alkyl)₃⁺, -C(=O)(CH₂)NH₂, -NHCO₂(C₁₋₄alkyl), SO₂(C₁₋₄alkyl), phenyl, C₃₋₇cycloalkyl, five to six membered heteroaryl, and four to seven membered heterocyclo, wherein each group R₁₈ in turn is optionally substituted with one to two of (C₁₋₄) alkyl, (C₂₋₄) alkenyl, CO₂H, CO₂(C₁₋₄alkyl), C(=O)H, C(=O)(C₁₋₄alkyl), halogen, cyano, hydroxy, (C₁₋₄)alkoxy, trifluoromethyl, trifluoromethoxy, NH₂, NH(C₁₋₄alkyl), N(C₁₋₄alkyl)₂, N(C₁₋₄alkyl)₃⁺, - 20 C(=O)(CH₂)NH₂, -NHCO₂(C₁₋₄alkyl), and/or SO₂(C₁₋₄alkyl). 25

20. A compound according to claim 19, having the formula,



or a pharmaceutically-acceptable salt, hydrate, prodrug, or enantiomer thereof, in which:

5 R_{1a} is cyano or halogen;

R_{1b} is halogen, C_{1-4} alkyl, cyano, nitro, $-CO_2H$, $-C(=O)H$, $-CO_2$ alkyl, or $-C(=O)$ alkyl;

R_2 is hydrogen, C_{1-6} alkyl, or C_{1-6} alkyl substituted with CO_2H or $CO_2(C_{1-4})$ alkyl;


10 R_{18} is selected from (C_{1-4}) alkyl, CO_2H , $CO_2(C_{1-4})$ alkyl, $C(=O)H$, $C(=O)(C_{1-4})$ alkyl, halogen, cyano, hydroxy, (C_{1-4}) alkoxy, (C_{1-4}) haloalkyl, (C_{1-4}) haloalkoxy, NH_2 , $NH(C_{1-4})$ alkyl, $N(C_{1-4})$ alkyl) $_2$, $N(C_{1-4})$ alkyl) $_3^+$, $-C(=O)(CH_2)NH_2$, $-NHCO_2(C_{1-4})$ alkyl, $-C(=O)NHSO_2(C_{1-4})$ alkyl, $SO_2(C_{1-4})$ alkyl,), thienyl, tetrazolyl, triazolyl, pyrazolyl, and imidazolyl;

f is 0, 1, 2 or 3; and

n is 0 or 1.

15

21. A compound according to claim 19, having the formula,



or a pharmaceutically-acceptable salt, hydrate, prodrug, or enantiomer thereof, in which:

R_{1a} is halogen, cyano, nitro, trifluoromethyl, OCF₃, aryl or heteroaryl;

R_{1b} is halogen, C₁₋₄alkyl, cyano, nitro, -CO₂H, -C(=O)H, -CO₂alkyl, or -C(=O)alkyl;

R₂ is hydrogen, C₁₋₆alkyl, or C₁₋₆alkyl substituted with CO₂H or CO₂(C₁₋₄alkyl);

5 R₁₈ is selected from (C₁₋₄) alkyl, CO₂H, CO₂(C₁₋₄alkyl), C(=O)H, C(=O)(C₁₋₄alkyl), halogen, cyano, hydroxy, (C₁₋₄)alkoxy, (C₁₋₄)haloalkyl, (C₁₋₄)haloalkoxy, NH₂, NH(C₁₋₄alkyl), N(C₁₋₄alkyl)₂, N(C₁₋₄alkyl)₃⁺, -C(=O)(CH₂)NH₂, -NHCO₂(C₁₋₄alkyl), -C(=O)NHSO₂(C₁₋₄alkyl), SO₂(C₁₋₄alkyl), thienyl, tetrazolyl, triazolyl, pyrazolyl, and imidazolyl;

10 *f* is 0, 1, 2 or 3; and

n is 0 or 1.

22. A pharmaceutical composition comprising at least one compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.

23. A pharmaceutical composition comprising at least one compound according to claim 15 and a pharmaceutically acceptable carrier or diluent.

20 24. A method of inhibiting an LFA-1/ICAM-associated condition in a mammal comprising administering to the mammal a therapeutically-effective amount of a compound according to claim 1.


25 25. The method of claim 24 in which LFA-1/ICAM-associated condition is selected from acute or chronic graft vs host reactions, acute or chronic transplant rejection, multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, osteoporosis, diabetes, cystic fibrosis, inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, ulcerative colitis, Alzheimer's disease, shock, ankylosing

spondylitis, gastritis, conjunctivitis, pancreatitis, multiple organ injury syndrome, myocardial infarction, atherosclerosis, stroke, reperfusion injury, acute glomerulonephritis, vasculitis, thermal injury, necrotizing enterocolitis, granulocyte transfusion associated syndrome, Sjogren's syndrome, eczema, atopic dermatitis, contact dermatitis, urticaria, scleroderma, psoriasis, asthma, pulmonary fibrosis, allergic rhinitis, oxygen toxicity, emphysema, chronic bronchitis, acute respiratory distress syndrome, chronic obstructive pulmonary disease (COPD), hepatitis B, hepatitis C, organ-tissue autoimmune disease, autoimmune thyroiditis, uveitis, systemic lupus erythematosus, Addison's disease, autoimmune polyglandular disease, and Grave's disease.

26. A method of treating an inflammatory or immune disease in a mammal animal comprising administering to the mammal in need of such treatment a therapeutically-effective amount of a pharmaceutical composition according to claim 22.

27. The method of claim 26 in which the inflammatory or immune disease is selected from acute or chronic transplant rejection, rheumatoid arthritis, osteoarthritis, diabetes, asthma, inflammatory bowel disease, and chronic obstructive pulmonary disease.

28. An intermediate useful for preparing a compound having therapeutic activity, the intermediate having the formula:



wherein:

L and K are O or S;

Z is N or CR_{4b};

R_{1a} is selected from halogen and cyano;

R_{1b} is selected from alkyl, substituted alkyl, halogen, cyano, nitro, OR₁₀, NR₁₀R₁₁,
C(=O)R₁₀, CO₂R₁₀, C(=O)NR₁₀R₁₁, NR₁₀C(=O)R₁₁, NR₁₀C(=O)OR₁₁, SR₁₀,
5 S(O)_oR_{10a}, NR₁₀SO₂R_{10a}, NHCH(alkyl)CO₂R₁₀, SO₂NR₁₀R₁₁, cycloalkyl,
heterocyclo, aryl, and heteroaryl;

R₂ is selected from C₁₋₆alkyl and -C(=O)(C₁₋₄alkyl);

R_{4a}, R_{4b} and R_{4c} are independently selected from hydrogen, halogen, alkyl, substituted
alkyl, alkenyl, substituted alkenyl, nitro, cyano, SR₁₄, OR₁₄, NR₁₄R₁₅,
10 NR₁₄C(=O)R₁₅, CO₂R₁₄, C(=O)R₁₄, -C(=O)NR₁₄R₁₅, aryl, heteroaryl,
cycloalkyl, and heteroaryl;

R₁₀ and R₁₁ (i) are selected independently of each other from hydrogen, alkyl,
substituted alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclo; or (ii) R₁₀ is
taken together with R₁₁ to form a heteroaryl or heterocyclo;





15 R_{10a} is alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclo; and

R₁₄ and R₁₅ (i) are selected independently of each other from hydrogen, alkyl,
substituted alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclo; or (ii) R₁₄ is
taken together with R₁₅ to form a heteroaryl or heterocyclo ring;

n is 0, 1 or 2; and

20 *o* is 1 or 2.

29. The intermediate according to claim 28, selected from one of:



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/31283

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07D 401/04, 401/14, 487/10, 487/20; A61K 31/4166
US CL : 548/301.4; 546/274.1, 274.4; 514/278, 386

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 548/301.4; 546/274.1, 274.4; 514/278, 386

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
STN CAS Database, File REGISTRY, FILE CAPLUS; EAST; WEST

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| X | US 4,931,444 (VAN WAUVE et al) 5 June 1990 (05.06.1990), see entire document. | 1-21. |
| A | US 6,087,509 (CLAUSSNER et al) 11 June 2000 (11.06.2000), see entire document. | 1-21. |
| A | US 5,750,553 (CLAUSSNER et al) 12 May 1998 (12.05.1998), see column 10. | 1-21. |
| A | US 5,346,913 (HSU et al) 13 September 1994 (13.04.1994), see entire document. | 1-21. |
| A | US 5,434,176 (CLAUSSNER et al) 18 June 1995 (18.06.1995), see column 6. | 1-21. |

☐ Further documents are listed in the continuation of Box C. ☒ See patent family annex.

| | |
|---|--|
| * Special categories of cited documents: | |
| "A" document defining the general state of the art which is not considered to be of particular relevance | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| "E" earlier application or patent published on or after the international filing date | "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "O" document referring to an oral disclosure, use, exhibition or other means | "&" document member of the same patent family |
| "P" document published prior to the international filing date but later than the priority date claimed | |

Date of the actual completion of the international search

15 December 2002 (15.12.2002)

Date of mailing of the international search report

07 FEB 2003

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Alan Rotman

Telephone No. 703.308.1235